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Abstract 
 
Oligosaccharides, as present in human milk or supplemented to food, are renowned for their 
biological activity in the gastrointestinal tract. So far, little is known about the implication 
of oligosaccharide structures on their gastrointestinal fate. The influence of diet-related 
oligosaccharides on the postnatal gastrointestinal development and on the establishment of 
a balanced microflora is of special interest. Therefore, the present research aimed at an 
advanced understanding of the gastrointestinal metabolization of diet-related 
oligosaccharides, focusing on infant nutrition.  
Capillary electrophoresis with laser-induced fluorescence detection (CE-LIF) was 
introduced as a sensitive, qualitative and quantitative method for the analysis of individual 
galactooligosaccharides (GOS) from complex food matrices. The method also showed to be 
useful for the monitoring and characterization of complex konjac glucomannan (KGM) 
oligosaccharides, resulting from enzymatic digestion of the KGM polysaccharide and in 
vitro fermentation with human gut flora. The analysis and identification of human milk 
oligosaccharides (HMOs) in breast milk and the characterization of oligosaccharides as 
present in the feces of breast-, formula- and mixed-fed babies was performed by CE-LIF 
coupled to a mass spectrometer (CE-LIF-MSn). The type of feeding determines the 
presence of diet-related oligosaccharides in baby feces. For breast-fed babies a gradual 
change in fecal oligosaccharide profile was found during the first six months postpartum. 
Three continuous stages of fecal oligosaccharide profiles were defined, comprising the 
presence of the genetically determined HMO-profile of the breast milk consumed (stage 1), 
the presence of HMO-units conjugated to blood group determinants from gastrointestinal 
mucins (stage 2) and predominantly oligosaccharides characteristic for follow-up feeding 
when solid food is introduced (stage 3). In total, sixteen fecal oligosaccharides, which 
pointed to the degradation and gastrointestinal metabolization of diet-related 
oligosaccharides and which were not present in human milk or infant formula, were 
identified in this research.  
Monitoring the gastrointestinal fate of diet-related oligosaccharides pointed to an 
individual-dependent gastrointestinal adaptation to enteral food during the postnatal period. 
 
 
 
Keywords: human milk oligosaccharides (HMOs), galacto-oligosaccharides (GOS), konjac glucomannan (KGM), 
breast milk, baby feces, gastrointestinal metabolization, blood-group specific conjugates, CE-LIF-MSn 
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Project outline 
Health-promoting oligosaccharides are of broad public interest, but little is known about 
their structure-function relationship. In order to understand the gastrointestinal fate of these 
oligosaccharides, it is necessary to: 
1) Have methods available to isolate, identify and quantify the oligosaccharides in 
complex food and body matrices.  
2) Monitor their gastrointestinal degradation and metabolization in vitro and in vivo. 
These requirements formed the basis of this research project. The research presented in this 
PhD thesis focuses on the characterization and gastrointestinal metabolization of human 
milk oligosaccharides and functional oligosaccharides supplemented to infant nutrition. For 
this purpose, valuable sample material, e.g. resulting from a hospital study with preterm 
born babies, was provided by the project partners. 
Functional oligosaccharides play an important role in infant nutrition. They influence the 
development and bacterial colonization and the gastrointestinal functioning of neonates, 
which are connected to short- and long-term infant health. An advanced understanding of 
the gastrointestinal fate of functional oligosaccharides in baby foods is thus of nutritional, 
medical, scientific as well as economical relevance. 
 
Gastrointestinal development and functioning 
The maturation of the gastrointestinal tract during the post-conceptional period is a gradual 
process (Figure 1). At term birth (> 36 weeks gestation), the lipid- and protein-digestion is 
still immature,1,2 but is expected to quickly reach its mature activity with the introduction of 
enteral food.3 The carbohydrases maltase and sucrase are present in mature levels at term 
birth, showing a gradual development in utero.1 On the other hand, lactase activity only 
increases markedly between the 24th and 40th post-conceptional week of gestation and its 
full activity is considered as a marker for gastrointestinal maturity.1,4 Rapid maturational 
changes in terms of digestive functioning, nutrient absorption, endocrinology, microbiology 
and immunology occur with the introduction of enteral food, and, later on, during weaning, 
which also implies a marked change in dietary habits.3 Special attention has to be paid to 
the development of the gastrointestinal microbiota. At birth, the gut presents a sterile 
environment, which is gradually colonized, depending on the feeding provided. The 
composition of the colonic microbiota is closely connected to the host’s well-being.5 
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Figure 1. Phases of intestinal maturation in utero and during first year postpartum, as adapted from Sangild 
(copyright © 2006 by the Society for Experimental Biology and Medicine).3 The development of the 
carbohydrases maltase, sucrase and lactase is schematized. 
 
Development of the gastrointestinal microbiota  
Approximately 1012 bacteria per gram gut content inhabit the adult colon and these bacteria 
are distributed within the gastrointestinal lumen or are attached to the mucosal surface 
layer.5 The intestinal flora comprises health-beneficial bacteria (e.g. Bifidobacteria) and 
potentially harmful bacteria (e.g. Clostridia), which commensally live together in a 
balanced proportion in healthy individuals.5 The gastrointestinal microbiota gradually 
develops during the first year of life.6 An overview on the postnatal development of the 
gastrointestinal microbiota is given in Figure 2, which summarizes the results from various 
studies on the neonatal development of the gastrointestinal microbiota.6-10 Oxygen is 
present in the colon at birth and is made responsible for the pronounced presence of 
facultative anaerobe bacteria (e.g. E.coli or other Enterobacteriaceae spp) during the first 
weeks. The development of this initial flora is feeding-dependent. During the first weeks of 
life the colonization pattern changes gradually to a stabilized flora, with a relatively 
“simple” flora in case of breast feeding. Bifidobacteria form a considerable part of this 
“simple” flora, as present during the pre-weaning phase.6,9 Bifidobacterium longum, 
Bifidobacterium bifidum and Bifidobacterium breve are characteristic representatives, with 
Bifidobacterium longum ssp infantis being the hallmark of the microbiota of breast-fed 
babies.6,11 Formula-fed babies show similar Bifidobacteria counts, but the contribution of 
other anaerobic bacteria (e.g. Bacteroides) and facultative anaerobic bacteria (e.g. E.coli) to 
the total microbiota is higher.6,9  
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Figure 2. Succession of gastrointestinal colonization in the postnatal period, as influenced by different ways of 
feeding. Dashed box summarizes different possibilities of infant nutrition during pre-weaning phase. 
Formula-fed+ = formula supplemented with prebiotic oligosaccharides. Mean values are only indicative, as they 
were derived from different studies.6-10 
 
The supplementation of prebiotic oligosaccharides to infant formula leads to increased 
counts of Bifidobacteria and Lactobacilli, while similar counts of facultative anaerobic 
bacteria is similar to what is observed for babies fed with non-supplemented formula.8  
A mixed flora is characteristic for the weaning cluster when solid food is introduced. The 
change in flora composition during weaning is less pronounced for formula-fed babies, but 
presents a major disturbance in the colon of breast-fed babies. During the first years of life, 
the microbiota gradually develops to its adult-like form, which is dominated by 
Bacteroides, followed by Bifidobacteria and Firmicutes (e.g. Clostridia and 
Ruminococci).6,9 Variations of the colonization pattern are mainly observed in case of 
caesarean delivery and preterm birth, which implicate a longer time period for the 
installation of the commensal gut flora.8,12 
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Gastrointestinal oligosaccharide metabolization in relation to health 
Gastrointestinal bacteria have different nutritional requirements and can be sub-divided into 
proteolytic bacteria, gas-utilizers and saccharolytic bacteria, with the latter group being 
most abundant. Besides endogenous carbohydrates, non-digestible, feeding-related 
carbohydrates are the main substrate available for colonic fermentation.5,13,14 Feeding can 
influence the gastrointestinal flora composition to a certain extent and non-digestible 
oligosaccharides specifically stimulating the growth of health-beneficial bacteria in the 
large intestine are called prebiotics.5 Due to their indigestibility in the upper gastrointestinal 
tract, HMOs from breast milk and oligosaccharides added to breast milk replacers are 
substrates for colonic fermentation and are of special interest in view of the postnatal 
establishment of the microbiota and infant health. 
 
Endogenous gastrointestinal carbohydrates 
Endogenous gastrointestinal carbohydrates are represented by glycoproteins (e.g. mucins) 
and other polysaccharide derivatives (e.g. glycosaminoglycans).5 The bioactive 
functionality of mucins, which are part of the gastrointestinal mucus layer are of special 
scientific interest.15-17 The gut surface is covered by a mucus gel layer bound to the 
epithelial cell surface and mucus is secreted into the gut lumen by gastrointestinal goblet 
cells.18,19 The production and erosion of mucus is a balanced system, with the latter one 
occurring by mechanical shear and enzymatic digestion by luminal proteases.20 These 
mucus gel layers are, besides mainly water and electrolytes, composed of mucins, which 
are polypeptides heavily glycosylated with mucin-type O-glycans.19 Colonic mucins have a 
core structure of Gal-(β1,3)-GalNAc (core 1), GlcNAc-(β1,6)-[Gal-(β1,3)]-GalNAc      
(core 2) or GlcNAc-(β1,3)-GalNAc (core 3), which are α-linked to a serine or threonine in 
the polypeptide backbone. The core structures can be decorated with sialic acid or 
elongated by linear or branched Gal-(β1,4)-GlcNAc-units, which can be further modified 
by sulfate esters. The terminal determinants of mucins are A, B, H(0)-blood group antigens, 
Lewis-antigens and sialyl-Lewis-antigens.18 The main antigens of mucins are summarized 
in Table 1. Their expression depends on the host’s Lewis (Le/le) and Secretor (Se/se) gene 
system. The Lewis-blood group system is genetically independent from the ABH(0) 
system, but the expression of the Lewis phenotypes is dependent of the ABH(0) secretor-
status, which determines the presence of (α1,2)-fucosylated oligosaccharides.21 In addition, 
ABH(0)-non-secretors show Lea-character [Le(a+b-)] and ABH(0)-secretors show Leb-
character [Le(a-b+)]. [Le(a-b-)]-secretors neither show Lea- nor Leb –character.21 
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Besides being lubricants, important other biological functions are ascribed to mucins. They 
participate in the control of the immune system and, dependent on their structural 
composition, they present receptors for specific bacteria and inhibit the adhesion of 
others.18 The mucosal glycoproteins can serve as nutrients for bacterial growth, e.g. for 
Bifidobacterium and Ruminococcus spp.15,22,23 Due to the consequent decrease of the 
protective mucus barrier, an advanced bacterial mucin-degradation is not desired.24 
 
Table 1. Antigenic determinant structures as found at the non-reducing terminus of mucin-type O-glycans.     
Their presence depends on the Secretor-/ Lewis type [Le(a-b+), Le(a+b-), Le(a-b-)], as indicated.  
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Human milk oligosaccharides (HMOs) 
Lactose and HMOs are the main components of the carbohydrate fraction in human milk.25 
Colostrum milk (1-4 days postpartum) contains 21-24 g/L HMOs, whereas for mature milk 
(as established approx. one month postpartum) the concentration ranges between 12-13 g/L 
and then decreases with proceeding time postpartum.25-29 The reducing end of HMOs is 
composed of a lactose unit, to which lacto-N-biose units (Gal-(β1,3)-GlcNAc) or 
lactosamine units (Gal-(β1,4)-GlcNAc) are attached.30 This results in a set of basic 
structures, either based on type 1 [Gal-(β1,3)-GlcNAc-(β1,3)-Gal-(β1,4)-Glc] or type 2  
[Gal-(β1,4)-GlcNAc-(β1,3)-Gal-(β1,4)-Glc] (Figure 3). High-Mw HMOs can be either 
linear or branched.  
β1,4
β1,4β1,3β1,3
glcNAc glucosegalactose
LNT
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LnNT
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L
LNH
LnNH
para-LNH
para-LnNH
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β1,4β1,3β1,4 β1,3 β1,4
 
Figure 3. Structural composition of core oligosaccharides of HMOs. L: lactose; LNT: lacto-N-tetraose; LnNT: 
lacto-N-neo-tetraose; LNH: lacto-N-hexaose: LnNH: lacto-N-neo-hexaose. The elongation of the core chains to 
lacto-N-octaose- and lacto-N-decaose-isomers is indicated. 
 
HMOs are synthesized in the mammary glands and can be further decorated by 
glycosyltransferases with fucose and sialic acid.30 Oligosaccharides in human milk can thus 
be divided into a neutral and an acidic fraction, with acidic oligosaccharides being present 
in a tenfold lower concentration than neutral oligosaccharides.31 The structural composition 
of HMOs has been extensively studied and results obtained by Kuhn et al,32,33            
Kobata et al,34,35 Montreuil,36 Strecker et al37,38 and many others contributed to a well-
defined picture on the glycobiology of oligosaccharides in human milk. Table 2 gives an 
overview on the structural composition of fucosylated and sialylated HMOs up to a core 
structure of six sugar units, as reviewed by Urashima et al.30  
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Table 2. Fucosylation and sialylation of HMO-core structures30 and their concentration in Le(a-b+)-, Le(a+b-)- 
and Le(a-b-)-breast milk.39 [lactose (L), lacto-N-tetraose (LNT), lacto-N-neo-tetraose (LnNT), [para]-lacto-N-
hexaose ([para-]LNH) and [para-]lacto-N-neo-hexaose ([para-]LnNH)].  
Fuc: fucose; Neu5Ac: sialic acid. nd: not determined, low concentration is expected. 
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The larger the molecules are, the lower is their concentration in breast milk. 
Oligosaccharides based on type 1 (LNT) are dominant in human milk.30 
Although not presented in Table 2, HMOs can as well be simultaneously sialylated and 
fucosylated, which increases the structural complexity of the molecules. So far, 
approximately 200 different structures have been detected in human milk40 whereof 
approximately 100 have been identified.30  
 
Genetic fingerprint of HMOs 
The presence and abundancy of HMOs in breast milk is genetically determined.41 The 
(α1,2)-fucosyltransferase (FUT2) and  (α1,3/4)-fucosyltransferases (FUT3, 4, 5, 6, 7, 9), 
which are responsible for the fucosylation of the HMOs in the mammary glands, 
correspond to the fucosyltransferases responsible for fucosylation of other body 
glycoproteins (e.g. on erythrocytes and mucins).42 The expression of FUT2 and FUT3 
depends on the maternal Secretor- and Lewis type, respectively.42 Accordingly, human milk 
can be classified into four groups:41 
1) Human milk from Le(a-b+)-secretors contains (α1,2)-, (α1,3)- and (α1,4)- 
fucosylated oligosaccharides, which accounts for 70% - 80% of the European 
population.41,43,44  
2) Human milk from Le(a+b-)-non-secretors contains (α1,3)- and (α1,4)-fucosylated 
oligosaccharides, but lacks (α1,2)-fucosylated oligosaccharides. This is found for 
approximately 20% of the European population.41,43,44  
3) Le(a-b-)-secretor-milk contains (α1,2)- and (α1,3)-fucosylated oligosaccharides 
and does not contain (α1,4)-fucosylated oligosaccharides. The occurrence of the 
Le(a-b-)-secretor status is only approximately 10%, as was determined for the 
French population. 41,43 
4) Le(a-b-)-non-secretor-milk is composed of (α1,3)-fucosylated oligosaccharides, 
but lacks (α1,2)- as well as (α1,4)-fucosylated oligosaccharides. The occurrence of 
this milk type was estimated as rather low (1%, as was determined for the French 
population).41,43  
 
The concentration of HMOs in breast milk of Le(a-b+)- Le(a+b-)- and Le(a-b-)-mothers is 
indicated in Table 2. 
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HMOs and health 
Breast-feeding is connected to a lowered risk of inflammatory bowel diseases and 
gastrointestinal, respiratory and urinary infections in the postnatal period.45-48 The health-
beneficial characteristics of breast milk are mainly connected to the complex HMO-
structures, which were also proposed to be involved in the development of the immune 
system.49 Even an influence on brain development has been proposed.50 Direct pathogen 
inhibition and bifidogenicity are well-studied examples of health-related structure-function 
relationships of HMOs. 
 
Direct pathogen inhibition  
HMOs can act as receptor analogs for preventing the adhesion of pathogenic bacteria to the 
mucosal surface. This ligand-receptor mechanism is based on the structural characteristics 
of HMOs, which are complementary to the structures of the carbohydrate epitopes in the 
mucosa.30 In vitro experiments showed that sialylated HMOs prevent the adhesion of 
S-fimbriated enteropathogenic E.coli and Influenza A virus.51 Special attention has to be 
paid to (α1,2)-fucosylated HMOs, which showed inhibition of campylobacter, norovirus 
and toxin-producing E-coli in vitro and a lower incidence of diarrhea in breast-fed infants 
in vivo.52-55 Babies who consumed milk rich in (α1,2)-fucosylated HMOs showed less 
incidence for diarrhea than babies, who received milk with low (α1,2)-fucosylated HMO–
levels.54 There is still insufficient knowledge in order to judge different types of breast 
milks on their functional value. 
 
Bifidogenicity 
The microbiota of breast-fed infants is described as “simple”, with a considerable 
contribution of Bifidobacteria.9 Bifidobacteria are known to inhibit the growth of pathogens 
by short chain fatty acid production and to stimulate the immune response, cholesterol 
assimilation and the synthesis of vitamins.56-58 Infant-specific Bifidobacterium species 
exhibit cellular transporter systems for intact HMOs59 or exhibit extracellular enzymes 
necessary to degrade HMOs, such as sialidase, (α1,2)-/(α1,3/4)-fucosidase and lacto-N-
biosidase-phosphorylase.11,60-62 Lacto-N-biose, the building block of type-I HMOs 
(Figure 3), has been described as essential bifidogenic factor of breast milk.63  
 
 
 
 
General Introduction 
 
 11 
Non-digestible oligosaccharides in infant food 
Prebiotic oligosaccharide-supplementation to infant formula aims at simulating the health-
promoting effect of HMOs. Due to the complexity of HMOs, their synthesis or extraction 
cannot be performed on a production scale to date. In view of the high galactose content in 
human milk and the lactose-based structural composition of HMOs, 
galactooligosaccharides (GOS) are frequently used for the supplementation of infant 
formula. In addition, long-chain fructooligosaccharides (FOS) are nowadays added to infant 
formula in order to simulate the higher molecular weight oligosaccharide fraction of human 
milk.64,65 
 
Preparation of GOS 
GOS are produced by transgalactosylation from lactose using fungal, yeast-derived or 
bacterial β-galactosidases (EC 3.2.1.23). The structural composition of the resulting GOS-
mixture is highly dependent on the origin of the enzyme and the incubation parameters, 
such as pH of the medium, temperature and substrate-concentration.66 The size of the 
oligosaccharides in the mixture ranges from dimers to pentamers, with β-(1,2)- and/or       
β-(1,3)- and/or β-(1,4)- and/or β-(1,6)-linkages between galactose-galactose or galactose-
glucose.67-69 Nonreducing galactooligosaccharides, containing α-(1,1)-linkages between 
glucose and galactose can be produced as well.70 
 
Preparation of FOS 
FOS can be obtained by extraction and hydrolysis of inulin from plants, which is a storage 
polysaccharide in e.g. chicory root and artichoke.71 Most inulin-type fructans are composed 
of (β-D-Fruf-(1,2))n-linkages with a non-reducing β-D-Fruf-(2,1)-α-D-Glcp terminus. The 
chain length of the fructans is dependent on the plant (usually DP4 - DP < 200).71,72 
Commercial inulin-type short chain and long chain FOS may consist of both,                    
(β-D-Fruf-(1,2))n-D-Fruf–series (Fn) and (β-D-Fruf-(1,2))n-β-D-Fruf-(2,1)-α-D-Glcp-series 
(GFn). 
FOS can also be prepared by transfructosylation of sucrose with β-fructofuranosidases    
(EC 3.2.1.26) or β-fructosyltransferases (EC 2.4.1.9).73-75 The result is a homologous             
GFn-oligosaccharide-series of DP 2-5.75  
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Health functions of GOS and FOS 
In vitro- and in vivo studies with prebiotic GOS and FOS demonstrated a specific 
stimulation of health-beneficial gut bacteria, although structurally different oligosaccharide 
mixtures were used in the respective studies.76-79 Correspondingly, the presence and 
expression of saccharidases (β-galactosidases and β-fructofuranosidases) from health-
beneficial bacteria and their mode of action has been described.80-82 Similar to HMOs, anti-
adhesive functions towards an enteropathogenic E.coli-strain were found for GOS              
in vitro.83 
For the application in infant formula, a mixture of GOS:FOS (9:1) has been used.84 This 
proportioning emulates the molecular size distribution of HMOs in breast milk. 
Furthermore, a synergistic effect of GOS and FOS on the stimulation of health-beneficial 
colonic bacteria was proposed.84 The FOS added to the infant formula have a size of        
DP > 10, as short-chain FOS can cause increased flatulence.71 Feeding infant formula 
supplemented with a combination of GOS and FOS resulted in the stimulation of 
bifidobacterial growth and was accompanied by increased stool frequency, soft stools and 
decreased fecal pH.85 The health-promoting effects observed were dose-dependent, with  
0.8 g/dL supplementation being considered as optimal and approved as safe by the EFSA 
authority.85,86 
 
Other potential oligosaccharides for functional food supplementation 
The supplementation of infant formula with GOS and/or FOS neglects the presence of 
acidic oligosaccharides in human milk. These may contribute to the gastrointestinal defense 
of pathogenic bacteria and to the systemic effects proposed for HMOs. So far, synthetically 
produced, sialylated oligosaccharides are not suitable for the application in food.87  Instead, 
acidic oligosaccharides from pectin (AOS) are being considered for their potential use in 
infant formula.88 Pectin, which is a plant cell wall polysaccharide contains acidic 
polygalacturonan-chains. AOS are obtained by enzymatic hydrolysis and are renowned for 
their curative functioning for diarrhea, which may be related to the anti-adhesive effects 
found for these oligosaccharides towards E. Coli.89  
 
GOS and FOS are structurally less complex than HMOs. The “simple” prebiotic 
oligosaccharide structures are, therefore, readily fermented in the proximal colon, although 
at different rates.90 Many colonic diseases, such as ulcerative colitis and Crohn’s disease 
occur in the distal colonic part and were suggested to result from a reduced immune 
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response to the commensal gut flora.91 Nature is rich in dietary fibres, which are defined to 
reach the colon intact.92 The more complex these substrates are, the higher the potential to 
survive the whole gastrointestinal tract passage and to reach the distal part of the colon. 
Complex storage polysaccharides can be found in various plants, such as acetylated 
glucomannan in the tubers of Amorphophallus-species and highly branched fructans in the 
stems of Agave-species.93,94 Industrial by-products, such as cereal bran, fruit pomace and 
sugar beet pulp contain large amounts of complex plant cell wall polysaccharides, such as 
pectic arabinogalactan, arabinan, rhamnogalactorunan, arabinoxylan and glucurono-
arabinoxylan, which can be used for the enzymatic production of complex oligosaccharide 
mixtures.95 In fact, a slower fermentability of acetylated xylo-oligosaccharides and xylo-
oligosaccharides decorated with methylglucuronic acid groups was found in vitro,96 making 
them potential candidates for novel prebiotics. 
 
Analysis of oligosaccharides from human milk and functional foods 
The analysis of oligosaccharides from human milk and functional foods is challenging, due 
to the wide structural variety and the presence of numerous isomeric forms in these 
mixtures. HMOs and functional oligosaccharides are usually embedded in low 
concentrations in food (< 10 % (w/w))97 and body liquids. These complex matrices may 
also contain other components, which disturb the analysis, due to their presence in larger 
quantities than the components of interest, e.g. proteins, fat, monosaccharides, lactose, 
sucrose and starch-derived oligosaccharides. Extraction, fractionation and enrichment may, 
therefore, be required prior to analysis. High-performance anion exchange chromatography 
(HPAEC) with pulsed amperometric detection (PAD) is the most frequently used method 
for analyzing HMOs and functional oligosaccharides.31,41,98-100 Although good resolutions 
are obtained by HPAEC-PAD, several disadvantages in view of the analysis of complex 
oligosaccharide mixtures are faced. These include the susceptibility of alkali-instable 
substituents to the eluent and the difficulty of a direct MS-coupling.101-103 For further mass 
information of the structural components, a supplementary method, such as matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), has to be 
applied.100,104 Accurate quantification of HMOs and functional oligosaccharides with 
techniques such as HPAEC is limited due to the fact that few standard substrates are 
commercially available or may even have to be self-produced by tedious extraction and 
purification. Usually approx. 10-20 HMOs  are taken as reference.31,41,98-100 The use of 
different standard-sets combined with the use of different analytical instrumentation and 
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methods complicates the comparison of literature data. As a consequence of these 
limitations, the quantitative determination of functional oligosaccharides added to food 
matrices is usually not performed on an individual oligosaccharide level. Their 
quantification is mostly based on the monosaccharide concentration, which is determined 
after enzymatic hydrolysis of the extracted oligosaccharides as defined in official methods 
(AOAC 997.08 for FOS and AOAC 2001.02 for GOS).97,105 The lack of knowledge and 
quantifiability of individual oligosaccharides is, however, disadvantageous for studying 
their structure-function relationship and quality control. Furthermore, it delays the legal 
approval of functional food ingredients, which requires advanced scientific proof of 
functionalities and quantities.106  
The coupling of separation techniques with on-line mass spectrometry is of increasing 
interest for the application to complex oligosaccharide mixtures. HPLC-Chip/MS on porous 
graphitized carbon material has been introduced for the analysis of HMOs and enabled the 
annotation of approximately 200 oligosaccharide structures.40 In other research fields 
dealing with complex oligosaccharides (e.g. enzymatic digests of plant polysaccharides), 
capillary electrophoresis with laser-induced fluorescence detection (CE-LIF) and            
CE-MS-hyphenation showed to be promising analytical tools of high sensitivity.103,107,108  
 
Oligosaccharide analysis in feces and urine 
Analysis of oligosaccharides in baby feces and urine provide information on the 
gastrointestinal metabolization. Their analysis does not solely focus on one or several 
structural components or bacteria as is the case for in vitro studies.11 Several studies have 
been performed on the recovery of HMOs and their metabolization products or of prebiotic 
oligosaccharides from infant formula in baby feces and urine. They are summarized in 
Table 3.28,64,109-113 The studies performed mainly focus on HMOs and only few studies deal 
with the gastrointestinal fate of prebiotic oligosaccharides. Most studies on the fecal 
recovery of HMOs and their metabolization products were performed in the 1980’s and 
early 1990’s, when analytical oligosaccharide screening was not yet established as a 
standard laboratory method. The sample throughput was limited, as preparative 
chromatography, which is time-consuming and requests large sample amounts, preceded 
analysis (usually 1H NMR or FAB-MS).110-112 The results obtained were diverse. In some 
studies exclusively HMOs were reported to be present in feces or urine,28,109,110 whereas in 
other studies blood group characteristic oligosaccharides were detected.111-113 Several 
factors, such as time of sampling, time of birth and genetic characteristics may influence 
the presence of oligosaccharides in feces and urine (Table 3). Unfortunately, the 
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oligosaccharide sets, as initially present in the respective diet, were mostly not studied. In 
case of breast milk, the HMO-composition was assumed, according to serological tests 
performed.110-113 Although indications were made on the gastrointestinal metabolization of 
diet-related oligosaccharides, no general conclusions could be drawn. 
 
Table 3. Overview on studies performed on the recovery of HMOs and diet-related oligosaccharides in baby feces 
and urine. n: number of participants. BG: blood group. Neu5Ac: sialic acid 
 
matrix n BG birth age sampling feeding  recovery year ref. 
feces 1  A term 1 month breast milk 
(secretor) 
BGA-oligosaccharides 1984 111 
feces 1  B term 3.5 months breast milk 
(non-secretor) 
non-secretor HMOs 1988 110 
feces 2  A preterm 1 week 
 
breast milk 
(pooled) 
non-secretor HMOs 
 
1988 112 
1 2 months BGA- oligosaccharides 
feces 4 
5 
 
A/0 
A/0 
 
preterm 
term 
 
1-5 weeks 
4-11 weeks 
 
breast milk 
(pooled) 
rate of free to bound  
Neu5Ac increased in 
time 
 
1991 113 
1 A term 2/4/6/8/10/12 
months 
breast milk 
(pooled) 
HMO- /BGA-content 
decreased in time  
feces 6 
 
n.d. term 1 month 
 
breast milk 
 
HMOs 
 
2001 28 
1 n.d. n.d. n.d. formula few unknown 
oligosaccharides 
feces 22 n.d. term 1 month formula 
(GOS/FOS 9:1 
0.8 g/dL) 
GOS/FOS 2005 64 
urine  9 n.d. preterm approx. 24days breast milk 
 
HMOs 1996 109 
9 formula 
(based on  
bovine milk) 
sialylated 
oligosaccharides  
(from  bovine milk) 
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Thesis outline 
As stated above, little is known on the gastrointestinal metabolization of diet-related 
oligosaccharides. A reason for that is the diversity of study approaches and analytical 
methods used.  The aim of this PhD research was to provide advanced knowledge on the 
characteristics and gastrointestinal metabolization of functional oligosaccharides with 
(potential) relevance for infant nutrition, by firstly introducing novel analytical techniques 
for the analysis of these oligosaccharides and secondly applying them for a selection of 
samples originating from in vivo and in vitro studies.  
In chapter 2, CE-LIF is introduced as a suitable analytical tool for the qualitative and 
quantitative analysis of GOS, as extracted from complex food matrices. The on-line 
coupling of CE-LIF to a mass spectrometer is applied for the analysis of HMOs in human 
milk and baby feces in chapter 3 and two novel HMO-degradation products are identified 
in the feces by means of MSn. 
Next, fecal oligosaccharide profiles of preterm born, two months old breast- and formula-
fed babies are studied in chapter 4 and diet- and genetically dependent trends are pointed 
out. In chapter 5, the fecal oligosaccharide profiles from breast-fed babies and the HMO-
profiles of the corresponding breast milks are followed during the first six months 
postpartum. Three distinct stages of fecal oligosaccharide profiles are highlighted and blood 
group characteristic HMO metabolization products are identified by CE-LIF(-MSn). The 
impact of the gastrointestinal development on the metabolization of diet-related 
oligosaccharides is discussed. 
Chapters 6 and chapter 7 deal with the complex konjac glucomannan polysaccharide and 
oligosaccharide sets obtained after enzymatic digestion of the polysaccharide with        
endo-β-(1,4)-mannanase and endo-β-(1,4)-glucanase, which are potential prebiotic 
substrates. In chapter 6, the in vitro fermentation of the konjac glucomannan 
polysaccharide and oligosaccharides is described and in chapter 7, the structural 
composition of the oligosaccharides, which emerged during in vitro fermentation, as well as 
the enzymatically produced oligosaccharide sets are studied. 
Finally, the results obtained in this research are discussed in chapter 8 and their impact on 
further research towards the gastrointestinal metabolization of feeding-related 
oligosaccharides is reflected.  
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Abstract 
The analysis and quantification of (galacto)oligosaccharides from food matrices demands 
both a reproducible extraction method as well as a sensitive and accurate analytical method. 
Three typical matrices, namely, infant formula, fruit juice, and a maltodextrin-rich 
preparation, to which a commercial galactooligosaccharide mixture was added in a product 
concentration range from 1.25 to 30%, served as model substrates. Solid-phase extraction 
on graphitized carbon material upon enzymatic amyloglucosidase pretreatment enabled a 
good recovery and a selective purification of the different galactooligosaccharide structures 
from the exceeding amounts of particularly lactose and maltodextrins. With the 
implementation of capillary electrophoresis in combination with laser-induced fluorescence 
(CE-LIF) detection, a new possibility facilitating a sensitive qualitative and quantitative 
determination of the galactooligosaccharide contents in the different food matrices is 
outlined. Simultaneous monitoring and quantifying prebiotic oligosaccharides embedded in 
food matrices presents a promising and important step toward an efficient monitoring of 
individual oligosaccharides and is of interest for research areas dealing with small 
quantities of oligosaccharides embedded in complex matrices, e.g., body liquids. 
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Introduction 
Prebiotic carbohydrates, mainly nondigestible oligosaccharides (NDOs), play a significant 
role in the fortification of food products with beneficial gut flora components. The amount 
of prebiotics added to a food matrix is usually low, because studies have revealed already 
beneficial effects by the ingestion of 2-10 g of NDOs/day.1-3 Evenmore, a supplementation 
with doses ≥ 15 g of NDOs/day may lead to abdominal pain, flatulence, and even 
diarrhea.4,5 Maltodextrins, lactose, and monomeric sugars are the common predominating 
carbohydrates in these food matrices, for example, in powdered milk-based products.6 
Therefore, quality control of functional food products is a demanding field regarding the 
sensitivity and accuracy of analytical methods. The presence of such methods is 
indispensable, and this need has even been reinforced by the recently established European 
Union (EU) Health Claim Regulation (EG 1924/2006), which demands scientific 
substantiation of the functional ingredients, concerning both their gastrointestinal 
functionality and quantity.7 Galactooligosaccharides are prominent representatives of 
prebiotic carbohydrates, implying their fermentability by beneficial intestinal bacteria and 
selective stimulation of the latter as well as the resistance to acid hydrolysis, enzymatic 
digestion, and absorption in the upper gastrointestinal tract.8 The frequent use of 
galactooligosaccharides in all kind of processed foods, such as acidic beverages, fermented 
milk products, confectionery, or baby food, can be related to their low caloric value, 
bulking capacity, low sweetness, noncariosity, excellent solubility, and heat and storage 
stability, even in an acidic environment.9-11 Galactooligosaccharides are usually produced 
from lactose. The incubation of lactose with fungal, yeast-derived, or bacterial                   
β-galactosidases enables transglycosylation reactions and results in a complex mixture of 
reducing as well as, in minor amounts, non-reducing galactooligosaccharides or also called 
trans-galactooligosaccharides (DP2-DP ≥ 4). In these mixtures, lactose, glucose, and 
galactose can be present as well, because of the fact that galactooligosaccharides are kinetic 
intermediates and also substrates for hydrolysis during production.9,12 The DP and linkages 
formed are strongly dependent upon the reaction conditions and enzymes used.11             
The existing Association of Official Analytical Chemists (AOAC) method for the 
determination of trans-galactooligosaccharides in food products [AOAC 2001.02]6 is based 
on high performance anion-exchange chromatography-pulsed amperometric detection 
(HPAEC-PAD) analysis of galactose after β-galactosidase incubation of the 
galactooligosaccharide-containing matrix, yielding the total amount of galactose present in 
the mixture. According to this AOAC method, the term galactooligosaccharides is defined 
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to include dimers (excluding lactose) and larger oligosaccharides. Although being a robust 
method, it does not provide any information on the individual oligosaccharides present. 
Such information would be highly desirable in view of the vast variability in structural 
features characteristic for galactooligosaccharide mixtures because the composition is used 
as a quality and identification parameter. Another disadvantage of the AOAC method is 
that high lactose contents present in the food matrix tend to influence the measurement of 
galactose.6 Capillary electrophoresis with laser-induced fluorescence detection (CE-LIF)  
has been shown to be a powerful and sensitive technique in the separation of                       
9-aminopyrene-1,4,6-trisulfonate (APTS)-tagged oligosaccharides derived from plant 
polysaccharides and other natural sources.13-15 Therefore, this method could also be of great 
value for the analysis of prebiotic oligosaccharides in complex matrices. Labeling 
carbohydrates with the fluorescent dye APTS is based on a reductive amination reaction.16 
APTS carries three negative charges, which provides the neutral carbohydrates with charge, 
a prerequisite for electrophoretic separation.17 Each carbohydrate molecule is attached to 
one fluorescent molecule. When an internal standard is included, CE-LIF is, therefore, a 
potential technique for quantitative analysis. Because APTS is only attached to reducing 
oligosaccharides, non-reducing oligosaccharides are not included in this derivatization 
method. Galactooligosaccharide mixtures are usually composed of predominantly reducing 
oligosaccharides. They are often applied in combination with fructooligosaccharides 
(mainly non-reducing oligosaccharides), e.g., in infant formula.18 A labeling of exclusively 
reducing oligosaccharides thus guarantees a selective detection of galactooligosaccharides 
in these mixtures. However, the small amount of non-reducing galactooligosaccharides is 
not included in the analysis and has to be taken into account differently (e.g., by means of a 
calibration curve). Besides a preliminary quantitative screening in the beginning of          
the 1990s, in which APTS was introduced as the fluorescent dye of choice for CE-LIF 
analysis of carbohydrates,16 the quantitative use of CE-LIF has only been studied in detail 
for monosaccharides and not for oligosaccharides.14,15 Characterization and quantification 
of galactooligosaccharides from food matrices in the first instance demands a reproducible 
extraction and purification from the predominating and disturbing components present, 
mainly monomers, lactose, and maltodextrins. To evaluate the suitability of CE-LIF as an 
analysis tool for commercially available galactooligosaccharides, the first part of this 
research is aimed at a reproducible extraction of galactooligosaccharides from complex 
food matrices. It focuses on the fine-tuning of a solid-phase extraction (SPE) method for 
oligosaccharides, on the basis of the use of graphitized carbon cartridges,19 in combination 
with an enzymatic amyloglucosidase pretreatment to remove maltodextrins.20 Next, CE-LIF 
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is tested for a reproducible quantification of oligosaccharides in general and, more 
specifically, galactooligosaccharides extracted from food matrices. 
 
Materials and Methods 
Vivinal GOS, Vivinal GOS-containing samples, enzymes and chemicals     
Vivinal GOS syrup, Vivinal GOS/maltodextrin preparation, and infant formula were 
provided by FrieslandCampina DOMO (Zwolle, The Netherlands). The Vivinal GOS syrup 
(reference material) was prepared by a β-galactosidase from Bacillus circulans and 
specified by the supplier with a dry matter of 75% (w/w), of which 59% (w/w) is 
galactooligosaccharides, 21% (w/w) is lactose, 19% (w/w) is glucose, and 1% (w/w) is 
galactose, as determined according to AOAC 2001.02.6 The galactooligosaccharides 
present in the mixture are predominantly reducing oligosaccharides, with                       
[β-D-Gal-(1,4)-β-D-Gal-(1,4)]n-Glc being the most abundant structural element for 
oligosaccharides of DP ≥ 3, as determined by nuclear magnetic resonance (NMR) 
analysis.21 Non-reducing oligosaccharides are present predominantly in the form of dimers; 
β-D-Gal-(1,1)-β-D-Glc and β-D-Gal-(1,1)-α-D-Glc make up about 3% of the 
oligosaccharide mixture.21 The Vivinal GOS/maltodextrin preparation was specified by the 
supplier to be composed of 48.5% (w/w) maltodextrins, 28.5% (w/w) Vivinal 
galactooligosaccharides, 10.1% (w/w) lactose, and 9.7% (w/w) mono- and other 
disaccharides. For infant formula, an approximate content of 3% (w/w) Vivinal 
galactooligosaccharides was given. No further sample specification was provided. Lactose 
(40%, w/w) and maltodextrin (10%, w/w) were found to be present in this matrix by 
analysis in our lab, using HPAEC-PAD. The fruit juice is a commercial product and was 
obtained from a local shop. It is specified to contain 12.3% (w/v) sugars (glucose, fructose, 
and saccharose) and 1.25% (w/v) Vivinal galactooligosaccharides.  
Amyloglucosidase (source: Aspergillus niger) was obtained from Boehringer (B208469, 
Boehringer, Mannheim, Germany). Monosaccharides and oligosaccharides used as 
standards were D-xylose (Sigma-Aldrich, St. Louis, MO), α-L-1,5-arabinooligosaccharides 
DP3-DP5 (Megazyme, Bray, Ireland), maltodextrin-oligosaccharides                       
(α-D-(1,4)-glucooligosaccharides) DP3-DP5 (Sigma-Aldrich, St. Louis, MO), and 
cellodextrin-oligosaccharides (β-D-(1,4)-glucooligosaccharides) DP3-DP5 (Sigma-Aldrich, 
St. Louis, MO). All other chemicals used were of analytical grade. 
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Fractionation  of Vivinal GOS                                              
Vivinal GOS was fractionated according to its DP by gel filtration on a BioGel P2 column 
(26 mm x 900 mm, 200-400 mesh; Bio-Rad, Hercules, CA). A total of 300 mg of 
VivinalGOS syrup dissolved in 10 mL of water was applied to the column and was eluted 
with millipore water (1.5 mL/min) at 60 ºC using an Akta Explorer system (GE Amersham, 
Uppsala, Sweden). The column efflux was first led through a refractive index (RI) detector 
(Shodex RI-72, Showa Denko K.K., Tokyo, Japan) before it was collected in fractions of     
5 mL. The fractions were pooled according to the RI profile and freeze-dried.  
 
Oligosaccharide extraction, enzymatic pretreatment and purification                  
For extraction of galactooligosaccharides, 100 mg of Vivinal GOS-containing matrix, 
respectively, infant formula, fruit juice, or the Vivinal GOS/maltodextrin preparation, was 
suspended in 50 mL of boiling water and kept at 80 ºC for 30 min [AOAC 2001.02].6     
Fruit juice was adjusted to pH 7 prior to extraction. In the case of dominant levels of 
maltodextrins being present, specific enzymatic degradation of these maltodextrins using 
148 μL of a 1% (w/v) amyloglucosidase solution per 1 mg/mL substrate solution was 
performed in 0.2 M sodium acetate (NaOAc) buffer (pH 4.5, 55 ºC, 24 h). The enzyme 
dosage was chosen according to the best result in the oligosaccharide profile and 
maltodextrin degradability obtained after testing different substrate/enzyme ratios. The 
enzyme was inactivated (10 min, 100 ºC), and the sample was centrifuged (5 min, 10000g, 
room temperature). High levels of mono- and dimers present in the food matrix or resulting 
from enzymatic degradation of maltodextrins were removed by SPE on nonporous 
graphitized carbon cartridges (bed weight, 150 mg; tube size, 4 mL; Alltech, Deerfield, IL). 
The cartridges were washed with 1.5 mL of 80:20 (v/v) acetonitrile (ACN)/water 
containing 0.1% (v/v) trifluoroacetic acid (TFA) followed by 1.5 mL of millipore water. A 
total of 1 mL of the GOS-containing sample was loaded onto the cartridge, which was 
eluted with 1.5 mL of water. Subsequently, mono- and dimers were eluted with 1.5 mL of 
2-5% (v/v) aqueous ACN, depending upon the sample matrix. Sample flowthrough, wash 
water, and mono- and dimers were trapped as one fraction. The oligosaccharides were 
eluted with 1.5 mL of 25:75 (v/v) ACN/water containing 0.05% (v/v) TFA and trapped as a 
separate fraction. The fractions were dried under a stream of air. The fraction containing 
mono- and dimers was rehydrated with 1mL of millipore water, and the oligosaccharide-
containing fraction was rehydrated with 500 μL of millipore water. The sample matrices 
(infant formula, fruit juice, and Vivinal GOS/maltodextrin preparation) were extracted in 
duplicate. 
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Analytical methods 
MALDI-TOF MS 
For matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) of oligosaccharides, an Ultraflex workstation (Bruker Daltronics, 
Bremen, Germany) equipped with a nitrogen laser of 337 nm was used. The measurement 
was performed in the positive mode. After a delayed extraction time of 200 ns, the ions 
were accelerated with a 25 kV voltage. The data were collected from averaging 100 laser 
shots, with the lowest laser energy necessary to obtain sufficient spectra intensity. The mass 
spectrometer was calibrated with a mixture of maltodextrins (AVEBE, Veendam,           
The Netherlands; mass range of 527-2309 Da) as sodium adducts. Samples (1mg/mL) were 
desalted with AG 50W-X8 resin (H+ form; Bio-Rad, Hercules, CA). The desalted samples 
(1 μL) were mixed directly on a MS target plate with 1 μL of matrix solution consisting of 
an aqueous solution of 2,5-dihydroxybenzoic acid (10 mg/mL; Bruker Daltonics, Bremen, 
Germany). The mix was dried under a stream of warm air. 
 
HPAEC  
HPAEC of lactose was performed on a Dionex ISC 3000 system (Dionex, Sunnyvale, CA), 
equipped with a Dionex Carbopac PA-1 column (2 mm x 250 mm) in combination with a 
Carbopac PA-1 guard column (2 mm x 50 mm). Samples (20 μL) were injected by means 
of a Dionex ISC 3000 autosampler. Elution was performed at 0.3 mL/min at room 
temperature using a gradient of 0-150 mM sodium acetate in 100 mM sodium hydroxide 
(NaOH) for 15 min. Each elution was followed by a washing step (10 min, 1 M NaOAc in 
100 mM NaOH) and an equilibration step (15 min, 100 mM NaOH). Detection was 
performed using a Dionex ED40 detector in the PAD mode. 
 
CE-LIF  
Separation of APTS-derivatized carbohydrates was performed using a ProteomeLab PA 
800 characterization system (Beckman Coulter, Fullerton, CA) equipped with a polyvinyl 
alcohol-coated capillary (50 μm x 50.2 cm). Detection was performed with a LIF detector 
(Beckman Coulter, Fullerton, CA) at an excitation wavelength of 488 nm and an emission 
wavelength of 520 nm after 40 cm capillary length. The capillary was pressure-rinsed with 
water (3 min, 30 psi) and separation buffer (2 min, 30 psi), composed of 25 mM acetate 
(pH 4.75) containing 0.4% (v/v) polyethylene oxide. The vials of the rinsing solutions were 
changed every 12 samples. Supplementary to the pressure rinsing, the capillary was rinsed 
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with water by applying current (20 min, 30 kV) to prevent sample carryover. Samples were 
loaded hydrodynamically (4 s at 0.5 psi, representing approx. 14 nL of sample solution) on 
the capillary, which was kept at 25 ºC. Separation was performed in the reversed polarity 
mode (20 min, 30 kV) in separation buffer.                                                                                       
Sample preparation for CE-LIF analysis 
Samples for CE-LIF were prepared using the ProteomeLab Carbohydrate Labeling and 
Analysis Kit (Beckman Coulter, Fullerton, CA). A total of 2 nmol of xylose was added as 
an internal standard and mobility marker to the samples (0.02-0.05 mg) instead of the         
5 nmol of maltose internal standard proposed by the guidelines of the kit. This mixture was 
dried using a SpeedVac Concentrator Savant ISS110 (Thermo Electron Corporation, 
Waltham, MA). The mono- and oligosaccharides present in the dried sample were 
derivatized with 2 μL of APTS and 2 μL of sodium cyanoborohydride and, afterward, filled 
up to 50 μL by millipore water. For CE-LIF, the samples were diluted 10-40 times. 
 
Results and Discussion 
Composition of Vivinal GOS 
Vivinal GOS syrup (75% DM) was used as a reference in this study. For characterizing the 
reference material, pools of Vivinal GOS were prepared by fractionation on BioGel P2 
size-exclusion material (Figure 1A). The pools each consisted of saccharides of one DP, 
with minor contamination of the preceding and following DP, as determined by        
MALDI-TOF MS. Evaluating the proportion (%) of the respective pool areas (RI response) 
in relation to the total area (representing the total carbohydrate content of Vivinal GOS) 
resulted in 23% pool 1 (P1; DP1), 39% pool 2 (P2; DP2), 23% pool 3 (P3; DP3),            
10% pool 4 (P4; DP4), 4% pool 5 (P5; DP5), and 1% pool 6 (P6; not considered for 
analysis). HPAEC analysis of Vivinal GOS resulted in a lactose content of 20%, which 
allowed us to define pool 2 as a mixture consisting of 20% lactose and 19% 
galactooligosaccharide dimers. The addition of components results in a 
galactooligosaccharide content of 57%, which is close to what was specified by the supplier 
(59%). In view of the subsequent extraction of Vivinal galactooligosaccharides from 
complex matrices and analysis and quantification by CE-LIF, it is of prime importance to 
analyze this reference galactooligosaccharide mixture itself by CE-LIF. The 
electropherograms of the DP1-DP5 pools, derivatized with the fluorescent dye APTS, 
showed distinct migration times (Figure 1B).  
Analysis of GOS by CE-LIF 
 
 31 
 
 
Figure 1. (A) Size-exclusion chromatography profile (RI response) obtained by BioGel P2 column separation of 
Vivinal GOS. P1-P6 = pool 1-6. (B) CE-LIF electropherograms of BioGel P2 pools. Pools representing DP1 and 
DP2 were diluted ten times before CE-LIF analysis. 
 
Although a separation according to the Mw of the molecules is known for CE-LIF,14 one 
has to accept a narrow time window of peak overlap in the beginning and end of the 
respective DP pools, as is visible for the last abundant peak of the DP3 pool and the first 
abundant peak of the DP4 pool. This may also slightly influence the subsequent 
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quantification. In the present case, the overlapping peak was accounted for DP3 because the 
DP3 peak is more abundant than the respective DP4 peak. With increasing DP, increased 
numbers of peaks were found as was expected for complex transgalactosylation products, 
indicating the gradual extension of oligosaccharides formed by the β-galactosidase used.   
A good peak resolution was obtained for the respective DPs. The presence of at least          
seven oligosaccharides could be found for the pool representing DP3, with at least ten for 
DP4 (pool 4) and at least eight for DP5 (pool 5) (Figure 1B). Our findings are comparable 
to those by Coulier et al.21 These authors annotated seven reducing DP3 oligosaccharides 
by NMR spectroscopy after isolation using size-exclusion chromatography (SEC) and 
hydrophilic interaction liquid chromatography (HILIC), as well as methylation analysis. In 
addition, four non-reducing minor oligosaccharides were tentatively assigned.21 The 
standard APTS-labeling conditions advised by the manufacturer (60 ºC, 1.5 h) were applied 
in this study. Testing different labeling conditions (change of derivatization time and 
temperature and APTS concentration) from those indicated, showed that the conditions set 
by the manufacturer were most optimal.  
 
Extraction of galactooligosaccharides from complex matrices 
Three different matrices (infant formula, fruit juice, and Vivinal GOS/maltodextrin 
preparation) were chosen to study the extractability and purification of Vivinal 
galactooligosaccharides added during the production process. The amount of 
galactooligosaccharides specified for these matrices was determined by the supplier 
according to the total galactose content after enzymatic hydrolysis of the 
galactooligosaccharides with β-galactosidase [AOAC 2001.02].6 The crude aqueous sample 
extracts obtained after heat treatment (80 ºC, 30 min) yielded electropherograms showing a 
number of dominating peaks representing monomers (t = 4-4.5 min) and/or lactose              
(t = 4.8 min), as exemplified for infant formula (curve I in Figure 2A). The large peaks 
caused an unstable baseline, and peaks resulting from oligosaccharides (t = 5-6.5 min) were 
hardly visible. For the precise analysis of the galactooligosaccharides, the aqueous sample 
extracts were loaded on cartridges filled with nonporous graphitized carbon material, for 
which the capability to separate carbohydrates stepwise after elution by an organic solvent 
is known.19 The concentration of the organic solvent applied (ACN) had to be adjusted for 
the different types of samples [2% (v/v) ACN for the Vivinal GOS/maltodextrin 
preparation and 5% (v/v) ACN for infant formula and fruit juice] to remove selectively the 
high amounts of mono- and/or dimers and not to affect the galactooligosaccharides ≥ DP3, 
which were used later on for quantification. CE-LIF analysis of the APTS-derivatized 
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galactooligosaccharide fractions showed an improved resolution of oligomeric peaks 
compared to the electropherograms, resulting from the initial aqueous extracts. However, 
maltodextrin-containing samples showed clearly the comigration of peaks originating from 
maltodextrin and galactooligosaccharides, as shown for infant formula (curve II in      
Figure 2A). Maltodextrins in food matrices can be removed by enzymatic incubation with 
amyloglucosidase.20 Applying the enzymatic pretreatment for the removal of maltodextrins 
prior to mono- and dimer removal in sample matrices containing Vivinal 
galactooligosaccharides was successful. The peak profile of oligomeric structures was 
comparable to the Vivinal GOS reference, as shown for infant formula in curve III in 
Figure 2A and curve I Figure 2B. As expected, the incubation of the 
galactooligosaccharide pools with amyloglucosidase did not result in any breakdown of 
galactooligosaccharides. Similar to the removal of maltodextrins, an appropriate enzymatic 
incubation would be necessary for matrices containing other disturbing reducing 
oligosaccharides. The quantitative recovery of galactooligosaccharides was investigated by 
standard addition. To the crude aqueous sample extract of infant formula, a known amount 
of Vivinal GOS was added. The standard addition yielded a recovery of 90% in the CE-LIF 
electropherograms, which was considered good because of the fact that Vivinal GOS is a 
multiple component analyte. The fingerprints of the galactooligosaccharides extracted from 
all three sample matrices are shown in Figure 2C. From the matrices tested, 
galactooligosaccharides could successfully be extracted on the basis of the comparison to 
the reference substrate. For only the fruit juice, some small irregularities were found in the 
trimeric (▲ in Figure 2C) and tetrameric (■ in Figure 2C) structures, which may point to a 
different batch of Vivinal galactooligosaccharides added to this food matrix.  
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Figure 2. CE-LIF electropherograms of galactooligosaccharides. (A) (I) Aqueous extract infant formula, (II) 
infant formula after SPE pretreatment, and (III) infant formula after amyloglucosidase and SPE pretreatment. 
Curve I in panel B and curve III in panel C = curve III in panel A. (B) (II) reference Vivinal GOS (mirrored view), 
after amyloglucosidase and SPE pretreatment. (C) (I) Vivinal GOS/maltodextrin preparation and (II) fruit juice, 
both after amyloglucosidase and SPE pretreatment.  
L = lactose. (*) = internal standard xylose. (▲/■) = deviating peak ratio in trimeric/tetrameric structures. 
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The mole-based fluorescent derivatization allows for the evaluation of the DP ratios of the 
galactooligosaccharides extracted. The ratio of DP3/DP4/DP5 was 1:0.6:0.1, 1:0.5:0.1, 
and 1:0.5:0.1 for galactooligosaccharides extracted from infant formula, fruit juice, and 
Vivinal GOS/maltodextrin preparation, respectively. The abundancy ratio for the Vivinal 
GOS reference CE-LIF profile was 1:0.5:0.2 and similar to that found by others.21 
Summarizing, the reproducible extraction of Vivinal galactooligosaccharides from complex 
matrices is nicely demonstrated. 
 
Quantification of oligosaccharides by CE-LIF 
The use of an internal standard carbohydrate and the fact that one APTS molecule is linked 
to the reducing end of each molecule theoretically enable the quantification of the 
components present in the oligosaccharide mixtures. Kabel et al successfully proved the 
quantifiability of monomers ranging in a concentration from 0.5 to 50 nmol by CE-LIF, 
dealing with an error of about 10%.14 Evangelista et al started the relative quantification of 
oligosaccharides by analyzing different amounts of APTS-derivatized gluco-heptaose and 
gluco-tetraose, which resulted in a linear correlation between peak area and molar amount 
of sugar.16 However, focusing on oligosaccharides, their quantification accuracy on CE-LIF 
should be validated in more detail with an extended range of different oligosaccharides. 
Commercially available standards of single DPs (DP3, DP4, and DP5) of maltodextrin-, 
cellodextrin-, and arabinooligosaccharides were chosen, representing α-D-(1,4)- and          
β-D-(1,4)-linked hexose-oligosaccharides and α-L-(1,5)-linked pentose-oligosaccharides, 
respectively. The CE-LIF response was investigated for stepwise, twofold increasing 
amounts of oligosaccharides, relative to their accurate respective starting concentration at    
1 nmol. A good correlation was found between the relative amount of labeled 
oligosaccharides and the LIF signal obtained for concentrations up to approximately         
30 nmol (Figure 3). The single measuring points ranged within an average deviation of      
≤ 10% to the regression line (R2 = 0.98). Increasing the amounts of labeled carbohydrates 
above a concentration of 30 nmol showed partly increased deviation values (10-25%), 
which emphasizes the necessity of operating in low nanomole ranges for accurate 
quantification purposes.  
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Figure 3. Relative quantification of oligosaccharides by CE-LIF, regression line (R2 = 0.98). ( ) ara 3, (□) ara 4, 
and (■) ara 5 = arabinotri-, tetra-, and penta-ose. (◊) m 3, (∆) m 4, and (▲) m 5 = maltotri-, tetra-, and penta-ose. 
(+) c 3, (x) c 4, and (-) c 5 = cellotri-, tetra-, and penta-ose. 
 
Quantification of Vivinal galactooligosaccharides extracted from complex food 
matrices  
Having established an appropriate extraction method and having proven the quantifiability 
of oligosaccharrides by CE-LIF allows the quantitative determination of the 
galactooligosaccharides extracted from food matrices. To simulate extraction and 
purification conditions, the amyloglucosidase- and nonamyloglucosidase-incubated   
Vivinal GOS reference mixtures were subjected to graphitized carbon material for setting 
up a calibration curve (Figure 4A). The mono- and dimeric sugars were partly removed by 
elution with 2% (v/v) ACN. Solutions containing 30, 50, 90, 120, and 240 μg of 
galactooligosaccharides [as defined by AOAC]6 were derivatized with APTS and analyzed 
by CE-LIF. From the electropherograms obtained, the amount (nmol) of 
galactooligosaccharides representing DP3-DP5 was calculated on the basis of the internal 
standard xylose added. Similar to the quantification trial with standard oligosaccharides, the 
calibration curve exhibits a good linear range for low nanomole amounts (approximately   
3-10 nmol) of derivatized oligosaccharides (R2 = 0.98). One has to take into account that 
the effective total amount of carbohydrates labeled in these oligosaccharide mixtures was 
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higher, but only oligosaccharides of DP3-DP5 were taken into consideration for 
quantification because of a partial and sample-dependent removal of the mono- and dimers. 
For 120 μg of reference galactooligosaccharides [according to AOAC]6 approximately      
11 nmol of DP3-DP5 was calculated (left scale y axes of Figure 4A), whereas the total 
amount of carbohydrates labeled (including residual mono- and dimers) was roughly 
calculated to be approximately 30 nmol (right scale y axes of Figure 4A). It highlights 
again that quantification of oligosaccharides should not be performed with amounts of total 
carbohydrates exceeding 30 nmol. It is the reason for the exclusion of the data points for 
240 μg of reference galactooligosaccharides (approximately 55 nmol of total carbohydrate 
content) for setting up the calibration curve (Figure 4A). Consecutively, the amount of 
galactooligosaccharides (nanomoles of DP3-DP5) was calculated from the 
electropherograms of the respective food extracts. The value was then translated to the 
galactooligosaccharide content (micrograms) in the product using the calibration curve. 
Galactooligosaccharides extracted from fruit juice were also quantified using the reference 
calibration curve because the small structural irregularities were only of intra-DP 
importance but did not affect the inter-DP ratio of DP3/DP4/DP5 oligosaccharides, as 
shown (Vivinal GOS reference, 1:0.5:0.2; fruit juice extract, 1:0.5:0.1). Samples were 
extracted in duplicate, and mean values were determined (Table 1).  
 
Table 1. Galactooligosaccharide contents in selected food products quantified by CE-LIF and according to 
product specifications 
 
 galactooligosaccharides calculated 
by CE-LIF 
product specifications 
Infant Formula  2.59  ± 0.11 g/100g                      ±3 g/100g 
Fruit juice              1.20  ± 0.01 g/100mL 1.25 g/100mL 
Vivinal GOS/ maltodextrin  
preparation        
            27.87  ± 1.84 g/100g                   28.5 g/100g 
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Figure 4. Quantification of Vivinal galactooligosaccharides using CE-LIF. (A) calibration curve (R2 = 0.98). (B) 
Recovery of Vivinal galactooligosaccharides DP3 based on content specifications of reference Vivinal GOS. 
Dotted lines = 100% recovery. Reference values = 30, 50, 90, 120, and 240 μg. (■) AGOS 1 and (□) AGOS 2 = 
amyloglucosidase-pretreated Vivinal GOS (duplicate measurement). (▲) GOS 1 and (∆) GOS 2 = 
nonamyloglucosidase-pretreated Vivinal GOS (duplicate measurement).  
(*) Amount (micrograms) of galactooligosaccharides as defined by AOAC 2001.02.6 
 
The results (infant formula, 2.59 ± 0.11 g/ 100 g, approximately 3 g/100 g specified;       
fruit juice, 1.20 ± 0.01 g/ 100 mL, 1.25 g/100 mL specified; and Vivinal GOS/maltodextrin 
preparation, 27.87 ± 1.84 g/100 mL, 28.5 g/100 g specified) showed that, irrespective of the 
matrix, the introduced method is a promising way for quantifying galactooligosaccharides 
with a low intersample deviation. To validate this new method, extensive collaborative 
studies as described by de Slegte would be necessary.6 This was not performed in the scope 
of this research.  
Vivinal GOS, which was available as a reference, was used as a prebiotic in all food 
matrices used in this study. However, there may be cases in which quantification should be 
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performed while the prebiotic reference material is not available. This issue can also be of 
interest for the determination of prebiotic oligosaccharides in complex body liquids, such as 
gastrointestinal contents and feces, to monitor the fate of prebiotic oligosaccharides in the 
human gastrointestinal tract. After unknown oligosaccharides were extracted and purified 
from the complex matrix, the peak migration times in the electropherogram should be 
assigned with the respective DP of the oligosaccharide in the first instance. This can be 
performed by MALDI-TOF MS after fractionation on size-exclusion material or by 
CE-LIF-MS coupling. The concentration of the respective peaks can subsequently be 
calculated on the basis of their Mw and CE-LIF area, related to the area of the internal 
standard used. As an example, the concentration of the DP3-DP5 structures present in the 
Vivinal GOS reference was determined, without using the calibration curve. The results 
were compared to the theoretical concentrations, which were determined on the basis of the 
BioGel P2 proportions (%) of DP3 (23% on DM), DP4 (10% on DM), and DP5 (4% on 
DM). The galactooligosaccharide reference solutions were investigated in their 
amyloglucosidase- and non-amyloglucosidase-pretreated forms, as exemplified for DP3 in 
Figure 4B. The theoretical amount (micrograms) of DP3 galactooligosaccharides 
calculated is represented by the x axis, whereas the DP3 galactooligosaccharides calculated 
(micrograms) from the CE-LIF response is indicated by the y axis in Figure 4B. The 
calculations were based on the internal standard xylose. The dotted line in Figure 4B 
represents the theoretical 100% recovery. DP4 and DP5 were quantified in the same way 
(data not shown). Remarkably, the data points belonging to the successively increasing 
concentrations of galactooligosaccharides were deviating to lower values with respect to the 
theoretical recovery to a small extent (Figure 4B). This results from the fact that one 
should stay in low nanomol ranges (≤ 30 nmol) for quantification. It may also result from 
an underestimation of peaks belonging to the respective DPs, because of the small overlap 
in the beginning and end of the DP pools, as was previously described. Quantifying 
complex oligosaccharides from scratch is possible, provided an appropriate sample cleanup 
and dilution is at hand. Recent studies on the lactose content of Vivinal GOS resulted in a 
concentration of only 10% lactose, because of the application of an improved gradient for 
HPAEC analysis,21 which allowed for the separation of lactose from other DP2 
components. Because dimers were not included for quantification in our study and sample 
specifications were based on AOAC 2001.02,6 these new data have no effect on our setup. 
However, the method should be reconsidered if DP2 oligosaccharides are of special 
interest. The same counts if non-reducing oligosaccharides are of importance, because they 
are not labeled by the fluorescent APTS.  
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With the method proposed, galactooligosaccharides could be selectively extracted, despite 
being embedded in complex food matrices in low amounts. The implementation of CE-LIF 
showed a promising possibility for the quantification of reducing oligosaccharides. The 
application of CE-LIF may be of high value for the investigation on residual prebiotic 
(galacto)oligosaccharides in complex body liquids, providing insight into the fate of these 
carbohydrates during their fermentation in the human gastrointestinal tract. 
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Abstract 
Mixtures of the complex human milk oligosaccharides (HMOs) are difficult to analyse and 
gastrointestinal bioconversion products of HMOs may complicate analysis even more. 
Their analysis, therefore, requires the combination of a sensitive and high-resolution 
separation technique with a mass identification tool. This study introduces for the first time 
the hyphenation of capillary electrophoresis (CE) with an electrospray mass spectrometer, 
capable to perform multiple MS analysis (ESI-MSn) for the separation and characterization 
of HMOs in breast milk and feces of breast-fed babies. Laser-induced fluorescence (LIF) 
was used for on- and off-line detections. From the overall 47 peaks detected in off-line    
CE-LIF electropherograms, 21 peaks could be assigned and 11 peaks could be tentatively 
assigned. The detailed structural characterization of a novel lacto-N-neo-tetraose isomer 
and a novel lacto-N-fucopentaose isomer was established in baby feces and pointed to 
gastrointestinal hydrolysis of higher-Mw HMOs. CE-LIF-ESI-MSn presents, therefore, a 
useful tool which contributes to an advanced understanding on the fate of individual HMOs 
during their gastrointestinal passage. 
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Introduction 
Still today, in times of rapid innovations in food technology with respect to nutritional 
needs, human breast milk is unambiguously the generally recommended form of nutrition 
for neonate infants.1-3 Human milk contains a broad range of bioactive components4 among 
them a complex mixture of oligosaccharides (3–19 g/L).5,6 Research on human milk 
oligosaccharides (HMOs) is challenging due to their enormous structural complexity, which 
is substantiated by the presence of a large number of isomers. HMOs contain a lactose (L) 
unit at their reducing end, elongated by N-acetylglucosamine (GlcNAc) ( (β1,3)-linked to 
the galactose (Gal) residue) as well as by consecutive linear or branched extension 
consisting of alternating Gals and GlcNAcs. The sugar units can be fucosylated (either 
(α1,2)- (α1,3)- or (α1,4)-linked) or sialylated (either (α2,3)- or (α2,6)-linked).7 So far, more 
than 100 structures have been unraveled in human milk.5,8,9 The structural composition of 
HMOs is closely related to their biological function (e.g. bifidobacterial stimulation, anti-
inflammatory properties).5,7,10-13 However, the exact relationship is not yet known. 
Referring to this, the gastrointestinal tract plays a key role as the location of possible 
bioconversion and brush border absorption of HMOs. Feces of breast-fed babies are rich in 
oligosaccharides14,15 and their analysis can give essential information on the fate HMOs 
undergo throughout the gastrointestinal tract passage. So far, only few publications have 
reported on the analysis of HMOs extracted from the feces of breast-fed babies.14-17 In the 
past, normal- and reversed-phase HPLC, high performance anion exchange 
chromatography and matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry analysis were the methods most frequently used for HMO analysis.18-21 
Nowadays, the hyphenation of effective separation techniques with an MS device plays an 
important role in the structural analysis of complex analyte mixtures.22 HPLC-Chip/TOF-
MS has been recently introduced as a potential analytical tool for the analysis of HMOs in 
breast milk.9,23 Capillary electrophoresis (CE) and CE-MS coupling are other state-of-the-
art methods, which recently show a tremendous development. They were introduced to a 
broad range of research fields (e.g. biomedical analysis) and are outstanding in view of 
separation efficiency and selectivity.22 Regarding the analysis of oligosaccharide mixtures, 
CE is well known for its high resolving power and sensitivity.24-27 Some commercially 
available HMO isomeric standards have even been successfully separated by CE, e.g. 
2’fucosyllactose (2’FL)/3’FL or lacto-N-fucopentaose I/II (LNFP I/II) .28-31 Laser-induced 
fluorescence (LIF) detection presents one of the most favorable and most frequently used 
ways of routine detection for carbohydrates separated by CE.32 The nonchromophoric 
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carbohydrates are commonly derivatized with a fluorophore, e.g. 9-aminopyrene-1,4,6-
trisulfonate (APTS) or 8-aminonaphtalene- 1,3,6-trisulfonate via reductive amination33,34 
prior to CE-LIF analysis. This results in a low-picomole sensitivity, mole-based fluorescent 
detection and the provision of charged groups, which is a prerequisite for electrophoretic 
separation.35 CE-LIF presents an attractive technique for the analysis of complex biological 
samples, but the identification of the migrating analytes depends on the analysis of 
reference standards, which are often expensive, difficult to obtain or even not available. 
Furthermore, co-migration cannot be excluded solely based on migration times of 
standards. CE-MS hyphenation presents an attractive way of overcoming these limitations. 
Some of the parameters applied for routine CE-LIF analysis have to be modified due to 
technical and compatibility limitations between CE and MS device, e.g. the extension of 
capillary length and the composition of the separation buffer.26,32,36-38 In contrast to          
LC-(UV/DAD)-MS, CE-LIF analysis implies a proceeding separation in the CE capillary, 
even after the LIF-detector window, due to the voltage set between cathode and anode at 
the MS interface. A solution for interlinking off-line CE-LIF analysis (no MS detector 
included) and CE-MS is the inclusion of an on-line LIF detector in front of the MS inlet to 
assure comparison between off-line CE-LIF electropherograms with MS base peak 
chromatograms. The first studies on the use of on-line CE-LIF-MS for the analysis of       
N-linked glycans showed promising results.37 This study introduces for the first time the 
hyphenation of ESI-MS with CE for the characterization of HMOs in breast milk and feces 
of breast-fed babies, simultaneously making use of an on-line LIF detector. Special 
attention was paid to the elucidation of a lacto-N-neo-tetraose (LnNT) and LNFP isomer 
not present in breast milk, but present in the feces of breast-fed babies. 
Materials and Methods 
Sample material, HMO reference material and chemicals 
Breast milk samples of five human individuals and fecal slurries (1:10 (w/v) in phosphate-
buffered saline) of three individual breast-fed preterm babies were provided by 
FrieslandCampina (FrieslandCampina, Deventer, The Netherlands). Preterm birth took 
place at 32 weeks of pregnancy. Feces were collected 22–24 days after birth. 3’FL, lacto-N-
tetraose (LNT), LNFP I-III, lacto-N-difucosylhexaose (LNDFH), fucosyllacto-N-hexaose II 
and a mixture composed of 3’sialyllactose, 6’sialyllactose and 6’sialyl-N-acetyllactosamine 
were purchased from Dextra Laboratories (Reading, UK). LNFP V was purchased from 
Sigma-Aldrich (St. Louis, MO). All other chemicals used were of analytical grade. 
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HMO extraction from breast milk and fecal extracts 
The extraction of carbohydrates from breast milk was accomplished as performed by Stahl 
et al20 and included a mild temperature treatment (30 min, 70 ºC), defatting at 4 ºC as well 
as a protein precipitation by adding the double amount (v/v) of cold ethanol. Diluted fecal 
slurries were kept overnight at 4 ºC and were filtered through a 0.22 µm membrane 
according to Moro et al,39 after a short enzyme inactivation (5 min, 100 ºC). The 
carbohydrates extracted from breast milk and fecal extracts were purified by SPE on 
graphitized carbon column cartridges (150 mg bed weight, 4 mL tube size; Alltech, 
Deerfield, IL).9 The cartridges were washed with 1.5 mL of 80/20 (v/v) ACN/water 
containing 0.1% (v/v) TFA followed by 1.5 mL of millipore water. One milliliter of the 
sample extract was loaded onto a cartridge, which was subsequently eluted with 1.5 mL 
millipore water to remove salts. Next, monomers and L were largely removed by eluting 
with 1.5 mL of an aqueous 2% (v/v) ACN solution. This fraction was not further considered 
for analysis. The remaining carbohydrates (HMOs) on the cartridge were eluted with       
1.5 mL of 40/60 (v/v) ACN/water containing 0.05% (v/v) TFA. The solution was dried 
under a stream of air and the dried sample was then rehydrated with 500 mL of millipore 
water. 
 
Off-line CE-LIF 
For CE analysis, SPE-extracted carbohydrates present were derivatized with the fluorescent 
APTS overnight at room temperature as reported elsewhere.24 Briefly, 1 nmol xylose was 
added to each sample volume (100–200 µL) as internal standard and mobility marker. The 
solutions containing the fluorescent derivatives were diluted twenty times before CE-LIF 
analysis. Off-line CE-LIF was performed on a ProteomeLab PA 800 characterization 
system (Beckman Coulter, Fullerton, CA), equipped with a LIF detector (excitation: 
488 nm, emission: 520 nm) (Beckman Coulter) and a polyvinyl alcohol-coated capillary 
(50 µm x 50.2 cm (Beckman Coulter), detector after 40 cm), kept at 25 ºC. The samples 
were loaded hydrodynamically (4 s at 0.5 psi, representing approx. 14 nL sample solution) 
on the capillary. Separation was performed in the reversed polarity mode (30 kV, 20 min) 
in the 25 mM acetate buffer containing 0.4% polyethylene oxide provided in the 
derivatization kit. Due to the low pKa of the sialic acid residues (pKa 2.6) and in order to 
provide the same pH as for CE-MS, the separation buffer was adjusted to pH 2.4 by adding 
1.2% (v/v) formic acid.36 Peaks were integrated manually using Chromeleon software 6.8 
(Dionex, Sunnyvale, CA). 
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On-line CE-LIF-ESI-MSn 
On-line CE-LIF-ESI-MSn experiments were performed on a P/ACETM System MDQ 
(Beckman Coulter). For the fluorescent detection, a Picometrics ZetaLIF discovery system 
was used (Picometrics, Toulouse, France) (excitation: 488 nm, emission: 520 nm). The LIF 
detection cell was placed approx. 25 cm from the ESI-MS source by an adjustable arm. 
Separation was performed on a fused silica capillary (50 µm x 85 cm (Beckman Coulter), 
capillary window fitted with an ellipsoid for LIF detection after 60 cm) in reversed polarity 
mode. LIF signals were sent to Beckmann 32Karat software via an Agilent SSXL4002 
converter (Agilent Technologies, Santa Clara, CA). Best separation results were obtained at 
20 and 15 kV in 0.3% (v/v) formic acid (pH 2.4) and a capillary temperature of 15 ºC, after 
sample injection at 10 psi for 2 s. The sample solutions containing the fluorescent 
derivatives were diluted four times or ten times before CE-LIF-MS analysis. The ESI-MS 
(LTQ ion trap, Thermo Fisher Scientific, Waltham, MA) was operated in the negative mode 
using a spray voltage of 1.9 kV and an MS-capillary temperature of 190 ºC. The end of the 
CE capillary was installed in front of the ESI source by leading it through a T-part designed 
in our laboratory38 and provided the coaxial addition of a sheath liquid 
(50/50 isopropanol/water) at 2 mL/min. Mass spectra were acquired from m/z 300 to 2000.       
MSn was performed in the data-dependent mode using a window of m/z 1 and collision 
energy of 35%. For increasing the S/N, ions of m/z 311, 314 and 329 were excluded from 
detection in MSn experiments. MSn data were interpreted using Xcalibur software 2.0.7 
(Thermo). Base peak chromatograms are shown in their smoothed forms. 
 
Results and Discussion 
Introducing on-line CE-LIF-MS for the analysis of breast milk and fecal samples 
Assuring the compatibility of CE separation and ESI-MS analysis requires the adaptation of 
several parameters commonly applied for off-line CE-LIF assays. In our system, it included 
the change of capillary material from neutral surface to fused silica36 and the introduction 
of a volatile separation buffer (formic acid 0.3% v/v, pH 2.4).32,38 Of main importance is the 
capillary length, which had to be extended considerably to a length of 85 cm in order to 
reach the MS inlet, leading to an on-going separation and longer migration times. In off-
line CE-LIF analysis, capillaries with a detection window after 40 cm are generally 
used.24,36-38 Placing an on-line LIF detector just in front of the MS inlet presents, therefore, 
an attractive means for transferring mass information to the electropherograms recorded by 
the off-line CE-LIF detector.37 In our system, this was accomplished by a Picometrics LIF 
CE-LIF-MSn of oligosaccharides in breast milk and baby feces
 
 49 
detection cell located on an adjustable arm, which was placed after 60 cm capillary length. 
An overview of the off-line and on-line CE-LIF electropherograms as well as the respective 
MS base peak chromatograms is shown in Figure 1A–E for a randomly chosen breast milk 
extract and a fecal extract of a breast-fed preterm baby.  
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Figure 1. APTS-derivatized HMOs extracted from breast milk (A–C) and feces of a breast-fed baby (D–F). (A, D) 
Off-line CE-LIF electropherograms. (B, E) On-line CE-LIF electropherograms. (C, F) MS base peak 
chromatograms. 
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Off-line CE-LIF resulted in the most detailed separation profile of the samples and could be 
well compared with the MS base-peak chromatograms. On-line LIF electropherograms 
showed some peak overlap, which was not the case for the MS base peak chromatograms, 
due to ongoing electrophoretic separation between LIF and MS detector. The time 
difference between on-line LIF peak detection and MS detection was 5 min, which is small 
compared with ≥ 10 min reported in earlier studies.26,36  
A sheath-flow interface was used for transferring liquid from the CE capillary outlet to the 
MS inlet. This results, however, in a dilution of the analyte and a reduced detection 
sensitivity.32 Appropriate MS detection requires thus a sample injection of increased 
pressure and length (2 psi/10 s in place of 0.5 psi/7 s) and less dilution of the solutions 
containing the APTS-derivatized carbohydrates compared with off-line CE-LIF (four times 
instead of twenty times). The higher injection volume resulted in overloaded on-line LIF 
electropherograms. Lowering the separation voltage from 20 to 15 kV and injecting a ten 
times instead of a four times diluted sample resulted in the most optimal on-line LIF 
separation profile, as shown for the electropherogram of breast milk (Figure 2).  
 
 
Figure 2. On-line CE-LIF electropherograms of APTS-derivatized HMOs extracted from breast milk. Separation 
conditions: FA buffer (0.3%, pH 2.4); separation-T: 15 ºC; injection: 2 s, 10 psi; (A) separation voltage: 20 kV, 
sample dilution: four times. (B) separation voltage: 15 kV, sample dilution: ten times. 1– 19: peaks detected; partly 
identified by assigning with MS data (Table 1). ∆t indicates the total sample migration range. 
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The overall oligosaccharide migration window was extended from 7.4 min (20 kV) to    
10.6 min (15 kV) (∆t = 3.2min). As a consequence, baseline separation was improved (e.g. 
peaks 9 and 10 or 11 and 12 (Figure 2)). Because of peak widening, which accompanies 
the separation at lowered voltage, now only the most abundant HMOs (Figure 2, peaks 1–3 
and 5, 7, 8, 10/11) resulted in peaks in the base peak chromatograms (data not shown) and 
thus implies less mass information. For breast milk, 19 peaks were detected in the on-line 
CE-LIF electropherograms, whereas 37 peaks were detected with off-line CE-LIF analysis. 
Off-line CE-LIF detection showed superior sensitivity, however, no mass information is 
obtained during off-line CE-LIF measurement. On-line LIF detection was, therefore, 
considered a valuable tool for properly interlinking the simultaneously obtained 
information on the m/z values of peaks to the corresponding off-line CE-LIF 
electropherogram. 
 
Characterization of breast milk and fecal extracts by CE-LIF-MS 
General overview 
The off-line CE-LIF electropherograms of a breast milk extract and of a fecal sample of a 
breast-fed baby are shown in Figure 3. The samples chosen represent the oligosaccharide 
patterns of individuals and the breast milk depicted does not correspond to the breast milk 
the preterm baby was fed with. However, the oligosaccharide pattern is representative for 
the patterns commonly observed in all samples extracted, taking into account individual 
variation. For both extracts, a detailed profile of major and minor peaks was obtained 
within a separation window of 4.5 min. Peaks observed between 3.5 and 4 min were 
defined as degradation products of the fluorescent APTS, as defined in an earlier study.38 
The peak marked with an asterisk (*) represents the internal standard and mobility marker 
xylose, which was added during sample preparation. For a better overview, peaks were 
classified as ‘‘low-Mw HMOs’’ (tmigr = 4.8–6.4 min), ‘‘intermediate-Mw HMOs’’         
(tmigr = 6.5–8 min) and ‘‘high-Mw HMOs’’ (tmigr > 8 min) in this study. The number of 
peaks detected were 37 and 36 for breast milk and fecal sample, respectively. Summing up, 
there were 47 different peaks present in the two electropherograms (peaks present in both 
electropherograms were counted once only). In total, 22 of these 47 peaks were assigned 
and 11 were tentatively assigned (Table 1), mainly by means of MS data obtained from on-
line CE-LIF-MS analysis and supported by MS2 fragmentation and the analysis of standard 
substrates. The mole-based labeling with APTS allowed to calculate the relative amounts of 
HMOs present per sample, based on the area of internal standard added (xylose, 1 nmol) 
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(Table 1). Monomers and lactose (L) were not considered as the sample pretreatment on 
graphitized carbon material and the ethanolic extraction of breast milk is connected with a 
loss of monomers and L.40,41 Components migrating t > 8 min could not be identified due to 
their low abundance. As the electrophoretic mobility is generally decreasing with the Mw 
of the oligosaccharides,24,38 these are most probably representing high-Mw HMOs. MS data 
gave first indications hereof (Table 1). 
 
Identification of oligosaccharides in breast milk and fecal extracts 
Obviously, HMOs are present in breast milk in adequate proportions for surviving the 
gastrointestinal tract passage and the overall CE pattern can be found back in the feces of 
breast-fed babies (Figure 3). Though, considering individual peaks of the 
electropherograms, marked differences were observed concerning their presence and 
relative abundance in breast milk and feces. The fecal samples originated from preterm 
babies. Preterm birth might imply differing gastrointestinal bioconversion compared with 
term babies. However, this was not studied within the scope of this research. 
 
 
Figure 3. Off-line CE-LIF electropherograms of APTS-derivatized HMOs extracted from (A) feces of a breast-fed 
baby and (B) breast milk. 1– 47: peaks detected; partly identified by assigning with MS data (Table 1).      
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Table 1. Structural assignment, composition and relative abundancy of peaks detected in representative off-/      
on-line CE-LIF electropherograms of APTS-derivatized HMOs extracted from breast milk and feces of a breast-
fed baby. APTS-derivatized carbohydrates detected in threefold negatively charged state by ESI-MS analysis      
(APTS = three protoneable sulfonate groups).  
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Low-Mw, neutral HMOs 
L was clearly the most abundant peak found in breast milk samples (Figure 3B, peak 4). 
Although in vivo studies reported immature lactase activity with preterm babies,42 the low L 
peak present in fecal extracts (Figure 3A, peak 4) indicated increased lactase activity at  
22–24 days after birth or a different gastrointestinal utilization, e.g. membrane transport by 
intestinal bacteria. It was not possible to define peak 5 (Figure 3B) present in breast milk, 
but not in the fecal extract, in spite of its abundance. MS base peak chromatograms of 
breast milk did not give any information here over. In fecal samples, a peak composed of a 
hexose and fucose unit (F-Hex) migrated at t = 4.92 min (Figure 3A, peak 6), which was 
present in much smaller quantities in breast milk. F-Hex was, therefore, considered as a 
fragment resulting from gastrointestinal degradation of HMOs. Within both, fecal extracts 
and breast milk, FL was the most abundant HMO (Figure 3, peak 9). Unfortunately, it was 
not possible in this study to distinguish between 3’FL (Gal-(β1,4)-[Fuc-(α1,3)]-Glc) and 
2’FL (Fuc-(α1,2)-Gal-(β1,4)-Glc), which is the more prominent isomer present in breast 
milk.7,31 Having a closer look on the HMOs up to an m/z 500 in breast milk, LNDFH 
(Figure 3B, peak 23), LNT (Figure 3B, peak 17), LNFP I/III (Figure 3B, peak 22),    
LNFP II (Figure 3B, peak 19) and difucosyllactose (DF-L) (Figure 3B, peak 13) were 
found to be prevailing (ratio 1:0.8:0.8:0.7:0.5). Within the fecal extract, these peaks were 
found to be present in a completely different ratio (ratio 1:0.1:1.7:0.4:0), indicating an 
active gastrointestinal bioconversion. The absence of DF-L within the fecal extract 
indicated gastrointestinal fucosidase activity (Figure 3A).11 On the contary, the remaining 
high abundance of FL and LNFP isomers in fecal extracts (Figure 3A, peaks 9 and 16, 19, 
22), which probably results from the enzymatic degradation of higher-Mw HMOs and 
DF-L, indicates a certain limitation of gastrointestinal fucosidase activity toward HMO 
structures. LNT, which is a nondecorated tetramer, seems to be a highly susceptible 
substrate for enzymatic attack, as it was present in only low amounts in the fecal extract 
(Figure 3A, peak 17). The peak ratios found were highly individual dependent, but always 
showed the same trend. 
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Acidic HMOs and intermediate-Mw HMOs 
Besides neutral HMOs, acidic HMOs decorated with one or more sialic acid groups form an 
important part of HMOs, although present in much lower amounts.5 Sialyllactose (SL), 
disialyllacto-N-tetraose (DS-LNT) and sialyllacto-N-tetraose (S-LNT) (Figure 3B, peaks 7 
and 19, 20) were identified in breast milk. Fecal extracts did not contain any SL or DS-LNT 
and showed a reduced abundance of S-LNT (Figure 3A, peak 20). These observations 
support results of in vivo studies on the gastrointestinal sialidase activity.11,15 The 
assignment of intermediate-Mw sialylated HMOs is complicated by the fact that their m/z 
values partly coincide with the m/z values of neutral HMOs. Therefore, peaks 26–32 and 
44–47 present in breast milk and fecal extracts (Figure 3) were assigned tentatively only. 
More detailed MSn analysis of these intermediate-Mw HMOs is necessary. In general, 
intermediate-Mw HMOs (Figure 3, peaks 24–47) showed a large complexity. A definite 
assignment was not possible so far due to frequent co-migration caused by the increasing 
number of possible isomers for these structures. 
 
Unknown HMOs 
The individual variation of HMOs in breast milk and their recovery in feces has been 
reported previously.7,17,23,31 However, in most cases the identification of HMOs was limited 
to the purified HMOs commercially available or connected with tedious preparative 
fractionation. CE-LIF-MS presents an efficient way for a sensitive and mole-based 
separation of the complex HMOs combined with a simultaneous availability of mass 
information. This is of special importance for the identification of peaks in the fecal extract, 
which were not present in breast milk. MS base peak chromatograms indicated the presence 
of a new LNFP structure (Figure 3A, peak 16) and a new LNT structure (Figure 3A,    
peak 11). Their characterization, based on MS fragmentations of commercially available 
HMO isomers, was of special interest in order to understand the gastrointestinal breakdown 
of HMO structures. It is, therefore, addressed separately. 
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Structural characterization of LNFP Y and LnNT Y in fecal extracts 
LNFP I, II, III and V 
Compared with breast milk, additional peaks were detected in the feces of breast-fed 
babies. In order to be able to characterize the unknown LNFP structure in fecal extracts of 
breast-fed babies (LNFP Y, m/z 431, Figure 3A, peak 16), CE-LIF-MS2 experiments on 
commercially available LNFP isomers were performed. Four isomeric LNFP structures are 
known to be present in breast milk,43,44 namely LNFP I, II, III and V (Figure 4A). The 
migration time of the unknown LNFP isomer did not coincide with any of the LNFP 
standards. MS2 fragmentation of underivatized LNFP isomers has been studied earlier.29,45 
Compared hereto, deviating MS2 fragmentation patterns were obtained in this study due to 
the APTS derivatization of the isomers LNFP I, II, III and V (Figure 4A). The fragments of 
interest were exclusively Y fragments.46 Due to the derivatization at the reducing end, no 
cross-ring cleavages were expected.29,44 LNFP I has a linear structure and m/z 328 
(corresponding to the loss of the terminal Fuc and Gal unit) is characteristic for this linear 
structure.29 For the branched LNFP II, III and V, m/z 328 demands the cleavage of two 
glycosidic linkages and explains the lower abundance of this fragment. Another main 
characteristic feature is the ratio of the fragments m/z 377 (loss of the terminal Gal; not 
possible for LNFP I) and 382 (loss of the Fuc residue). LNFP II and V, which both possess 
a (β3,1)-linked terminal Gal, show an abundance of m/z 377 < m/z 382, whereas for    
LNFP III, which possesses a (β4,1)-linked terminal Gal, the abundancy is                       
m/z 377 > m/z 382. LNFP V showed a predominating fragmentation ion of m/z 464     
[Gal-[Fuc]-Glc-APTS]. It is characteristic for a Fuc residue being attached to the reducing 
glucose (Glc) moiety and, therefore, such fragmentation is not possible for any of the other 
LNFP isomers.  
 
LNFP Y 
The fragmentation pattern of LNFP Y (Figure 3A, peak 16) did not coincide with any of 
the known LNFP isomers. Based on the assumption that LNFP Y results from 
gastrointestinal degradation, the structural characteristics of higher-Mw HMOs were 
studied. The unit –Gal-(β1,6)- frequently occurs at the branching points of these higher-Mw 
HMOs (exemplified for fucosyllacto-N-hexaose II (F-LNH II), m/z 553, Figure 4B). 
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Figure 4. (A) MS2 fragmentation patterns of APTS-derivatized standards LNFP I, II, III and V (m/z 431). (B) 
Identification of LNFP Y in feces of breast-fed babies. (B I) MS2 fragmentation pattern of m/z 431 (precursor ion: 
APTS-derivatized standard F-LNH II, m/z 553). (B II) MS2 fragmentation pattern of LNFP Y.                             
[2-] [3-]: charge state of APTS-molecule. 
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F-LNH II (m/z 553) was chosen for a MS-fragmentation study. The MS2 spectrum of        
F-LNH II contained the fragment m/z 431 (LNFP), which corresponds to the loss of a Gal 
and a GlcNAc unit at the branching point of F-LNH II. This m/z 431 fragment was of 
special interest as it contained the –Gal-(β1,6)- unit and was, therefore, subjected to a 
subsequent MS fragmentation. The fragmentation pattern showed m/z 377 > m/z 382, 
which is representative for its (β1,4)-linked terminal Gal (see LNFP III), and an increased 
signal for m/z 310 (Hex-APTS), deduced from its –Gal-(β1,6)- unit. The m/z–value 310 
was not prominently present in any other LNFP isomer fragmentation pattern (Figure 4B). 
LNFP Y in fecal extracts showed the same MS-fragmentation pattern and was, therefore, 
characterized as a breakdown product of higher-Mw HMOs, possessing a –Gal-(β1,6)- unit 
and a (β4,1)-linked terminal Gal (Figure 4B). LNFP isomers are present in considerable 
quantities in fecal extracts. The hydrolysis of the –GlcNAc-(β1,3)-Gal linkage at branching 
points of higher-Mw HMOs (Figure 4B) results in the formation of LNFP structures or 
larger structures further hydrolysable to LNFP. The –GlcNAc-(β1,3)-Gal- linkage was 
therefore assumed to be a preferred site of enzymatic attack during the gastrointestinal 
passage. Compared hereto, defucosylation was considered to be of minor importance. 
 
LNT, LnNT and LnNT Y 
Further characterization was as well needed for the unknown LnNT structure found in fecal 
extracts of breast-fed babies (LnNT Y, m/z 382, Figure 3A, peak 11). Two LNT isomers 
were detected in breast milk (Figure 3B, peaks 15 and 17). For breast milk, the presence of 
two LNT isomers is known, namely LNT (Gal-(β1,3)-GlcNAc-(β1,3)-Gal-(β1,4)-Glc) and 
LnNT (Gal-(β1,4)-GlcNAc-(β1,3)-Gal-(β1,4)-Glc), representing nonfucosylated LNFP I, II, 
V and LNFP III, respectively.7,9,47 The migration time and MS2 pattern of the LNT standard 
was the same as peak 17 (Figure 3). Peak 15 (Figure 3) was, therefore, assigned as LnNT 
and showed a very similar MS2 pattern to LNT, as expected. In the fecal extract, three 
isomeric LNT structures were detected (Figure 3A, peak 11 [LnNT Y], 15 [LnNT] and 17 
[LNT]). The MS2 pattern of LnNT Y differed from the ones of LnNT and LNT, but showed 
the same pattern as LNFP Y, including an abundantly present fragment m/z 310, typical for 
a Gal-(β1,6)-linkage. LnNT Y was therefore characterized as a defucosylated LNFP Y 
structure (Gal-(β1,4)-GlcNAc-(β1,6)-Gal-(β1,4)-Glc) and was present in lower abundance 
compared with LNFP Y (1:0.2, Table 1). 
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Concluding remarks 
The hyphenation of on-line CE-LIF with ESI-MS showed to be a useful tool for the 
annotation of off-line CE-LIF separation profiles of APTS-derivatized HMOs from breast 
milk. Analyzing fecal extracts of breast-fed babies gave a valuable insight in the fate of 
HMOs during the gastrointestinal passage. The identification of LnNT Y and LNFP Y, two 
new isomers not initially present in breast milk allowed to draw conclusions on the 
gastrointestinal degradation of higher-Mw HMOs.  
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Abstract 
So far, little is known on the fate of oligosaccharides in the colon of breast- and formula-fed 
babies. Using capillary electrophoresis with laser induced fluorescence detector coupled to 
a mass spectrometer (CE-LIF-MSn), we studied the fecal oligosaccharide profiles of 
twenty-seven two months old breast-, formula- and mixed-fed preterm babies. The 
interpretation of the complex oligosaccharide profiles was facilitated by beforehand 
clustering the CE-LIF data points by agglomerative hierarchical clustering (AHC). In the 
feces of breast-fed babies, characteristic human milk oligosaccharide (HMO) profiles, 
showing genetic fingerprints known for human milk of secretors and non-secretors, were 
recognized. Alternatively, advanced degradation and bioconversion of HMOs, resulting in 
an accumulation of acidic HMOs or HMO bioconversion products was observed. 
Independent of the prebiotic supplementation of the formula with galactooligosaccharides 
(GOS) at the level used, similar oligosaccharide profiles of low peak abundance were 
obtained for formula-fed babies. Feeding influences the presence of diet-related 
oligosaccharides in baby feces and gastrointestinal adaptation plays an important role 
herein. Four fecal oligosaccharides, characterized as HexNAc-Hex-Hex, Hex-[Fuc]-
HexNAc-Hex, HexNAc-[Fuc]-Hex-Hex and HexNAc-[Fuc]-Hex-HexNAc-Hex-Hex, 
highlighted an active gastrointestinal metabolization of the feeding-related 
oligosaccharides. Their presence was linked to the gastrointestinal mucus layer and the 
blood-group determinant oligosaccharides therein, which are characteristic for the host’s 
genotype. 
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Introduction 
Dietary prebiotic carbohydrates, such as human milk oligosaccharides (HMOs) and 
galactooligosaccharides (GOS), have a considerable impact on the neonatal gastrointestinal 
development. They influence the intestinal microbial colonization, which is responsible for 
the absorption and metabolisation of food ingredients, the establishment of the immune 
system, act as receptor analogs for pathogenic bacteria and prevent constipation.1-6 HMOs 
are a mixture of structurally complex, lactose-based oligosaccharides, composed of 
galactose (Gal), glucose (Glc), N-acetyl-glucosamine (GlcNAc) and frequently decorated 
by fucose (Fuc) and sialic acid (Neu5Ac).7 HMOs are present in human milk to an extent of 
3-19 g/L.7,8 The qualitative and quantitative composition of HMOs in breast milk is 
individual-dependent. Human milk can be classified according to the presence and absence 
of (α1,3/4)- and (α1,2)-fucosylated oligosaccharides, which indicate the activity of the 
Lewis (Le)- and Secretor (Se)-gene of the mother, with the latter being responsible for the 
expression of (α1,2)-fucosyltransferase (FUT2).5,8,9 Due to the complexity and individual-
dependent profile of HMOs it has not been possible to reproduce HMOs for the use as 
prebiotic supplements of breast milk replacers so far. Prebiotic GOS are structurally similar 
to HMOs, however, less complex. They are high in galactose content and carry a lactose 
unit at the reducing end. GOS are frequently added to infant formulas for term and preterm 
babies.10 Especially preterm infants (born after a gestational age of 24-36 weeks), are 
vulnerable for infections due to their impaired immunity.11 This results in frequent 
antibiotic use and this is one of the factors, which can distort the intestinal flora. Although 
human milk is the preferred feeding to these infants, human milk is not always available 
and substitution with preterm formula is important,12 e.g. in order to establish a balanced 
microflora. 
Several studies on the intestinal flora composition of term and preterm born babies have 
been performed in order to evaluate the value of HMOs in breast milk and prebiotic 
oligosaccharides in infant formula.13,14 However, little is known on the gastrointestinal fate 
of the individual oligosaccharide structures. Diet-related oligosaccharides can be traced 
back in baby feces, but they have rarely been studied in detail.14-16 A more profound 
knowledge of the gastrointestinal fate of oligosaccharides would be helpful for the 
understanding of the structure-function relation of feeding-related oligosaccharides. 
We recently introduced the hyphenation of capillary electrophoresis with laser-induced 
fluorescence detection to a mass spectrometer capable to perform multiple MS analysis 
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(CE-LIF-MSn) for the separation and characterization of HMOs in breast milk and feces of 
breast-fed babies.17  
In the present study we applied CE-LIF-MSn for a broad-range screening of 
oligosaccharides present in feces of breast-, formula- and mixed-fed preterm babies. The 
formula was either fortified with prebiotic GOS (0.4 g/dL) or did not contain any prebiotic 
oligosaccharides. Agglomerative hierarchical clustering (AHC) was performed on the    
CE-LIF data points in order to observe general trends. Subsequently, CE-LIF-MSn 
oligosaccharide profiles were described in order to study the individual-dependent and 
genetically determined gastrointestinal degradation of feeding-related carbohydrates. 
MSn analysis was applied for the identification of unknown oligosaccharides. 
 
Materials and Methods 
Set-up study and sample collection  
Twenty-seven fecal samples of approximately two months old preterm infants (born after 
27-35 weeks of gestation and a birth weight between 770 g and 2285 g) were selected from 
a clinical study on the investigation of the effect of the supplementation of preterm infant 
formula with prebiotic GOS or lactoferrin on the performance of preterm babies, which was 
set up and performed prior to our research intention. The study was performed at the     
level III neonatal intensive care unit of the Isala clinics, Zwolle, The Netherlands. Enteral 
feeding of the babies was started after birth as soon as possible and full enteral feeding was 
established 5-19 days after birth. Fecal samples were taken 6 weeks after full enteral 
feeding was established and samples were frozen at -20°C until analysis. The babies 
received either exclusively expressed human milk from their own mother (n = 5) or preterm 
infant formula (n = 6) [supplemented with 0.4 g/dL GOS (Frisolac prematuur, 
FrieslandCampina DOMO, Zwolle, The Netherlands), or without GOS (Frisolac prematuur, 
GOS replaced by maltodextrin), or supplemented with 0.1 g/dL lactoferrin]. Sixteen babies 
got mixed feeding (breast milk and formula). Breast milk meals contributed to > 80%,        
> 60% or < 55% of the total number of feeding, which the babys got during the study 
period (Table 1). The babies were randomly assigned to one of the three formula groups. 
The study was performed double-blind and was approved by the medical ethical review 
board of the hospital. Written informed consent was obtained from all the parents. Except 
for baby A2, the blood group of the babies was known (Table 1). Among the twenty-seven 
babies studied were two twin pairs and one triplet pair, but they were not further specified 
in this study. Lactoferrin-supplementation was not of interest for the present study on the 
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analysis of fecal oligosaccharides and no differences were observed in the fecal 
oligosaccharide profiles of formula-fed babies with and without lactoferrin 
supplementation. Babies who got preterm infant formula supplemented with lactoferrin 
(A7, B4, B7, B8, B14) were thus assigned to the control group and were not further 
specified.  
 
Table 1. Feeding groups, blood groups of babies and sample codes for fecal samples used in this study and 
examined by AHC and CE-LIF-MS. *Formula supplemented with 0.4 g/dL GOS. n.d.: not defined. 
 
Composition of feeding  
(% of feeding  
to total feeding) 
     n 
(babies) 
AHC codes (Figure 1) 
(blood group indicated in brackets) 
Breast milk (100%)     5 A1(0), A4(A), A9(A), A11(A), A13(B) 
Breast milk (> 80%)  
and formula 
    6 A2(n.d.), A3(0), A5(0), A8(0), A10(A), A12(0) 
Breast milk (> 60%)  
and formula 
    2 A6*(A), A7(A)
   
Formula (> 45%)  
and breast milk  
    8 B5(A), B6(A), B7(A), B8(A), B10(A), B12*(B), B13(A), 
B14(AB) 
Formula (100%)     6 B1*(A), B2*(0), B3(B), B4(0), B9(A), B11(0) 
 
 
HMO reference material and chemicals 
2’Fucosyllactose, lacto-N-tetraose, lacto-N-fucopentaose I-III, lacto-N-difucohexaose, 
fucosyllacto-N-hexaose II and a mixture composed of 3’sialyllactose, 6’sialyllactose and 
6’sialyl-N-acetyllactosamine were purchased from Dextra Laboratories (Reading, UK). All 
other chemicals used were of analytical grade. 
 
Oligosaccharide extraction from feces 
Oligosaccharides from feces were extracted according to Moro et al.14 Watery fecal slurries 
(50 mg/mL) were kept overnight at 4 °C and were centrifuged (15 min, 3500g) and filtered 
through a 0.22 μm membrane. Fecal enzymes were inactivated by heat (5 min, 100 °C). 
The carbohydrates extracted from fecal extracts were purified by solid phase extraction on 
graphitized carbon column cartridges (150 mg bed weight, 4 mL tube size; Alltech, 
Deerfield, Il) as described previously.17,18 In short, the cartridges were washed with 80/20 
(v/v) acetonitrile (ACN)/water containing 0.1% (v/v) trifluoroacetic acid (TFA) followed 
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by millipore water. After loading the sample extract onto the cartridge, monomers and 
lactose were largely removed by eluting with an aqueous 2% (v/v) ACN solution. The 
remaining carbohydrates on the cartridge were eluted with 40/60 (v/v) ACN/water 
containing 0.05% (v/v) TFA. The solution was dried under a stream of air and the dried 
sample was then rehydrated with millipore water. 
 
Monosaccharide composition  
The crude fecal extracts (not purified on graphitized carbon columns) were hydrolyzed with 
2 M TFA for 1 h at 121 °C followed by evaporation and repeated washing with methanol. 
The hydrolysates were re-dissolved in millipore water and analyzed with HPAEC-PAD for 
their monosaccharide composition.19 For the determination of sialic acid, mild sample 
hydrolysis with 0.1 M TFA for 40 min at  80 °C was applied20 before HPAEC analysis19.  
 
CE-LIF 
For CE-LIF analysis, the carbohydrates present in the fecal extracts were derivatized with 
the fluorescent 9-aminopyrene-1,4,6-trisulfonate (APTS) overnight at room temperature as 
reported elsewhere.21,22 One nanomole xylose was added as internal standard and mobility 
marker. CE-LIF was performed on a ProteomeLab PA 800 characterization system 
(Beckman Coulter, Fullerton, CA), equipped with a laser induced fluorescence detector 
(LIF) (excitation: 488 nm, emission: 520 nm) (Beckman Coulter) and a polyvinyl alcohol-
coated capillary (50 µm x 50.2 cm (Beckman Coulter), detector after 40 cm), kept at 25 °C. 
Samples were loaded hydrodynamically (4 s at 0.5 psi, representing approx. 14 nL sample 
solution) on the capillary. Separation was performed in the reversed polarity mode (30 kV, 
20 min) in a 25 mM acetate buffer containing 0.4% polyethylene oxide provided in the 
ProteomeLab Carbohydrate Labeling and Analysis Kit (Beckman Coulter). Due to the low 
pKa of the sialic acid residues (pKa 2.6) and in order to provide the same buffer-pH as for 
CE-MS analysis, the separation buffer was adjusted to pH 2.4 by adding 1.2% (v/v) formic 
acid.17 Peaks were integrated manually using Chromeleon software 6.8 (Dionex, 
Sunnyvale, CA). 
 
CE-LIF-ESI-MSn 
CE-LIF-ESI-MSn experiments were performed on a P/ACETM System MDQ (Beckman 
Coulter) according to Albrecht et al.17 For the fluorescent detection (excitation: 488 nm, 
emission: 520 nm), a Picometrics ZetaLIF discovery system was used (Picometrics, 
Toulouse, France). Separation in 0.3% (v/v) formic acid (pH 2.4) was performed on a fused 
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silica capillary (50 µm x 85 cm (Beckman Coulter), capillary window fitted with an 
ellipsoid for LIF detection after 60 cm) in reversed polarity mode (20 kV, 15 °C, 40 min). 
Samples were injected at 10 psi for 2 s.  LIF signals were sent to Beckmann 32Karat 
software via a SSXL4002 converter (Agilent Technologies, Santa Clara, CA). The ESI-MS 
(LTQ ion trap, Thermo Fisher Scientific Inc., Waltham, MA) was operated in the negative 
mode using a spray voltage of 1.9 kV and an MS-capillary temperature of 190 °C. The end 
of the CE capillary was installed in front of the ESI source by leading it through a T-part 
designed in our laboratory23 and provided the coaxial addition of a sheath liquid                       
(50/50 isopropanol/water) at 2 μL/min. Mass spectra were acquired from m/z 300 to 2000. 
MSn was performed in the data dependent mode using a window of 1 m/z and collision 
energy of 35%. For increasing the S/N ratio, ions of m/z 311, 314 and 329 were excluded 
from detection in MSn experiments (mass exclusion list). MSn data were interpreted using 
Xcalibur software 2.0.7 (Thermo).  
 
Statistical analysis 
The areas of the peaks in the CE-LIF electropherograms were normalized on the internal 
standard xylose. Agglomerative hierarchical clustering (AHC) was performed on the 
CE-LIF data points of all the fecal extracts using XLSTAT 2010.2.03 (Addinsoft, 
New York, NY). Data points starting from the migration time of the internal standard 
xylose (t = 4.1 min) were included in the statistical analysis. 3334 data points were 
subjected to AHC per sample electropherogram. The similarities for AHC were determined 
by the Pearson correlation coefficient and agglomerated using the unweighted pair group 
method. The results are presented as dendrogram, showing clustering patterns and the 
similarities among the clusters. 
 
Results 
Twenty-seven fecal samples from preterm babies were analysed. Thirteen babies received a 
feeding exclusively or predominantly composed of breast milk, with breast milk 
contributing to > 60% of the total feeding, which the baby received during the study period. 
The other fourteen babies received a feeding exclusively or predominantly composed of 
preterm infant formula (Frisolac prematuur), supplemented with 0.4 g/dL GOS or the same 
formula without GOS supplementation. The infant formula contributed to > 45% to the 
total feeding (Table 1).  
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Monosaccharide composition of the fecal extracts  
For a first screening, the HMO-constituting sugars [fucose (Fuc), galactose (Gal), glucose 
(Glc), N-acetylglucosamine (GlcNAc), sialic acid (Neu5Ac)] and N-acetylgalactosamine 
(GalNAc) and mannose (Man), which are known to be supplementary present in the 
glycoconjugates of the human gastrointestinal mucosa,7,20 were determined by high 
performance anion exchange chromatography (HPAEC) after acid hydrolysis of the fecal 
samples. The molar sugar proportions, presented relative to Gal = 1 in Table 2A, are 
grouped according to the main feeding the babies received. Similar molar proportions were 
obtained for samples analyzed in duplicate but highly diverse proportions were found for 
the different samples. Nevertheless, mean values were calculated. The high standard 
deviations (stdev) indicated variations in the fecal sugar compositions despite of the similar 
feeding received. Overall, the sugar proportions found for the predominantly breast-fed 
babies (group A) can be described as Fuc, GlcNAc > Glc >> GalNAc, Man, Neu5Ac, 
whereas for predominantly formula-fed babies (group B) it was GlcNAc > Fuc > Glc, 
GalNAc > Man, Neu5Ac. The mean proportions of GlcNAc, GalNAc, Man and Neu5Ac 
for formula-fed babies were higher than for breast-fed babies. Some sub-groups could be 
observed within the feeding groups. The predominantly breast-fed babies A4-A10 showed 
similar fecal relative proportions of Fuc, Glc and GlcNAc, but sub-divisions of the sample 
sub-groups were indicated by the different GalNAc-, Man- and Neu5Ac-proportions, which 
were low or even zero for samples A4, A9 and A10. Samples A1-A3 and A11-A13 showed 
highly diverse sugar proportions. The proportions of GalNAc, found for these specific 
breast-fed babies, were more comparable to what was found for formula-fed babies. The 
predominantly formula-fed babies B1-B2, who got GOS-supplemented formula, and 
B13-B14 could be distinguished within the formula-fed group due to the lowered 
proportions of all or several of the sugars Fuc, Glc, GlcNAc, GalNAc and Neu5Ac and may 
indicate an increased relative galactose content. 
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Table 2A. Sugar composition of fecal samples, presented relative to Gal = 1 and ordered according to the feeding 
groups of babies. Dashed lines indicate sample groups for which similarities in sugar composition were observed. 
Mean values and their standard deviations (mean±stdev) are presented for the feeding groups.  
 
 Fuc Gal Glc GlcNAc GalNAc Man Neu5Ac 
Exclusively or predominantly breast-fed babies (A) 
A1 0.09 1.00 0.34 0.78 0.19 0.09 0.21 
A2 
A3 
1.07 
0.56 
1.00 
1.00 
0.32 
0.51 
0.84 
0.50 
0.23 
0.04 
0.00 
0.08 
0.07 
0.08 
A4 0.97 1.00 0.69 0.69 0.00 0.00 0.01 
A5 0.82 1.00 0.51 0.58 0.05 0.04 0.01 
A6  0.81 1.00 0.43 0.63 0.13 0.05 0.03 
A7 0.85 1.00 0.42 0.57 0.09 0.05 0.03 
A8 0.72 1.00 0.38 0.70 0.10 0.05 0.10 
A9 0.90 1.00 0.55 0.53 0.03 0.00 0.01 
A10 0.86 1.00 0.51 0.51 0.05 0.00 0.05 
A11 0.55 1.00 0.65 0.85 0.58 0.19 0.00 
A12 0.63 1.00 0.32 0.83 0.36 0.23 0.18 
A13 0.44 1.00 0.42 1.21 0.20 0.08 0.07 
mean±stdev 0.71±0.25 1.00 0.46±0.11 0.71±0.19 0.16±0.15 0.07±0.07 0.06±0.06 
Exclusively or predominantly formula-fed babies (B) 
B1 0.41 1.00 0.34 0.60 0.19 0.48 0.08 
B2 0.43 1.00 0.71 0.80 0.15 0.13 0.14 
B3 0.50 1.00 0.57 0.73 0.28 0.17 0.10 
B4 0.43 1.00 0.71 1.44 0.35 0.37 0.26 
B5 0.66 1.00 0.11 1.05 0.20 0.13 0.07 
B6 0.57 1.00 0.12 0.97 0.35 0.19 0.09 
B7 0.75 1.00 0.23 0.96 0.50 0.06 0.16 
B8 0.56 1.00 0.26 0.97 0.23 0.05 0.12 
B9 0.75 1.00 0.27 1.11 0.31 0.08 0.10 
B10 0.58 1.00 0.20 1.09 0.22 0.07 0.08 
B11 0.48 1.00 0.84 1.16 0.28 0.18 0.25 
B12 0.67 1.00 0.30 1.02 0.30 0.11 0.14 
B13 0.29 1.00 0.30 0.46 0.21 0.14 0.16 
B14 0.33 1.00 0.24 0.85 0.32 0.25 0.00 
mean±stdev 0.53±0.14 1.00 0.37±0.23 0.94±0.24 0.28±0.09 0.17±0.12 0.12±0.06 
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Agglomerative hierarchical clustering (AHC) of CE-LIF oligosaccharide profiles  
Sugar composition analysis indicated variations within feeding groups and the possible 
presence of sub-groups with high similarities. Lower standard deviations were obtained by 
averaging the sugar proportions obtained for A5-A7, A9-A10 and B3-B12 (Table 2B), 
compared to what was obtained for the total feeding group. These sample-groups thus 
represent sub-groups.        
 
Table 2B. Mean±stdev of sugar composition of fecal sample-sub-groups A5-A7, A9-A10 and B3-B12, presented 
relative to Gal = 1. 
 
 Fuc Gal Glc GlcNAc GalNAc Man Neu5Ac 
A5-A7 
mean±stdev 0.83±0.01 1.00 0.45±0.04 0.59±0.02 0.09±0.03 0.05±0.01 0.02±0.01 
A9-A10        
mean±stdev 0.88±0.02 1.00 0.53±0.02 0.52±0.01 0.04±0.01 0.00±0.00 0.03±0.02 
B3-B12        
mean±stdev 0.58±0.11 1.00 0.37±0.23 1.07±0.17 0.29±0.08 0.14±0.09 0.13±0.06 
        
 
The sugar building units can represent numerous, structurally different oligosaccharides. 
The fecal extracts were, therefore, analyzed for their oligosaccharide profiles by CE-LIF. 
AHC was then performed on the data points for all    CE-LIF electropherograms in order to 
investigate the similarity between the samples. Two main clusters and one sample (A1), 
which did not match with any of the two clusters, are obtained (Figure 1). The first cluster 
was composed of samples from exclusively and predominantly breast-fed babies (A2-A10). 
Samples A2 and A3 showed low similarity to samples A4-A10, which could be further 
divided into the sub-clusters A4/A5-A7 and A8/A9-A10.  
The second cluster was mainly composed of samples from exclusively and predominantly 
formula-fed babies. Three breast-fed babies (samples A11-A13) were also located in the 
second cluster. Several sub-clusters were observed for feces from the formula-fed group, 
with the most homogenous cluster being composed of samples B4-B11. In line with the 
exceptional sugar proportions observed for babies A1-A3, A11-A13, B1-B2 and B13-B14, 
low similarities to the other samples of the same feeding group were found with AHC for 
these samples as based on the CE-LIF profiles.  
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Figure 1. AHC dendrogram of CE-LIF data sets from the 27 fecal samples analyzed. A: exclusively breast-fed 
babies. A: predominantly breast-fed babies. B: exclusively formula-fed babies. B: predominantly formula-fed 
babies. *: supplementation of formula with 0.4 g/dL GOS. See Table 1 for the assignment of the sample codes to 
the respective feeding group. 
 
Characterization of the CE-LIF oligosaccharide profiles 
Breast-fed babies showing fecal oligosaccharide profiles similar to breast milk 
Fucosyllactose (FL), difucosyllactose (DF-L), lacto-N-neo-tetraose(LnNT)-isomers, lacto-
N-tetraose(LNT), lacto-N-fucopentaose(LNFP)-isomers, lacto-N-difuco-hexaose(LNDFH)-
isomers, fucosyllacto-N-hexaose(F-LNH)-isomers, difucosyllacto-N-hexaose(DF-LNH)-
isomers and trifucosyllacto-N-hexaose(TF-LNH)-isomers are HMOs and their degradation 
products, which were found to be present in individual-dependent proportions in the feces 
of two exclusively and five predominantely breast-fed babies (A4-A10), corresponding to 
what was previously reported.17 Representative electropherograms for these sub-groups are 
shown in Figure 2. Peaks, which have been annotated by CE-LIF-MSn and/or using 
standards are listed in Table 3. The oligosaccharide profiles could be discriminated 
according to their respective secretor-(A4-A8) or non-secretor-(A9, A10) fingerprint. The 
(α1,2)-fucosylated HMOs, such as DF-L (Fuc-(α1,2)-Gal-(β1,4)-[Fuc-(α1,3)]-Glc; peak 7), 
LNFP-I (Fuc-(α1,2)-Gal-(β1,3)-GlcNAc-(β1,3)-Gal-(β1,4)-Glc; peak 18) or LNDFH-I 
(Fuc-(α1,2)-Gal-(β1,3)-[Fuc-(α1,4)]-GlcNAc-(β1,3)-Gal-(β1,4)-Glc; peak 20) are 
characteristic for Le(a-b+)9-secretor-milk and were present in the fecal oligosaccharide 
profiles A4-A8. Two representative examples (A4, A7) are shown in Figure 2. Besides the 
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well-known HMO-peaks and their degradation products17 (Figure 2-A4) also an unknown 
structure of m/z 328 (Figure 2-A7, peak 6) and two unknown structures of m/z 377 
(Figure 2-A7, peaks 12 and 13) could be present in the secretor-profiles of breast–fed 
babies, as exemplified by sample A7 in Figure 2. Strikingly, m/z 328 and m/z 377-I were 
never present in the HMO-profiles from exclusively breast-fed babies, but in some cases 
present in the profiles of mixed-fed babies. 
Secretor-milk-specific HMOs containing (α1,2)-fucose residues were absent in samples   
A9 and A10. This phenomenon is typical for non-secretor milk Le(a+b-).5,9 CE-MS 
analysis indicated isomeric structures for F-LNH and DF-LNH in secretor-profiles, visible 
as shoulders (Figure 2, peaks 24 and 25) which thus may contain (α1,2)-fucose linkages. 
Only single-shaped peaks were observed for F-LNH and DF-LNH in these non-secretor 
profiles, as exemplified by sample A10 in Figure 2. On the other hand, LNFP II and two 
not further specified LNDFH isomers contributed with a higher proportion to the total 
oligosaccharide content in non-secretor profiles (Figure 2-A10,  peaks 15 and 21,22).  
 
Figure 2. CE-LIF electropherograms of APTS-derivatized oligosaccharides extracted from baby feces. (A4) HMO 
secretor profile of exclusively breast-fed baby A4. (A7) HMO secretor profile including unknown 
oligosaccharides of mixed-fed baby A7. (A10) HMO non-secretor profile of mixed-fed baby A10.                      
See Table 3 for peak annotation.*internal standard xylose. 
3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
LI
F 
in
te
ns
ity
migration time (min)
A4
A7
A10
1
2
*
4
5 7 9
10
14
15
17
18/19
20
21
25
26
1 2
*
7
6 9
10
14
12/13
15
17
18/19 20
21
25
2624
2422
1
2
*
10
14
15
17
19
21
22 24
25
Oligosaccharides in feces of breast- and formula-fed babies
 
 75 
Table 3. Structural composition of oligosaccharides detected in CE-LIF electropherograms (Figures 2-4). The 
oligosaccharides are attached to an APTS-molecule and are present in their threefold negative charge in the ESI-
MS profiles.  
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*      xylose ISTD 15 431 3 1 1 0 LNFP II 
1      monomers 16 576 3 1 0 2 DS-LNT 
2      dimers 17 479 3 1 0 1 S-LNT* 
3 357 2 0 0 1 SL* 18 431 3 1 1 0 LNFP I 
4 309 2 0 1 0 FL* 19 431 3 1 1 0 LNFP III 
5 382 3 1 0 0 LnNT Y 20 479 3 1 2 0 LNDFH I 
6 328 2 1‘ 0 0 m/z 328 21 479 3 1 2 0 LNDFH*  
7 358 2 0 2 0 DF-L 22 479 3 1 2 0 LNDFH* 
8 479 3 1 0 1 S-LNT* 23 498 3 2 1‘ 0 m/z 498 
9 382 3 1 0 0 LnNT 24 552 4 2 1 0 F-LNH* 
10 431 3 1 1 0 LNFP Y 25 601 4 2 2 0 DF-LNH* 
11 479 3 1 0 1 S-LNT* 26 650 4 2 3 0 TF-LNH* 
12 377 2 1‘ 1 0 m/z 377-I IIIa-d 314 3 0 0 0 Hexo-
trioses* 
13 377 2 1‘ 1 0 m/z 377-II IVa-c 368 4 0 0 0 Hexo-
tetraoses* 
14 382 3 1 0 0 LNT *: isomers not further specified; ‘: GlcNAc=HexNAc 
 
Breast-fed babies showing fecal oligosaccharide profiles not similar to breast milk 
For three exclusively and three partially breast-fed babies (samples A1-A3, A11-A13), 
which stood out in the clustering profile due to their low similarity, fecal oligosaccharide 
profiles were found, that did not depict a characteristic HMO pattern with CE-LIF     
(Figure 3). Exclusively acidic HMOs predominated in sample A1 (Figure 3-A1). In human 
milk, acidic HMOs are present in a tenfold lower concentration compared to neutral 
oligosaccharides.7 SL, three sialyllacto-N-tetraose (S-LNT)-isomers (Figure 3-A1, peaks 8 
and 11,17) and one disialyllacto-N-tetraose (DS-LNT)-isomer (Figure 3-A1, peak 16) were 
found in this oligosaccharide profile by CE-LIF-MS analysis. Their origin from breast milk 
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was confirmed by their presence in the acidic fraction obtained by anion exchange 
chromatography of HMOs (results not shown). Remarkably, in sample A12 solely SL was 
found (results not shown). 
Only a few, but dominant HMOs were found for A2 and A3, which were LNFP II and 
LNDFH I as shown for A2 (Figure 3-A2, peaks15 and 20). An unknown structure of      
m/z 377 was present as well (Figure 3-A2, peak 12), which corresponded to peak 12 in 
Figure 2-A7, assigned as 377-I. No oligosaccharides were found to be present in the profile 
of sample A13 (results not shown). 
Interestingly, an oligosaccharide, previously assigned as 377-II in the fecal profiles of 
breast-fed babies showing secretor-HMO-profiles (Figure 2-A7), was found to prevail in 
the profile of the breast-fed baby A11 (Figure 3-A11, peak 13), together with a structure of 
m/z 498 (Figure 3, A11, peak 23). Besides the presence of m/z 377-II and m/z 498, the 
oligosaccharide level found for sample A11 was quite low.  
 
 
Figure 3. CE-LIF electropherograms of APTS-derivatized oligosaccharides extracted from baby feces. (A1) 
Exclusively acidic HMOs of exclusively breast-fed baby A1. (A2) Accumulation of LNFP II/LNDFH I of mixed-
fed baby A2. (A11) Accumulation of structures with m/z 377-II/498 of exclusively breast-fed baby A11.            
See Table 3 for peak annotation.*internal standard xylose. 
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Fecal oligosaccharide profiles of formula-fed babies 
Similar fecal oligosaccharide profiles were obtained for ten formula-fed or predominantly 
formula-fed babies (B2, B4-B12), irrespective of having received formula-feeding 
supplemented with 0.4 g/dL GOS. Representative electropherograms are shown in Figure 4 
for GOS-fed baby B12 and formula-fed baby B5. By means of CE-MS, the two main 
oligosaccharide peak-clusters were identified as hexose-trimers and –tetramers (Figure 4, 
peaks IIIa-d and IVa-c, respectively). The oligosaccharide profiles of samples B1, B3, B13 
and B14 could be distinguished from the other peak profiles of formula-fed babies due to 
the abundant presence of an unknown structure of m/z 328, as represented by baby B3, 
(Figure 4-B3, peak 6), which was as well present as a minor component in the 
oligosaccharide profiles of predominantly breast-fed babies showing a secretor-profile  
(Figure 2-A7, peak 6).  
 
 
Figure 4. CE-LIF electropherograms of APTS-derivatized oligosaccharides extracted from baby feces. (B12) 
mixed-fed baby B12 (GOS-supplemented formula). (B5) mixed-fed baby B5 (control formula). (B3) exclusively 
formula-fed baby B3 (control) showing abundant oligosaccharide of m/z 328. 
See Table 3 for peak annotation.*internal standard xylose. 
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Annotation of the unknown peaks m/z 377-I/-II, 328 and 498 
As described above, four unknown compounds of the masses m/z 328, m/z 377             
(isomers I and II) and m/z 498 were observed in several fecal extracts. Although having the 
same m/z values and migrating closely together in CE-LIF, the MS fragmentation patterns 
of m/z 377-I (found for several partially breast-fed babies (Figure 2 and Figure 3,         
peak 12)) and m/z 377-II (found for several exclusively and partially breast-fed babies 
(Figure 2 and Figure 3, peak 13)) showed marked differences (Figure 5A).  
The compound m/z 377-I was annotated as Hex-[Fuc]-HexNAc-Hex-APTS (Figure 5A), as 
supported by its mass fragments Hex-APTS, HexNAc-Hex-APTS, Fuc-HexNAc-Hex-
APTS and Hex-HexNAc-Hex-APTS (Table 4).  
For the compound 377-II,  the presence of the fragments Hex-APTS, Hex-Hex-APTS,    
Fuc-Hex-Hex-APTS and HexNAc-Hex-Hex-APTS, as summarized in Table 4, led to an 
annotation of HexNAc-[Fuc]-Hex-Hex-APTS (Figure 5A).  
The fragmentation pattern of m/z 328 (found as minor component for several partially 
breast-fed babies and as dominant peak for several formula-fed babies (Figure 2 and 
Figure 4, peak 6)) lacked the fragment Hex-APTS, although showing an abundant        
Hex-Hex-APTS fragment (Figure 5B and Table 4). This characteristic fragmentation was 
also found for a mixture of the single-substituted, Hex-Hex-based structures 3’SL 
(Neu5Ac-(α2,3)-Gal-(β1,4)-Glc) and 6’SL (Neu5Ac-(α2,6)-Gal-(β1,4)-Glc) (data not 
shown). HexNAc-Hex-Hex-APTS was thus annotated for m/z 328. 
The MS fragments, which resulted for m/z 498 (Figure 5B) (breast-fed baby A11        
(Figure 3-A11, peak 23)) are summarized in Table 4. The presence of fragments Fuc-Hex-
HexNAc-Hex-Hex-APTS and HexNAc-Hex-HexNAc-Hex-Hex-APTS provide 
complementary information on the substitution of the terminal hexose unit with Fuc as well 
as HexNAc. This led to the annotation of HexNAc-[Fuc]-Hex-HexNAc-Hex-Hex-APTS for 
m/z 498. Unfortunately, the definitive identification of the new structures by NMR was not 
possible due to the low sample amounts available. 
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Figure 5. MS2 fragmentation patterns and structural composition of (A) m/z 377-I/-II. (B) m/z 328 and m/z 498. 
[2-] [3-]: charge state of APTS-molecule. 
323/485
310
274/411
328
260/391
309/464
328
310
200 250 300 350 400 450 500
0
50
100
0
50
100
R
el
at
iv
e
A
bu
nd
an
ce
m/z
328[3-]323[3-]
310[2-]
411[2-]274[3-]
261 270 301
393
341
391[2-]
328[3-]
310[2-]
260[3-]
464[2-]
309[3-]
274[3-]
301
m/z 377-II
m/z 377-I
A
200 300 400 500
m/z
0
50
100
0
50
100 391[2-]
351
301
391[2-]
449[3-]
351
431[3-]310[2-]
328[3-]270 382[3-]
R
el
at
iv
e
A
bu
nd
an
ce
310391328
449
431
382
270
260[3-]
fucose hexNAc hex
B
m/z 328
m/z 498
(310)260/391
Chapter 4
 
 80
Table 4. Presence and annotation of MS2 fragments of m/z 328 (Table 3, peak 6), 377-I.-II (Table 3, peaks 12  
and 13) and 498 (Table 3, peak 23). 
 
  m/z 328 m/z 377-I m/z 377-II m/z 498 
m/z fragment pair structural composition   
m/z 207[3-]/310[2-] Hex-APTS - + + + 
m/z 255[3-]/383[2-] Fuc-Hex-APTS - - - - 
m/z 260[3-]/391[2-] Hex-Hex-APTS + - + + 
m/z 274[3-]/411[2-] HexNAc-Hex-APTS - + - - 
m/z 309[3-]/464[2-] Fuc-Hex-Hex-APTS - - + - 
m/z 323[3-]/485[2-] Fuc-HexNAc-Hex-APTS - + - - 
m/z 328[3-]/492[2-] HexNAc-Hex-Hex-APTS/ 
Hex-HexNAc-Hex-APTS 
- + + + 
m/z 382[3-]/574[2-] Hex-HexNAc-Hex-Hex-APTS - - - + 
m/z 431[3-]/647[2-] Fuc-Hex-HexNAc-Hex-Hex-
APTS 
- - - + 
m/z 449[3-]/674[2-] HexNAc-Hex-HexNAc-Hex-
Hex-APTS 
- - - + 
 
Discussion 
Breast-fed babies  
Three out of the five exclusively breast-fed babies showed the absence of a characteristic 
HMO profile after approximately two months of life. On the other hand, for the majority of 
predominantly, but not exclusively, breast-fed babies (five out of eight), fecal HMO-
profiles were obtained. The individual-dependent, genetically determined HMO-profiles of 
secretor- [Le(a-b+)]- and non-secretor- [Le(a+b-)] breast milk5 were mirrored in these fecal 
HMO-profiles and resulted in different degrees of similarities among the samples.  
Mixed feeding can thus delay an advanced HMO-degradation and metabolization at two 
months after birth. A lower adaptation to the feeding and a microbiota not exclusively 
specified in the degradation and metabolization of HMOs for these babies was indicated.  
The presence of exclusively acidic oligosaccharides, such as SL, S-LNT, DS-LNT-isomers, 
as observed in the feces of the breast-fed baby A1 (Figure 3-A1), the accumulation of 
specific HMOs (Figure 3-A2) or unknown structures (Figure 3-A11) and the absence of 
specific oligosaccharides (sample A13) can thus be interpreted as biomarkers for an 
advanced gastrointestinal and gastromicrobial development  and explain the diversity found 
for these samples with CE-LIF, expressed by their low similarities in AHC. The increased 
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presence of GlcNAc and the non-HMO sugars GalNAc and Man, which are known to be 
present in the glycoconjugates of the human gastrointestinal mucosa,20 may indicates an 
involvement of mucin oligosaccharides in the gastrointestinal re-design of diet-related 
HMOs. To understand the gastrointestinal bioconversion of HMOs, more study is needed. 
 
Blood group A-specific metabolization products in the feces of breast-fed babies  
Breast-fed babies, for whom HexNAc-[Fuc]-Hex-Hex-APTS (m/z 377-II) and HexNAc-
[Fuc]-Hex-HexNAc-Hex-Hex-APTS (m/z 498) were annotated in their fecal 
oligosaccharide profiles, all had blood group A (Table 1), as was exemplified by babies A7 
and A11 in Figure 2 and Figure 3. GalNAc-(α1,3)-[Fuc-(α1,2)]-Gal is the antigenic 
determinant structure of blood group A,24 which corresponds to the non-reducing HexNAc-
[Fuc]-Hex-group found for m/z 377-II and m/z 498 and is further supported by the 
increased presence of the non-HMO-sugar GalNAc in the respective samples. The 
oligosaccharides GalNAc-(α1,3)-[Fuc-(α1,2)]-Gal-(β1,4)-Glc (corresponding to m/z 377-II) 
and GalNAc-(α1,3)-[Fuc-(α1,2)]-Gal-(β1,3)-GlcNAc-(β1,3)-Gal-(β1,4)-Glc (corresponding 
to m/z 498), which are unknown for human milk, were previously identified in the feces of 
a single, eight weeks old, prematurely born breast-fed blood group A-secretor baby.15,16 
Blood group characteristic oligosaccharides are not expected to occur in human milk.15,25 
However, the occurrence of trace amounts has previously been suggested but the structural 
composition of these oligosaccharides has not been proven.26 The gastrointestinal mucosa is 
known to carry a broad range of cell-surface glycoconjugates, which are built up from Gal, 
Glc, GalNAc, GlcNAc, Man, Fuc and Neu5Ac.20 The antigenic determinant structures of 
these glycoconjugates are, among other factors, determined by the host’s ABO histo-blood 
group type.5 A sole microbial degradation of these structures from mucus epitopes27,28 was 
not expected. Our results indicate a gastrointestinal bioconversion of the HMOs, with an 
involvement of these blood group specific mucus epitopes. This is similar to what has been  
hypothesized in previous studies in view of the high yield of these fecal oligosaccharides 
detected in the respective sample.15,16 Our assumption of bioconversion is further supported 
by the fact that neither m/z 377-II nor m/z 498 was detected in the feces of any of the 
formula-fed babies.  
Blood-group specific oligosaccharides can be absent in the feces of breast-fed blood 
group A secretor babies (Figure 2-A4), they can be present additionally to HMOs 
(Figure 2-A7, peak 13) or they can be present as exclusive components (Figure 3-A11, 
peaks 13 and 23). Blood group A non-secretor babies (A9 and A10; Figure 2-A10) lacked 
the presence of theses oligosaccharides, due to the presence of a terminal (α1,2)-Fuc-
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linkage for these structures.15,29 The extent to which blood group specific oligosaccharides 
are present in feces depends on the secretor status of the baby and may depend on the 
presence of secretor-breast milk and on the state of development and adaptation of the 
gastrointestinal microbiota to the HMOs provided.  
 
Presence of unknown oligosaccharide m/z 377-I in the feces of breast-fed babies  
Hex-[Fuc]-HexNAc-Hex-APTS (m/z 377-I), which was found for several predominantly 
but not exclusively, breast-fed babies (Figure 2-A7 and Figure 3-A2) seems to be 
dependent on the gastrointestinal presence of HMOs, but does not depend on the respective 
blood group (Table 1). The compound m/z 377-I may result from the gastrointestinal 
degradation of the para-isomers of higher-Mw HMOs, which carry a terminal Gal-(β1,3)-
GlcNAc-(β1,3)-Gal-(β1,4)-unit (e.g. F-para-LNH I, Gal-(β1,3)-GlcNAc-(β1,3)-Gal-(β1,4)-
[Fuc-(α1,3)]-GlcNAc-(β1,3)-Gal-(β1,4)-Glc).  
Another possibility is the origin from gastrointestinal mucin-type-O-glycans, for which 
repeats of Gal-GlcNAc-units were described.30 The presence of intestinal bacteria-/enzyme-
sets able to degrade these structures for these HMO-fed babies has to be assumed in that 
case.  
 
Formula-fed babies  
Ten out of fourteen fecal extracts from exclusively and predominantly formula-fed babies 
showed similar fecal CE-LIF patterns, independent of feeding a preterm formula without 
GOS or a preterm formula supplemented with 0.4 g/dL GOS, as was represented in    
Figure 4 by samples B12 and B5. The hexo-trioses and hexo-tetraoses, which are present in 
a low abundance in these fecal profiles, as well as the numerous unidentified peaks were, 
therefore, assumed to origin from the gastrointestinal mucus layer and not from the 
supplemented GOS, as also indicated by the high GlcNAc-, GalNAc- and Man-proportions 
found for these samples (Table 2A and Table 2B). A higher contribution of monomeric 
Gal was expected for the exclusively GOS-fed babies (B1, B2), due to the low proportions 
of the other sugars determined in these two samples relative to Gal (Table 2A). However, 
no conclusions could be drawn from the CE-LIF profiles due to the fact that monomeric 
sugars were partly removed during sample-preparation for CE-LIF-MS. For fecal samples 
originating from 24 days old preterm born babies who received formula supplemented with 
0.5 g/dL, we found hexose-oligosaccharides related to the supplemented GOS (unpublished 
results). In addition, GOS and fructooligosaccharides (FOS) were recovered in the feces of 
one months old babies, who received a formula supplemented with a mixture of 0.8 g/dL 
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GOS/FOS (9:1) by Moro et al.14 In the present study, the fecal samples were taken at the 
age of two months and the fecal flora may be more developed and adapted to GOS than in 
the study of Moro et al14 and able to completely degrade GOS. The fecal recovery of 
supplemented oligosaccharides to infant formula may thus depend on their concentration 
and on the stage of gastrointestinal development of the baby.  
 
Presence of unknown oligosaccharide m/z 328 in the feces of breast- and formula-fed 
babies   
HexNAc-Hex-Hex-APTS (m/z 328) was found in minor proportions for several mixed-fed 
babies showing secretor-HMO profiles and as major component for the four formula-fed 
babies B1, B3, B13, B14 (exemplified by Figure 2-A7 and Figure 4-B3). The presence of 
HexNAc-Hex-Hex is not dependent on the gastrointestinal presence of HMOs or the type of 
infant formula. Furthermore, this unknown structure was not present in any of the fecal 
profiles of exclusively breast-fed babies and babies showing non-secretor HMO-profiles. A 
mucosal origin is assumed for HexNAc-Hex-Hex and the pronounced expression of 
HexNAc-Hex-Hex for formula-fed babies may indicate an enhanced mucus-degradation. 
This may point to a lack of intestinal feeding and thus to the need of the microbiota to 
degrade sugar units from the gastrointestinal mucus layer. The observed dependency of 
HexNAc-Hex-Hex on the presence of secretor-breast milk in case of breast feeding may 
implicate the involvement of (α1,2)-fucosylation prior to the gastrointestinal release of this 
compound.  
 
Concluding remarks 
Overall, the fecal recovery of oligosaccharides from human milk and formula seems to be 
dependent on the adaptation of the gastrointestinal microbiota to the respective feeding and 
the concentration of oligosaccharides herein. The host’s genotype plays also an important 
role in the gastrointestinal oligosaccharide metabolisation and was identified as a 
determinant factor responsible for the presence of the blood group characteristic 
oligosaccharides GalNAc-[Fuc]-Gal-Glc, GalNAc-[Fuc]-Gal-GlcNAc-Gal-Glc, and may be 
involved in the formation of the structures annotated as Hex-[Fuc]-HexNAc-Hex and 
HexNAc-Hex-Hex in the feces.  
Fecal oligosaccharide profiles contain valuable information. To understand the 
gastrointestinal bioconversion of HMOs, more study is needed.  
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Abstract 
The characterization of oligosaccharides in the feces of breast-fed babies is a valuable tool 
for monitoring the gastrointestinal fate of human milk oligosaccharides (HMOs). In the 
present study we monitored fecal oligosaccharide profiles together with the HMO-profiles 
of the respective breast milks up to six months postpartum, by means of capillary 
electrophoresis with laser induced fluorescence detection and mass spectrometry. Eleven 
mother/child pairs were included. Mother’s Secretor- and Lewis-type included all 
combinations [Le(a-b+), Le(a+b-), Le(a-b-)]. The fecal HMO-profiles in the first few 
months of life are either predominantly composed of neutral or acidic HMOs and are 
possibly effected by the HMO-fingerprint in the respective breast milk. Independent of the 
initial presence of acidic or neutral fecal HMOs, a gradual change to blood group specific 
oligosaccharides was observed. Their presence pointed to a gastrointestinal degradation of 
the feeding-related HMOs, followed by conjugation with blood group specific antigenic 
determinants present in the gastrointestinal mucus layer. Eleven of these “hybride”-
oligosaccharides were annotated in this study. When solid food was introduced, no HMOs 
and their degradation- and metabolization products were recovered in the fecal samples.  
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Introduction 
Exclusive breast feeding during the first six months after birth is officially recommended by 
the WHO1 and efforts are made to support and promote breast feeding among mothers 
worldwide.2,3 Important components of breast milk are human milk oligosaccharides 
(HMOs), present to 3-19 g/L.4,5 They are composed of a core of galactose, glucose,           
N-acetyl-glucosamine and decorated with fucose and sialic acid to different extents.4 
Numerous studies have pointed out the biological importance of HMOs, e.g. their role in 
inhibiting the adhesion of pathogenic bacteria to the epithelial surface or the establishment 
of gut microbiota.6,7 The HMO-composition of breast milk cannot be generalized though, as 
it is genetically determined.7 The mother’s Secretor- and Lewis type determine the 
fucosylation pattern and thus the set of HMOs present in breast milk.8 Breast milks from 
Le(a-b+)-secretors, Le(a+b-)-non-secretors and Le(a-b-)-secretors/-non-secretors can be 
distinguished and have been thoroughly studied in view of their structural composition as 
well as their development during different stages of lactation.8,9 Differences in HMO-
profiles may have an influence on the biological functioning of breast milk.7 The 
gastrointestinal fate of the complex HMOs remains vague, though. In the 1980s and early 
1990s, several studies have been performed in order to investigate fecal oligosaccharides 
from breast-fed babies.10-13 Blood group A active oligosaccharides were found in the feces 
of a single blood group A breast-fed baby and a gastrointestinal metabolization of the 
feeding-related HMOs was supposed.10 On the other hand, no HMO metabolization 
products were found for a single blood group B breast-fed baby.12 In a third study, no 
indication for gastrointestinal HMO-metabolization was found as HMO-profiles similar to 
the respective breast milks were observed.14 In other studies HMOs and blood group 
characteristic oligosaccharides were detected in urine of breast-fed babies and lactating 
women,15,16 pointing out their gastrointestinal absorbance and importance on a systemic 
level. Clearly, further research is needed in order to understand the gastrointestinal fate of 
complex HMOs and their possible conjugation with blood group antigenic structures. The 
application of novel analytical methods, which provide low detection limits and require 
limited preparative sample work in combination with a short analysis time, may open new 
possibilities in this context. It may help to establish an advanced scientific underpinning of 
the feeding-guidelines set up for neonates. Capillary electrophoresis with laser induced 
fluorescence detection (CE-LIF), combined with mass spectrometry, has been shown to be 
a suitable tool for the analysis of HMOs in breast milk and baby feces.17 
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In the present study we, therefore, followed the HMO-profiles in breast milk and feces over 
time by CE-LIF/MS. Eleven mothers, representing three different Secretor- and Lewis 
groups [Le(a-b+), Le(a-b-), Le(a+b-)], and their breast-fed babies were included in this 
study.  
 
Materials and Methods 
Set-up study and sample collection  
The eleven mothers, who were recruited in this study, each gave birth to a healthy child 
after 36-39 weeks of gestation. Ten of these respective babies, who were exclusively breast-
fed during several months postpartum were as well recruited. Breast milk (5 mL) and fecal 
samples (±200 mg) were collected at 14-19 days (assigned as 14d), 1 month (assigned as 
1m), 2 months (assigned as 2m), 3 months (assigned as 3m), 4 months (assigned as 4m),  
5 months (assigned as 5m) and 6-7 months (assigned as 6m) postpartum. Not for all 
mother/child-pairs, samples were obtained at each time point. An overview of the samples 
collected is given in Table 1. The blood groups of the mothers were obtained by A,B,H(0) 
secretor testing or oral communication with the mothers. Except for baby I (blood group 
H(0)), the blood groups of the babies were not known.  
 
Table 1. Overview on breast milk/fecal sample pairs A-K, classified according to the respective secretor-status of 
the mothers, as determined by CE-LIF/MS. º: secretor-status confirmed by saliva-testing. 
(14d/1m/2m/3m/4m/5m/6m): time points, for which samples were collected. [BG(x)]: [blood group(mother)].       
#: baby and mother had same blood group. *: only breast milk samples obtained. n.d.: not determined 
 
 
Secretor [Le (a-b+)] 
 
Aº (14d/1m/2m/3m/4m) [BG(A)] 
 
Eº (14d/1m/2m/6m) [BG(H(0))] 
Bº (2m/3m/4m/5m/6m) [BG(H(0))] F (14d/1m/2m) [BG(n.d.)] 
Cº (14d/1m/2m/3m) [BG(H(0))] G (2m/3m) [BG(B)] 
Dº (1m/2m/3m/6m) [BG(B)] Hº (6m) [BG(A)] 
   
 
Secretor [Le (a-b-)] 
 
Iº (14d/1m/2m/3m/4m/5m/6m) [BG(H(0))]# 
   
 
non-secretor [Le(a+b-)] 
 
Jº (14d/1m/2m)* [BG(H(0))] 
 
K (14d/1m) [BG(n.d.)] 
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It was not possible to study the development of fecal oligosaccharide profiles for babies 
from non-secretor mothers, due to limited numbers of samples available.  
For two babies (E, H) solid food was already introduced when the fecal sample was 
collected at 6m postpartum. All babies showed an average growth during their first six 
months of life. Written informed consent was obtained from all the mothers. Samples were 
stored at -80°C until further analysis.  
 
HMO reference material and chemicals 
2’Fucosyllactose, lacto-N-tetraose, lacto-N-fucopentaose I-III, lacto-N-difucohexaose I, 
fucosyllacto-N-hexaose II and a mixture composed of 3’sialyllactose, 6’sialyllactose and 
6’sialyl-N-acetyllactosamine were purchased from Dextra Laboratories (Reading, UK). 
All other chemicals used were of analytical grade. 
 
A,B,H(0)-secretor-testing 
Saliva (5 mL) was collected from eight of the participating mothers. The A,B,H(0)-
secretor-status was tested by the Dutch blood bank (Sanquin Diagnostiek, Amsterdam, 
The Netherlands), using an immunohematology method as established by the American 
Red Cross.18 The expression of secretor-gene-specific antigens may not yet be fully 
developed with newborns during the first months postpartum.19 Therefore, A,B,H-secretor-
typing was not performed for the respective babies.  
 
Oligosaccharide extraction from breast milk and feces 
The extraction of carbohydrates from breast milk was accomplished as performed by 
Stahl et al.20 It included pasteurization (30 min, 70 °C), defatting at 4 °C as well as a 
protein precipitation by adding the double amount (v/v) of cold ethanol. Oligosaccharides 
from feces were extracted according to Moro et al.21 Aqueous fecal slurries 
(50–100 mg/mL) were kept overnight at 4 °C, centrifuged (15 min, 3500g) and filtered 
through a 0.22 μm membrane. Fecal enzymes were inactivated by heat (5 min, 100 °C). The 
carbohydrates extracted from milk and fecal extracts were purified by solid phase 
extraction on graphitized carbon column cartridges (150 mg bed weight, 4 mL tube size; 
Alltech, Deerfield, Il) as described previously.17,22 In short, the cartridges were washed with 
80/20 (v/v) acetonitrile (ACN)/water containing 0.1% (v/v) trifluoroacetic acid (TFA) 
followed by millipore water. After loading the sample extract onto the cartridge, monomers 
and lactose were largely removed by eluting with an aqueous 2% (v/v) ACN solution. The 
remaining carbohydrates on the cartridge were eluted with 40/60 (v/v) ACN/water 
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containing 0.05% (v/v) TFA. The solution was dried under a stream of air and the dried 
sample was then rehydrated with millipore water. 
 
Monosaccharide composition  
The crude fecal extracts (not purified on graphitized carbon columns) were hydrolyzed with 
2 M TFA for 1 h at 121 °C followed by evaporation and repeated washing with methanol. 
The hydrolysates were re-dissolved in millipore water and analyzed with HPAEC-PAD for 
their monosaccharide composition.23 For the determination of sialic acid, mild sample 
hydrolysis with 0.1 M TFA for 40 min at 80 °C was applied24 before HPAEC analysis.23  
 
CE-LIF 
For CE-LIF analysis, the carbohydrates present in the fecal extracts were derivatized with 
the fluorescent 9-aminopyrene-1,4,6-trisulfonate (APTS) overnight at room temperature as 
reported elsewhere.25 One nanomole xylose was added as internal standard and mobility 
marker. CE-LIF was performed on a ProteomeLab PA 800 characterization system 
(Beckman Coulter, Fullerton, CA), equipped with a laser induced fluorescence detector 
(LIF) (excitation: 488 nm, emission: 520 nm) (Beckman Coulter) and a polyvinyl alcohol-
coated capillary (50 µm x 50.2 cm (Beckman Coulter), detector after 40 cm), kept at 25 °C. 
Samples were loaded hydrodynamically (4 s at 0.5 psi, representing approx. 14 nL sample 
solution) into the capillary. Separation was performed in the reversed polarity mode (30 kV, 
20 min) in the 25 mM acetate buffer containing 0.4% polyethylene oxide provided in the 
ProteomeLab Carbohydrate Labeling and Analysis Kit (Beckman Coulter). Due to the low 
pKa of the sialic acid residues (pKa 2.6) and in order to provide the same buffer-pH as for 
CE-MS analysis, the separation buffer was adjusted to pH 2.4 by adding 1.2% (v/v) formic 
acid.17 Peaks were integrated manually using Chromeleon software 6.8 (Dionex, 
Sunnyvale, CA). 
 
CE-MSn 
CE-MSn experiments were performed on a PA800+ System (Beckman Coulter) according 
to Albrecht et al.17 Samples were injected at 10 psi for 2 s. Separation in 0.3% (v/v) formic 
acid (pH 2.4) was performed on a fused silica capillary (50 µm  x 85 cm (Beckman Coulter) 
in reversed polarity mode (20 kV, 15 °C). The end of the CE capillary was installed in front 
of the ESI source (LTQ Velos, Thermo Fisher Scientific Inc., Waltham, MA) by leading it 
through a T-part designed in our laboratory26 and provided the coaxial addition of a sheath 
liquid (50/50 isopropanol/water) at 3 μL/min. The ESI-MS was operated in the negative 
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mode using a spray voltage of 1.9 kV and an MS-capillary temperature of 190 °C. Mass 
spectra were acquired from m/z 300 to 2000. Due to the known migration behavior of 
HMOs and related structures, no supplementary detector was used between CE instrument 
and MS, as described before,17 providing a more robust analysis set-up. MSn was performed 
in the data dependent mode using a window of 1 m/z and collision energy of 35%. For 
increasing the S/N ratio, ions of m/z 311, 314 and 329 were excluded from detection in 
MSn experiments. MSn data were interpreted using Xcalibur software 2.0.7 (Thermo).  
Based on the m/z-value as determined by CE-MS, the nanomole-concentration of 
oligosaccharides was translated to g/L.  
 
Results and Discussion 
Oligosaccharides in breast milk 
Characterization of breast milk oligosaccharides (HMOs) 
In order to study the fecal oligosaccharide profile of breast-fed babies during their first 
months of life, it is first of all important to characterize the breast milk, which served as 
feeding at the respective time points. Table 1 presents an overview of the samples obtained 
from the eleven mother/child pairs A-K. Three representative HMO-fingerprints, as found 
for breast milk samples 14 days postpartum, are shown in Figure 1.  
The HMO-profiles were recorded by CE-LIF and the structural compositions of the peaks 
were characterized by CE-MSn (Table 2). Secretor-characteristic (α1,2)-, (α1,3)- and 
(α1,4)-fucosylated HMOs8 were found in the milk of eight out of the eleven mothers. They 
were, therefore, assigned as Le(a-b+)-secretors (Figure 1-I and Table 1). This is in 
accordance with the predominance of Le(a-b+)-secretors as found among the European 
population.27,28 The breast milks of Le(a-b+)-secretors could be sub-classified into two 
groups according to their peak proportions of  LNFP I/III (peak 25) / LNDFH I (peak 26). 
For the first group, a rather equal ratio was observed, with LNFP I/III / LNDFH I < 1.5:1 
on average, as exemplified in Figure 1-I. The second group had a LNFP I/III / LNDFH I -
ratio of  ≥ 2:1. An example hereof is shown in Figure 2. From the seven Le(a-b+)-breast-
milk samples available during the first two months, four  (B, C, F, G) could be sub-
classified in group 1 and three  (A, D, E) in group 2.  
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Figure 1. CE-LIF electropherograms of APTS-derivatized HMOs extracted from (I) breast milk of Le(a-b+)-
secretor-mother C. (II) Le(a+b-)-non-secretor-mother K. (III) Le(a-b-)-secretor-mother I.            
See Table 2 for peak annotation.*internal standard xylose. 
 
Due to the inactivity of the secretor-gene, non-secretors [Le(a+b-)] are not able to 
synthesize (α1,2)-fucosylated HMOs, such as 2’fucosyllactose (2’FL; peak 4, co-migrating 
with 3’FL), lacto-N-fucopentaose I (LNFP I; peak 25, co-migrating with LNFP III) and 
lacto-N-difucohexaose I (LNDFH I; peak 26). The respective structures were not present in 
the electropherograms of mothers J and K. They were, therefore, assigned as non-secretors. 
A non-secretor-milk pattern is shown in Figure 1-II and represents a characteristic 
oligosaccharide profile observed for this group. Higher-Mw HMOs, such as              
fucosyl-/difucosyl-/trifucosyl- and lacto-N-hexaose-isomers (F-LNH, DF-LNH, TF-LNH 
and LNH), represented a higher percentage of the total oligosaccharide-content in the non-
secretor profile (24±8%) compared to the Le(a-b+)-secretor group (7±2%). Even           
lacto-N-octaose- and lacto-N-decaose isomers were detectable. With regard to the          
low-Mw HMOs, lacto-N-tetraose was the main HMO in the non-secretor profiles, 
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constituting 33±2% of the total oligosaccharide content, whereas for Le(a-b+)-secretors this 
value was 9±5%.  
 
Table 2. Structural composition of oligosaccharides detected in CE-LIF electropherograms (Figures 1-5).  
APTS-derivatized oligosaccharides were present in their threefold negative charge in the ESI-MS profiles.  
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*      xylose ISTD 20 601 4 2 0 1 S-LNH* 
1      monomers 21 412 3 0 2 0 m/z 412# 
2 260 2 0 0 0 lactose 22 425 2 1 2 0 m/z 425# 
3 357 2 0 0 1 SL* 23 479 3 1 0 1 S-LNT* 
4 309 2 0 1 0 FL* 24 601 4 2 0 1 S-LNH* 
5 309 2 0 1 0 m/z 309# 25 431 3 1 1 0 LNFP I/III 
6 382 3 1 0 0 LnNT Y 26 479 3 1 2 0 LNDFH-I 
7 358 2 0 2 0 DF-L 27 479 3 1 2 0 m/z 479# 
8 479 3 1 0 1 S-LNT* 28 650 4 2 1 1 FS-LNH* 
9 382 3 1 0 0 LnNT 29 504 4 2 0 0 LNH 
10 528 3 1 1 1 FS-LNT* 30 485 4 1 1 0 m/z 485# 
11 358 2 0 2 0 m/z 358# 31 533 4 1 2 0 m/z 533# 
12 479 3 1 0 1 S-LNT* 32 547 3 2 2 0 m/z 547# 
13 363 3 0 1 0 m/z 363# 33 498 3 2 1‘ 0 m/z 498# 
14 377 2 1 1 0 m/z 377# 34 552 4 2 1 0 F-LNH* 
15 431 3 1 1 0 LNFP Y 35 601 4 2 2 0 DF-LNH* 
16 358 2 0 2 0 m/z 358# 36 650 4 2 3 0 TF-LNH* 
17 382 3 1 0 0 LNT 37 674 5 3 1 0 F-LNO* 
18 431 3 1 1 0 LNFP II 38 747 6 4 0 0 LND* 
19 576 3 1 0 2 DS-LNT* 39 795 6 4 1 0 F-LND* 
*: isomers not further specified; #see Figure 4B for structural characterization 
 
(Alpha1,4)-fucosylated HMOs, such as LNFP II (peak 18) and LNDFH I (peak 26), are 
absent in the milk of Lewis-negative secretors Le(a-b-).8 These oligosaccharides were not 
present in the breast milk of mother “I”, who was, therefore, assigned as Le(a-b-)-secretor 
(Figure 1-III). Instead, (α1,2)- and (α1,3)-fucosylated oligosaccharides dominated, as 
visualized by the FL- and LNFP I/III -peaks (Figure 1-III, peaks 4 and 25). They made up 
76% of the total oligosaccharide content of the Le(a-b-)-profile. The FL-peak encompasses 
2’FL (Fuc-(α1,2)-Gal-(β1,4)-Glc) and   3’FL (Gal-(β1,4)-[Fuc-(α1,3)]-Glc). The LNFP I/III 
-peak includes LNFP I [Fuc-(α1,2)-Gal-(β1,3)-GlcNAc-(β1,3)-Gal-(β1,4)-Glc] and 
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LNFP III [Gal-(β1,4)-[Fuc-(α1,2)]-GlcNAc-(β1,3)-Gal-(β1,4)-Glc]. These structures co-
migrated in CE-LIF.  
Sialyllactose(SL; peak 3)-, two sialyllacto-N-tetraose(S-LNT; peaks 12 and 23)-, 
disialyllacto-N-tetraose(DS-LNT; peak 19)- and fucosyl-sialyllacto-N-hexaose(FS-LNH; 
peak 28)-isomers were the most abundant acidic HMOs found in the breast milks, as 
determined by CE-MS. These acidic oligosaccharides constituted 9±2% of the total 
oligosaccharide content in the milk of Le(a-b+)- and Le(a+b-)-mothers and 3% in the milk 
of the Le(a-b-)-mother. However, the actual number may be higher as high-Mw acidic 
HMOs were not taken into account and the abundant DS-LNT co-migrated with LNDFH II, 
influencing the quantification of this compound. 
By means of saliva analysis, the secretor-status of eight out of the eleven mothers was 
determined and the prediction on the secretor-status on basis of the CE-LIF patterns was 
confirmed (Table 1).  
 
Development of the HMO-profile of breast milk in time 
In order to include non-identified oligosaccharides for quantification, which is possible 
with CE-LIF due to the mole-based detection of the APTS-derivatized oligosaccharides,29 
concentrations are expressed in nmol in this study. The total HMO-concentration was 
translated to 14±5 g/L for the 14d-breast milk samples (see materials and methods). This is 
a common concentration range found for breast milk early after birth.9 The concentration of 
HMOs as present in breast milk 14d postpartum decreased by ± 40% on average during the 
first three months and is comparable to what has been previously reported.9 Overall, the 
proportions of the individual HMOs changed during the first months after birth. 
A representative example is given for breast milk A at the time points 14d, 2m and 4m 
(Figure 2). For comparison, peak ratios are presented relative to LNDFH I in the table of 
Figure 2. A characteristic ratio of LNFP I/III / LNDFH I ≥ 2:1 was observed 14d after birth 
for breast milk A (vide supra).  This ratio decreased during the course of lactation, which 
was also found for the other individuals of this group. On the contrary, such a change was 
not observed for individuals who initially showed a ratio of LNFP I/III / LNDFH I < 1.5:1.  
Within most profiles, but most noticeably for the Le(a-b-)-secretor-profile, an increased 
contribution of FL (Figure 1, peak 4, composed of 2’FL and 3’FL) to the oligosaccharide 
profile after advanced lactation time was observed. This increase resulted in a plateau value 
of the reduced oligosaccharide concentration as present after three months or even resulted 
in a subsequent increase of on average 14% between three and six months. Previous studies 
related this increase to the increase of (α1,3)-fucosylated HMOs in time.9 As (α1,2)- and 
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(α1,3)-fucosylated oligosaccharides co-migrate with CE-LIF, this explanation could only be 
assumed for the present study. As milk samples from non-secretors were only available for 
a limited time-range (Table 1), a decrease in total oligosaccharide concentration during the 
first two months could only be indicated for this group in our study. A decrease in total 
oligosaccharide content in the milk of non-secretors during the first three months 
postpartum has been previously stated by Thurl et al.9 
 
 
Figure 2. CE-LIF electropherograms of APTS-derivatized HMOs extracted from breast milk of Le(a-b+)-secretor-
mother A at 14 days (I), 2 months (II), 4 months (III) postpartum.  
Table indicates peak ratios relative to LNDFH I = 1. See Table 2 for peak annotation.*internal standard xylose. 
 
Fecal oligosaccharides of breast-fed babies 
One or more fecal samples were obtained from ten breast-fed babies at the time points 
indicated in Table 1. Contrary to the corresponding breast milks, which only changed in 
HMO-proportions and not in their overall HMO-fingerprint during the first six months 
postpartum, two major changes in the fecal oligosaccharide profiles were observed. 
Although the time-period inbetween these major changes was individual-dependent, three 
SL (3) FL (4) LNT (17) LNFP I/III (25) LNDFH I (26)
I - 2 weeks 0.8 5.6 1.3 2.0 1.0
II - 2 months 0.5 6.1 1.2 1.5 1.0
III - 4 months 0.5 6.2 0.9 1.3 1.0
LI
F 
in
te
ns
ity
migration time (min)
7.00 8.00 9.00 10.003.00 4.00 5.00 6.00
I
II
III
*
1
2
3
4
7 912
17
18
19
25
26
34 35
36
1
1
3
3
7
7 9
17
17
18
19
19
18
23
23
23
25
26
26
28
28
28
34
34
35
35 36
36
29
29
29
Chapter 5 
 
 98
successive stages of fecal oligosaccharide profiles in time could be defined. The first stage 
comprises the first weeks or months of life, when the gastrointestine is not yet adapted to 
the enteral food. The second stage represents a stabilized gastrointestinal ecosystem, which 
is then disturbed by the introduction of solid food in the third stage. The findings will be 
discussed below per stage, followed by a general discussion.  
 
Stage 1: Neutral or acidic HMO-profiles in feces 
Fecal oligosaccharide profiles obtained just after birth and up to two months postpartum 
could be sub-divided according to their respective fingerprints, which were dominated by 
either neutral or acidic oligosaccharides. 
 
Neutral HMOs 
Fecal oligosaccharide profiles, which were overall corresponding to the HMO-profile of the 
respective breast milks, were found for four babies (E, F, G, I). As a representative, the 
HMO-profile of the breast milk G and the corresponding fecal oligosaccharide profile, both 
taken two months postpartum, are shown in Figure 3A and the peak ratios relative to 
LNDFH = 1 are indicated. Changes in peak presence and abundance in the fecal extract can 
be linked to the activity of gastrointestinal enzymes: Lactose is absent in the fecal extract, 
indicating lactase activity.30 The lowered proportion of the FL- and LNFP I/III -peak in the 
fecal extract (Figure 3A, peaks 4 and 25) points to fucosidase activity.31 The decreased 
proportion of SL (Figure 3A, peak 3) and the reduction in DS-LNT (Figure 3A, peak 19) 
can be connected to intestinal sialidase activity. LNT [Gal-(β1,3)-GlcNAc-(β1,3)-Gal-
(β1,4)-Glc] (Figure 3A, peak 17) is absent in the fecal sample, as was previously 
reported.14,17 LNT, which contains the bifidogenic factor lacto-N-biose [Gal-(β1,3)-
GlcNAc]6 is thus indeed a desired substrate for the developing gastrointestinal microbiota 
characteristic for breast-fed babies in an early stage postpartum. Even more, due to the 
presence of the degradation product LNFP Y [Gal-(β1,4)-[Fuc-(α1,3)]-GlcNAc-(β1,6)-Gal-
(β1,4)-Glc] (Figure 3A, peak 15) and the absence of F-LNH-isomers (Figure 3A, peak 34), 
it can be assumed, that F-LNH-isomers, which carry a non-substituted lacto-N-biose unit at 
their branching point (e.g. F-LNH II: Gal-(β1,4)-[Fuc-(α1,3)]-GlcNAc-(β1,6)-[Gal-(β1,3)-
GlcNAc-(β1,3)]-Gal-(β1,4)-Glc), are important oligosaccharides for gastrointestinal 
bacteria during the first months postpartum. A non-HMO-component of m/z 363 
(Figure 3A, peak 13) was present in the feces of baby G in stage 1, but only contributed to 
2% of the total oligosaccharide content. As this is a dominant oligosaccharide of stage 2, 
the component will be discussed there. 
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Figure 3. CE-LIF electropherograms showing (A) HMOs of Le(a-b+)-secretor-milk from mother G (A-I) and 
neutral fecal HMO-profile of baby G (A-II) at 2 months postpartum. (B) HMOs of Le(a-b+)-secretor-milk from 
mother A (B-I) and acidic fecal HMO-profile of baby A (B-II) at 14 days postpartum. Table indicates peak ratios 
relative to LNDFH I = 1 for Figure 3A.  
See Table 2 for peak annotation.*internal standard xylose. 
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Acidic HMOs 
Remarkably, for three babies (A, D, K), a fecal oligosaccharide profile composed of 
39±13%  acidic HMOs was found. As a comparison, for babies F, G and I, who showed a 
mainly neutral fecal HMO-profile, the percentage of the acidic oligosaccharides was only 
7±1%. An exception was baby E, for which, besides a characteristic neutral HMO-profile, 
acidic oligosaccharides contributed to 15%. The babies showing predominantly acidic fecal 
oligosaccharides had Le(a+b-)-non-secretor-(K)- or Le(a-b+)-secretor-mothers (A, D). In 
the HMO-profiles of the respective breast milks no elevated contribution of acidic HMOs 
was found. As a representative, the HMO-profile of the breast milk A and the 
corresponding fecal oligosaccharide profile, both taken 14d postpartum, are shown in 
Figure 3B. Noticeably, babies A, D and E, who showed increased proportions of acidic 
fecal HMOs, consumed milk with a LNFP I/III / LNDFH I -proportion of ≥ 2:1 
(exemplified by Figure 2 and Figure 3B). Instead, for breast milk of the mothers F and G, 
whose babies showed neutral HMO-profiles, the proportion of LNFP I/III / LNDFH I 
was < 1.5:1 (exemplified by Figure 3A).  
 
The HMO-profiles of breast milk from Le(a-b+)-secretors may thus have an influence on 
the gastrointestinal fate of these oligosaccharides in the first few months postpartum. The 
HMO-profiles of Le(a-b-)-secretor- and Le(a+b-)-non-secretor-milk may influence the fecal 
oligosaccharide profiles in a different way. On the other hand, also other factors than the 
composition of the respective breast milk may determine the fecal oligosaccharide profile, 
e.g. a reduced gastrointestinal sialidase activity, which may inhibit a further enzymatic 
degradation of the acidic oligosaccharides.32 
 
For the fecal samples, which were taken up to two months postpartum from baby C, no 
oligosaccharide profile comparable to human milk was found and the prevailing peaks 
could not be identified by CE-MS. The values (m/z) in the MS fragmentation pattern were 
unusual for carbohydrates and may point to the presence of glycoprotein-components in 
this single case. For baby B, fecal samples were collected only from month two onwards 
and the oligosaccharide profiles observed were already indicative for stage 2, as will be 
discussed next. 
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Stage 2: Predominance of metabolization products 
Development of the fecal oligosaccharide profiles in time 
The absence of HMOs and the prevalence of a few, individual-dependent, dominant peaks, 
which were subsequently characterized as gastrointestinal HMO-metabolization products 
(see below) is characteristic for fecal oligosaccharide profiles of stage 2. The time-point, at 
which the neutral or acidic fecal HMO-profile of stage 1 had completely disappeared was 
baby-dependent. For all babies, oligosaccharides characteristic for stage 2 were at three 
months postpartum present to a larger proportion than oligosaccharides characteristic for 
stage 1. This development of the fecal oligosaccharide profile is exemplified for baby A in 
Figure 4. Mainly acidic oligosaccharides are still observed after two months and 
exclusively metabolization products are observed after four months. The inlay in Figure 4 
shows the total fecal oligosaccharide content, which was set to 100% for day 14. Similar to 
what was found for other babies, an increase in fecal oligosaccharide concentration could 
be observed during the first few months, which may be correlated to an increased intake of 
breast milk. Good feeding practice estimates an approximate intake of breast milk 
equivalent to one fifth of the baby’s weight per day. The average decrease of approximately 
40% of the initial HMO-concentration in breast milk during the first three months, as 
shown for the mothers in this study, may therefore be compensated by an increased milk 
intake. The considerable drop in fecal total oligosaccharide concentration after three 
months is remarkable and could be the consequence of an adapted bacterial flora, which has 
colonized under the influence of breast milk during the first few months postpartum.33 The 
inlay in Figure 4 also indicates the contribution of the novel oligosaccharides to the total 
oligosaccharide content, related to the total oligosaccharide content of 100%, as set for day 
14. After four months, the predominant metabolization products represent more than      
80% of the total oligosaccharide peaks present at that time point for baby A. This dominant 
presence of gastrointestinal metabolization products corresponds to what was found for all 
the other babies. The corresponding breast milk for baby A is shown in Figure 2 and does 
not indicate major changes in oligosaccharide profile and only indicated changes in the total 
oligosaccharide concentration at the respective time points. Although having a secretor-
mother of the type Le(a-b-), baby I showed the same trend in fecal oligosaccharide 
development as found for babies from Le(a-b+)-mothers, albeit with a slower switch from 
stage 1 to stage 2. A HMO-profile corresponding to the respective breast milk was still 
present after two months, not showing any indication for metabolization (which was 
already clearly visible for baby G at two months, Figure 3A). Although no conclusions 
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could be drawn, this may be connected to the preterm delivery of baby I and points at a 
delayed gastrointestinal development.34  
 
Figure 4. CE-LIF electropherograms showing fecal oligosaccharide profiles for baby A at 14 days (I), 2 months 
(II) and 4 months (III) postpartum. Inlay depicts development of total oligosaccharide concentration and 
contribution of metabolization products to total oligosaccharide content in time.  
See Table 2 for peak annotation.*internal standard xylose. 
 
Characterization of metabolization products  
Four different oligosaccharide sets were found for the eight babies from whom samples 
showing metabolization products (stage 2) were available. Representative 
electropherograms are shown in Figure 5A. The structures characteristic of the 
oligosaccharide profiles were studied by MS-fragmentation after separation with CE.         
A summary of the annotated MS-fragments is given in Table 3. The fragments could be 
affiliated to oligosaccharides characteristic for either blood group A, B, or H(0). In 
addition, the fragments indicated the presence of similar structural backbones, which may 
result from HMO-building blocks (Figure 5B). Blood groups were not determined for the 
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babies participating in the present study, but for the respective mothers, the blood group 
was mostly known (Table 1). A correlation to the baby’s blood group may thus be possible 
in some cases. Due to the low amounts of sample, the annotation of the emerging structures 
could not be confirmed by means of NMR. 
 
Blood group A-characteristic oligosaccharides 
For two babies (A, F), oligosaccharide profiles corresponding to Figure 5A-I were 
observed. The three predominating structures present in Figure 5A-I had m/z-values of 377 
(peak 14), 425 (peak 22) and 498 (peak 33). Their structural compositions [HexNAc-[Fuc]-
Hex-Hex (m/z 377), HexNAc-[Fuc]-Hex-[Fuc]-Hex, (m/z 425) and HexNAc-[Fuc]-Hex-
HexNAc-Hex-Hex (m/z 498)] were annotated according to their respective MSn 
fragmentation patterns (Table 3). All had a terminal HexNAc-[Fuc]-Hex-unit (Figure 5B). 
Supplementary, a fourth structure with a terminal HexNAc-[Fuc]-Hex-unit, assigned as 
HexNAc-[Fuc]-Hex-[Fuc]-HexNAc-Hex-Hex (m/z 547), was found in the fecal sample 
taken after two and three months from baby A (Figure 4, peak 32). It was only present in 
trace amounts and co-migrated with structure m/z 498 in the four-month-sample (Figure 4 
and Figure 5A-I, peak 33). The m/z 498 represents the monofucosylated analogon of the 
difucosylated m/z 547 (Figure 5B). The increase of m/z 498 at the expense of m/z 547 may 
thus indicate enzymatic defucosylation in time. HexNAc-[Fuc]-Hex is the antigenic 
determinant for blood group A and composed of GalNAc-(α1,3)-[Fuc-(α1,2)]-Gal.35 In a 
previous study we detected m/z 377 and m/z 498 in the feces of a breast-fed two months old 
preterm baby of blood group A.36 Previously, the same blood group A characteristic 
oligosaccharides were detected in the feces of an eight weeks old preterm baby of blood 
group A.10 Hence, the presence of m/z 377 (peak 14), m/z 425 (peak 22), m/z 547 (peak 32) 
and m/z 498 (peak 33) in the present study was associated with a blood group A-affiliation 
of the babies A and F, with baby A having a mother belonging to blood group A. 
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Figure 5. (A) CE-LIF electropherograms showing (A-I) blood group A-characteristic oligosaccharides from     
baby A after 4m. (A-II) blood group B-characteristic oligosaccharides from baby G after 3 months. (A-III/-IV) 
Blood group H(0)-characteristic oligosaccharides from baby D after 6 months and baby I after 3 months.            
(B) Summary of oligosaccharides resulting from gastrointestinal metabolization of HMOs, as present in Figures 4 
and Figure  5A and characterized by CE-MS.*internal standard xylose. 
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Table 3. Mass fragments and structural composition of unknown, APTS-derivatized oligosaccharides of the     
CE-LIF electropherograms (Figure 5). The APTS-derivatized oligosaccharides were present in their                
twofold [2-] and threefold [3-] negative charge in the fragmentation profiles. 
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m/z fragment 
pair 
structural composition           
 
207[3-]/ 
310[2-] 
Hex-APTS + + + + + + + + + 
255[3-]/ 
383[2-] 
Fuc-Hex-APTS - + - - + - - - - 
260[3-]/ 
391[2-] 
Hex-Hex-APTS + + + + + + + + + 
309[3-]/ 
464[2-] 
Fuc-Hex-Hex-APTS + + - + + + -  + 
314[3-]/ 
472[2-] 
Hex-Hex-Hex-APTS - - - + + - -  - 
328[3-]/ 
492[2-] 
HexNAc-Hex-Hex-APTS + + + - - + -  - 
358[3-]/ 
537[2-] 
Fuc-Hex-[Fuc]-Hex-APTS - + - - + - -  - 
363[3-]/ 
545[2-] 
Hex-Hex-[Fuc]-Hex-APTS 
Hex-[Fuc]-Hex-Hex-APTS 
- - - - + - -  - 
377[3-]/ 
566[2-] 
Fuc-HexNAc-Hex-Hex-APTS 
HexNAc-[Fuc]-Hex-Hex-APTS 
HexNAc-Hex-[Fuc]-Hex-APTS 
- + - - - + - + - 
382[3-]/ 
574[2-] 
Hex-HexNAc-Hex-Hex-APTS - - + - - + - + - 
431[3-]/ 
647[2-] 
Fuc-Hex-HexNAc-Hex-Hex-APTS - - + - - + - + - 
449[3-]/ 
674[2-] 
HexNAc-Hex-HexNAc-Hex-Hex-APTS - - + - - - - - - 
479[3-]/ 
719[2-] 
Fuc-Hex-[Fuc]-HexNAc-Hex-Hex-
APTS 
- - - - - + - - - 
485[3-]/ 
723[2-] 
Hex-[Fuc]-Hex-HexNAc-Hex-Hex-
APTS 
Hex-Hex-[Fuc]-HexNAc-Hex-Hex-
APTS 
- - - - - + - - - 
 
Blood group B-characteristic oligosaccharides 
Baby G showed an oligosaccharide profile as shown in Figure 5A-II during stage 2. The 
three characteristic structures found in the fecal oligosaccharide profile have the values   
m/z 363 (peak 13), m/z 412 (peak 21) and m/z 533 (peak 31). Their structural compositions 
[Hex-[Fuc]-Hex-Hex (m/z 363), Hex-[Fuc]-Hex-[Fuc]-Hex, (m/z 412) and                    
Hex-[Fuc]-Hex-[Fuc]-HexNAc-Hex-Hex (m/z 533)] were determined according to their 
Chapter 5 
 
 106 
respective MSn fragmentation patterns (Table 3). All carry a terminal Hex-[Fuc]-Hex-unit 
(Figure 5B). Hex-[Fuc]-Hex is the antigenic determinant for blood group B and is 
composed of Gal(α1,3)-[Fuc(α1,2)]-Gal.35 The mother of baby G belongs to blood group B. 
This is the first time that blood group B-characteristic oligosaccharides have been detected 
in the feces of a breast-fed baby. A fourth structure of m/z 485 (peak 30) was found in 
minor amounts and co-migrated with m/z 533. The m/z 485-value represents the 
monofucosylated analogon of m/z 533 (Figure 5B), similar to the monofucosylated 
m/z 498, which replaced the difucosylated analogon m/z 547 for blood group A after four 
month. Due to its low abundance an MS-fragmentation was not possible for m/z 485. 
 
Oligosaccharides indicating affiliation to blood group H(0) 
Three babies (B, D, E) showed fecal oligosaccharide profiles corresponding to what is 
shown in Figure 5A-III. The two dominating structures in Figure 5A-III had the          
m/z-values 309 (peak 5) and 479 (peak 27) and were assigned as Fuc-Hex-Hex (m/z 309) 
and [Fuc]-Hex-[Fuc]-HexNAc-Hex-Hex (m/z 479) according to their fragmentation 
patterns (Table 3). The fragmentation patterns and m/z values corresponded to the HMO-
structures 2’FL and LNDFH I, but showed different migration times. Thus, the fecal 
oligosaccharides may represent structural isomers of these HMOs as proposed in       
Figure 5B. Alternatively, the reducing end sugar may be galactose instead of the glucose. 
The unknown structure m/z 479 may correspond to a LNDFH-isomer, not known for breast 
milk (lacto-N-neo-difucohexaose: Fuc-(α1,2)-Gal-(β1,4)-[Fuc-(α1,3)]-GlcNAc-(β1,3)-  
Gal-(β1,4)-Glc), which was previously identified in the urine of lactating women.15 The 
antigenic determinant for blood group H(0) is a pre-cursor of the antigenic determinant of 
blood groups A and B and is composed of Fuc-(α1,2)-Gal.35  
The components m/z 377 (peak 14) (blood group A specific) and m/z 363 (peak 13) (blood 
group B-specific) were present only in minor proportions in the profiles of babies B, D and 
E, as exemplified by baby D in Figure 5A-III. On the other hand, m/z 479, which is 
abundantly present in the profiles of babies B, D and E, was found in low proportions only 
in the blood group B characteristic profile (Figure 5A-II). Hence, an affiliation to blood 
group H(0) was proposed for babies B, D and E. Indeed, two of the respective mothers were 
known to have blood group H(0). 
 
Baby I, who had a Le(a-b-)-secretor-mother, had blood group H(0). A different fecal peak 
profile for stage 2 was observed (Figure 5A-IV) compared to what was described for the 
three babies B, D, E. For these babies, blood group H(0) was only expected, due to the 
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oligosaccharide profiles observed (Figure 5A-III). Their mothers were Le(a-b+)-secretor-
mothers. 
Three peaks of exceptionally low abundance were detected from three months onwards for 
the baby of the Le(a-b-)-secretor. Two of the peaks (Figure 5A-IV, peaks 11 and 16;      
m/z 358) were assigned as Fuc-[Fuc]-Hex-Hex according to their mass fragmentation 
pattern (Table 3). They are structurally related to Fuc-Hex-Hex (m/z 309), as present in the 
feces of the babies for whom blood group H(0) was expected. A double-fucosylated      
non-reducing end was found for m/z 358 (Figure 5B). Component m/z 358 was as well 
present in the profiles of the babies, for whom blood group H(0) was expected          
(Figure 5A-III), but was dominated by other structures in that case. Similar to the babies 
for whom blood group H(0) was expected, traces of the blood group A-characteristic 
structure m/z 377 were detected in the fecal profile of baby I from the Le(a-b-)-secretor-
mother (Figure 5A-IV, peak 14). The genetically determined HMO-fingerprint in breast 
milk may influence the gastrointestinal formation of metabolization products in stage 2. 
 
Stage 3: Oligosaccharides characteristic for follow-up feeding 
For two babies (E, H), fecal samples were collected at t ≥ six months, when solid food was 
part of the diet next to breast milk. No fecal HMOs, and also no oligosaccharides 
characteristic for stage 2 were found. Instead, a homologous series of hexose-
oligosaccharides was observed. These oligosacchrides co-migrated with a maltodextrin-
standard and probably result from diet-related (resistant) starch. The glucose/galactose 
proportion was exceptionally high for samples of stage 3 (3.8:1) as resulted from 
monosaccharide composition analysis of these samples. As a comparison, the 
glucose/galactose proportion was 0.7:1 for stage 1 and 0.4:1 for stage 2 on average. The 
presence of a diverse gastrointestinal microbiota by the time solid food is introduced may 
be reflected in the peak profile.33 The microflora present thus largely degrades HMOs and 
does not stimulate the bioconversion to blood group characteristic structures. Yet, it is not 
adapted to fully degrade the carbohydrate structures newly introduced by the feeding, e.g. 
starch. Indeed, microbiological studies have shown a significant change in gastrointestinal 
flora composition with the introduction of solid food for breast-fed babies.33 
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Overview of HMO-metabolization in the gastrointestine of neonates 
Following the fecal oligosaccharide profiles of breast-fed babies and comparing them to the 
HMO-profiles of the respective breast milks during the first months postpartum enabled us 
to get a detailed picture on the gastrointestinal fate of HMOs. The ongoing gastrointestinal 
development and the adaptation towards the feeding during that time was depicted, which 
finally led to an almost complete disappearance of the feeding-related HMOs at the time 
when solid food was introduced. A schematic overview on the suggested gastrointestinal 
bioconversion of HMOs is given in Figure 6. Although some general trends were observed, 
the timing of the fecal oligosaccharide development remained baby-specific. In the first few 
months (stage 1), HMOs are degraded to monomers and dimers, serving as energy source 
for the developing gastrointestinal microbiota, with among them lacto-N-biose, which can 
be used by the health-promoting Bifidobacteria.6 Degradation products (such as LNFP Y) 
are detected in the feces of these babies in combination with a HMO-profile depicting the 
fingerprint of their mother’s milk. Alternatively, a selection of acidic HMOs is detected, 
which may be a result of the set of HMOs provided with the respective breast milk. 
Independent of the initial presence of neutral or acidic oligosaccharides (stage 1), a gradual 
change to an oligosaccharide profile dominated by parts of HMOs decorated with blood 
group specific epitopes was observed with proceeding time (stage 2). HMOs are degraded 
in the gastrointestinal tract during stage 2, resulting in a uniform set of basic units, which 
are subsequently conjugated to blood group characteristic oligosaccharides. The 
involvement of blood group characteristic epitopes, which are located in the gastrointestinal 
mucus layer,35 are proposed to play an important role for this enzymatic re-structuration of 
the HMOs. This results in a personalized fecal oligosaccharide profile during stage 2. The 
exact mechanism and biological significance of this gastrointestinal re-design remains to be 
investigated. Finally, the absence of HMOs and their blood group-characteristic derivatives 
in stage 3, points to the installation of an adult-like flora at the time of weaning.33 We thus 
propose, that fecal oligosaccharide profiles can be used as mirrors for monitoring the 
individual-dependent gastrointestinal adaptation to enteral food during the first months 
postpartum. 
 
 
 
 
 
                                                                                          Oligosaccharides in breast milk and baby feces during first six months 
 
 109 
 
 
 
 
Figure 6. Schematic overview on the proposed gastrointestinal degradation and metabolization of HMOs             
as observed for stage 1 and stage 2.  
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Abstract 
The application of capillary electrophoresis with laser-induced fluorescence detection    
(CE-LIF) as a tool for the characterization of complex carbohydrate structures was 
investigated for konjac glucomannan (KGM) oligosaccharide mixtures and the monitoring 
of their structural changes during 72 h of in vitro fermentation with human gut flora. 
Different types of KGM oligosaccharide mixtures were produced from a KGM 
polysaccharide using endo-β-(1,4)-mannanase and endo-β-(1,4)-glucanase. Distinction of 
structures emerging from different enzymatic KGM digests and detection of acetylated 
oligosaccharides were possible by both CE-LIF and matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Using CE-LIF 
it could be shown that the endo-β-(1,4)-glucanase digest exhibited a large degradability of 
the DP2, DP3, DP5, and DP6 components during in vitro fermentation, whereas the      
endo-β-(1,4)-mannanase digest was digested only slightly, thereby highlighting the 
influence of structural characteristics on the fermentability by human gut flora. 
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Introduction 
The profiling of complex oligosaccharides is an analytical challenge, complicated by the 
presence of numerous isomeric structures. However, the monitoring of structural features of 
complex carbohydrate substrates during in vitro and in vivo fermentation trials with human 
gut flora is a crucial step for judging their fate in the human colon and thus their prebiotic 
potential. Prebiotics are defined to be nondigestible food ingredients that beneficially affect 
the host by selectively stimulating the growth and/or activity of one or more desired 
bacteria species in the colon and thus improve host health.1 Prebiotics are associated with 
nondigestible oligosaccharides (NDOs), meaning they are transiting the human small 
intestine inert2 and, being oligosaccharides, they are defined to consist of 3-10 
monosaccharide units according to IUB-IUPAC. However, there is no rational or 
physiological limit for setting the latter limits of DP10.3 Frequently used prebiotic 
substrates are lactose-based galactooligosaccharides (GOS) and fructooligosaccharides 
(FOS)/inulin, and large numbers of studies have been performed that investigated the 
prebiotic potential of GOS and FOS,4,5 confirming their selective stimulation of beneficial 
gut bacteria. A drawback of these commonly used prebiotics might be their fast 
fermentation in the proximal part of the colon.3,6 Many colonic diseases, such as ulcerative 
colitis and tumors, occur in the distal part of the gastrointestinal tract. Targeting the more 
distal colonic regions is therefore an important issue in the fields of prebiotic research and 
design.3,7 Due to their possible resistance to bacterial metabolization in the proximal colon, 
complex carbohydrate structures are of increasing interest and need to be tested in vitro and 
in vivo for their prebiotic suitability. Earlier studies on the in vitro fermentability of 
differently substituted xylooligosaccharides (XOS) showed that nonsubstituted XOS were 
fermented more easily than the more complex structures of acetylated XOS, although the 
effect of adaptation to the substrate has not been described.8 
Hence, having a combination of acetylation of the sugars and a backbone of two different 
sugars, konjac glucomannan (KGM) and oligosaccharides derived thereof seem to be 
promising prebiotic substrates. KGM is a neutral polysaccharide derived from the tuber of 
Amorphophallus konjac C. Koch and native to Southeast Asia.9 It is composed of β-(1,4)-
linked D-mannose and D-glucose residues in a molar ratio of 1.6:1.10 Five to ten percent of 
the hexose residues are acetylated.11 However, it has not yet been established if the acetyl 
groups are attached to the glucose or mannose residues, and our knowledge concerning the 
sequence of the mannose and glucose residues over the polysaccharidic chain is still 
limited. Although efforts have been made to investigate the monosaccharide sequence, still 
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blockwise12 as well as random distributions10 are being considered. KGM is estimated to be 
a slightly branched polysaccharide with branches consisting of 11-16 hexose residues 
(mannose, glucose, and galactose).13 Besides its potential prebiotic characteristics, KGM is 
also known to have beneficial effects on human health and has been consumed in Asia for 
centuries. Being a soluble dietary fiber, it can positively influence hyperglycemia and 
hypercholesterolemia and may result in a delayed stomach emptying, hence providing a 
feeling of satiety and possibly facilitating weight loss.14-16 Studies of the effect of KGM on 
the fecal microflora in Balb/c mice revealed a dose-dependent bifidogenic effect, especially 
for hydrolyzed KGM.17 However, the influence of fermentation on KGM structures has not 
yet been studied in detail, mainly due to limited analytical capabilities. Recently, capillary 
electrophoresis with laser induced fluorescence detection (CE-LIF) has been shown to be a 
suitable technique for the study of complex oligosaccharide mixtures, which are laborious 
and difficult to analyze using reversedphase high-performance liquid chromatography    
(RP-HPLC) or high-performance anion exchange chromatography (HPAEC) and mass 
spectrometry coupling (HPAEC-MS).18-21 Therefore, in this study CE-LIF and matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) 
were used to elucidate the structural characteristics and the in vitro fermentation by human 
gut flora of structurally different KGM oligosaccharide mixtures. 
 
Materials and Methods 
Materials and enzymes 
The konjac glucomannan polysaccharide (KGM native) was obtained from Kalys (Kalys, 
St-Ismier, France). The standards used for HPAEC and CE-LIF were cellodextrin             
[β-(1,4)-linked glucose oligosaccharides] and D-(+)-mannose, both from Sigma-Aldrich 
(St. Louis, MO), as well as manno-β-(1,4)-biose, manno-β-(1,4)-triose, manno-β-(1,4)-
tetraose, and manno-β-(1,4)-pentaose, all obtained from Megazyme (Bray, Ireland). The 
crude cellulase preparation used was produced by Trichoderma viride (Maxazyme, DSM 
Food Specialties, Delft, The Netherlands). Endo-β-(1,4)-glucanase VI [EC 3.2.1.4, GH 
family 7, specific activity = 11 mU/mg of protein on CM-cellulose (type Akucell AF 0305, 
Akzo, Arnhem, The Netherlands), 20 mM sodium citrate buffer, pH 3.5, 30 ºC] was 
purified from this commercial cellulase preparation according to the method of        
Beldman et al.22 Endo-β-(1,4)-mannanase [EC 3.2.1.78, GH family 5,                       
specific activity = 33 U/mg of protein on palm kernel mannan (extracted and prepared by 
Düsterhöft et al,23 0.05 M sodium acetate buffer, pH 5, 30 ºC] was purified from a 
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commercial Aspergillus niger enzyme mixture (Gamanase III, Novozymes, Bagsvaerd, 
Denmark) according to the method of Düsterhöft et al.24 
 
Preparation of oligosaccharides from konjac glucomannan polysaccharide  
Digestions with the crude cellulase preparation and with the pure endo-β-(1,4)-mannanase 
were performed in 0.05 M sodium acetate buffer at pH 5. KGM results in highly viscous 
solutions and tends to form clumps. Therefore, it had to be prepared by adding the KGM 
powder slowly to vigorously stirred water. The KGM polysaccharide solution (10 mg/mL) 
was incubated with a 0.1% (v/v) cellulase concentration. The enzyme level applied for 
endo-β-(1,4)-mannanase was 70 μL of enzyme solution (3.3 U/mL) per milliliter of 
substrate solution (5 mg/mL). The incubation with endo-β-(1,4)-glucanase VI was 
performed in 20 mM sodium citrate buffer at pH 3.5, and 363.6 μL of enzyme solution    
(0.8 U/mL) was added per milliliter of substrate solution (5 mg/mL). The enzyme dosages 
were chosen according to the best results in oligosaccharide profile obtained after testing 
different substrate to enzyme ratios. The incubation parameters were 30 ºC and 24 h at 
shaking conditions for all enzymes. After hydrolysis, the enzymes were inactivated          
(10 min, 100 ºC), and the hydrolysate was centrifuged (5 min, 10000g, room temperature). 
Saponification was performed for 16 h at 4 ºC, shaking conditions (25 mL of 0.2 M sodium 
hydroxide (NaOH) per 200 mg of substrate), with parts of the KGM digests to obtain 
deacetylated material. The solutions were desalted by adding an excess of anion-exchange 
resin (AG 50W-X8 resin; Bio-Rad, Hercules, CA) and freeze-dried.  
For a more detailed structural characterization, the oligosaccharides in the digests were 
fractionated according to their DP. Fractionation was performed on a Spectra System HPLC 
(Thermo Finnigan, Waltham, MA) equipped with a BioGel P2 column (26 mm x 900 mm, 
200-400 mesh, Bio-Rad) thermostated at 60 ºC and eluted with Milli-Q water at               
0.3 mL/min. Samples (3-13 mg) were either injected by means of an autosampler or 
directly applied onto the column. The column efflux was first led through a refractive index 
detector (Shodex RI72, Showa Denko K.K., Tokyo, Japan) before it was collected in 
fractions of 10 min by a fraction collector (Superfrac, GE Amersham, Uppsala, Sweden). 
Appropriate fractions were pooled and freeze-dried for further analysis. 
Prior to the fermentation experiment, monomers were removed from the initial KGM 
digests. The cellulase and endo-β-(1,4)-mannanase digest were subjected to gel filtration on 
a Superdex 30 prep grade column (600 mm x 120 mm, 24-49 μm bead size; GE Amersham, 
Uppsala, Sweden). Samples of up to 2 g were applied on the column and were eluted with 
distilled water (25 mL/min) at room temperature using an Akta Explorer system              
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(GE Amersham). A Shodex RI-72 detector (Showa Denko K.K.) was used to monitor the 
refractive index. Fractions were collected each 2 min with a Superfrac fraction collector 
(GE Amersham) and examined for monomers using HPAEC-PAD. Monomer-free fractions 
were freeze-dried.  
 
Fermentation  
The fermentation broth used was prepared according to the method of Kabel et al.8             
A solution of each konjac glucomannan substrate in water [1% (w/v)] was prepared (S1); 
for the blank S1 consisted of pure water. The substrates used were fermented in duplicate. 
For solution 2 (S2) bacto yeast nitrogen base (Difico, Detroit, MI) was dissolved in water 
(6.7 g/L). Solution 3 (S3) was composed of 40% (v/v) of a watery salt solution [magnesium 
sulfate (0.2 g/L), calcium chloride (0.2 g/L), potassium hydrogen phosphate (1 g/L), 
potassium dihydrogen phosphate (1 g/L), sodium hydrogen carbonate (10 g/L), and sodium 
chloride (2 g/L)], 5% (w/v) casein enzymatic hydrolysate (N-Z Amine A, Sigma-Aldrich), 
and 0.5% (w/v) sodium thioglycolate]. S2 and S3 were adjusted to pH 6-7 by 1 M NaOH. 
The three solutions S1, S2, and S3 were combined in a ratio of (v/v) 17:1:2 in serum flasks, 
which were filled at 50% and closed by a butyl rubber stopper. Taking into account 
Maillard reactions, filter-sterilized S2 was added only after the flasks had been autoclaved 
(15 min, 121 ºC).  
To create anaerobic conditions, the air in the serum flasks was exchanged for a nitrogen 
atmosphere (0.7 bar underpressure) by using the Anaerobic Lap system (8 cycles)           
(GR Instruments B.V., Wijk bij Duurstede, The Netherlands).  
Fecal samples were obtained from three healthy human volunteers in sterile plastic cups 
and were processed shortly after defecation to avoid aerobic conditions. The processing of 
the samples was performed according to methods of Kabel et al. and Hartemink.8,25  
A 10% (w/v) mixed fecal slurry was prepared by adding one spoon (∼5 g) of each fecal 
sample to 150 mL of buffered peptone water containing L-cysteine hydrochloride (0.5 g/L, 
pH 6.7). The fecal slurry was mixed, and after an equilibration time of 30 min, the 10-fold 
diluted feces were diluted 100 times further by adding them to serum flasks containing a 
sterilized solution (pH 6.7) of neutralized bacterial peptone (1 g/L), sodium chloride          
(8 g/L), and L-cysteine hydrochloride (0.5 g/L) and a nitrogen atmosphere. Serum flasks 
containing fermentation medium were inoculated with 20% (v/v) of the volume of S1, S2, 
and S3 present in the flask using the 1000-fold fecal dilutions. The serum flasks, 
representing one KGM substrate each, were incubated at 37 ºC. 
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Samples were removed eight times between 0 and 72 h. Enzymes were inactivated by 
heating (5 min, 100 ºC, 1100 rpm). The samples were centrifuged, and the supernatants 
were stored at -80 ºC for further analysis. For a screening of the bacterial growth, the pH of 
the supernatants was measured, and the optical density of the bacterial residue was 
determined at 600 nm (GeneQuant pro spectrophotometer, Biochrom, Cambridge, U.K.). 
 
Analytical methods  
Monosaccharide composition 
The neutral sugar content and composition were determined by gas-liquid chromatography 
according to the method of Englyst et al using inositol as an internal standard.26 Samples 
were pretreated with aqueous 72% sulfuric acid (H2SO4) (w/w) (1 h, 30 ºC), followed by 
hydrolysis with 1M H2SO4 (3 h, 100 ºC) before they were analyzed as volatile alditol 
acetates on a Carbo Erba Mega 5160 GC (Thermo Finnigan). 
 
Degree of acetylation (DA)  
The degree of acetylation was determined according to the method of Voragen et al.27 The 
ester bonds were saponified by 0.4 N NaOH in a water-isopropanol mixture, and the 
released acetic acid was determined on a Spectra System HPLC (Thermo Finnigan) 
equipped with an Aminex HPX 87H column (Bio-Rad) and a Shodex RI72 detector (Showa 
Denko K.K.). The eluent used was 5.0 mM H2SO4 (0.6 mL/min, 40 ºC). 
 
HPSEC 
The molecular weight distribution of large oligosaccharide and polysaccharide fractions 
was investigated by high performance size exclusion chromatography (HPSEC) using a 
Spectra System HPLC (ThermoFinnigan) equipped with a refractive index detector Shodex 
RI72 (Showa Denko K.K.). Twenty microliter sample solutions (5 mg/mL) were injected 
automatically, using a Thermo AS3000 autosampler. Separation was performed on three 
TosoH Biosep-TSK-Gel G columns in series (4000PWXL-3000PWXL-2500PWXL, each 
7.5 mm x 300 mm; TosoH, Japan) in combination with a PWXL guard column 
(6 mm x 40 mm; TosoH). For elution, 0.2 M sodium nitrate was used at a flow rate of       
0.8 mL/min at 30 ºC. The system was calibrated with pullulan standards (Sigma-Aldrich; 
mass range from 180 Da to 790 kDa).  
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MALDI-TOF MS  
For MALDI-TOF MS of oligosaccharides, an Ultraflex workstation (Bruker Daltronics, 
Bremen, Germany) equipped with a nitrogen laser of 337 nm was used. The measurement 
was performed in the positive mode. After a delayed extraction time of 200 ns, the ions 
were accelerated with a 25 kV voltage. The data were collected from averaging 100 laser 
shots, with the lowest laser energy necessary to obtain sufficient spectra intensity. The mass 
spectrometer was calibrated with a mixture of maltodextrins (AVEBE, Veendam,           
The Netherlands; mass range of 527-2309 Da as sodium adducts). For sample preparation, 
samples (1 mg/mL) were desalted with anion-exchange material (AG 50W-X8 resin;       
Bio-Rad). The desalted samples (1 μL) were mixed directly on a MS target plate with          
2 μL of matrix solution consisting of a watery solution of 2,5-dihydroxybenzoic acid        
(10 mg/mL; Bruker Daltonics). The mix was dried under a stream of warm air. 
 
HPAEC  
The oligosaccharide profile was monitored by HPAEC (Dionex ISC 3000; Dionex, 
Sunnyvale, CA), equipped with a Dionex Carbopac PA-1 column (2 mm x 250 mm) in 
combination with a Carbopac PA-1 guard column (2 mm x 50 mm). Samples (20 μL) of a 
concentration of 0.1 mg/mL were injected by means of a Dionex ISC3000 autosampler. The 
oligomers were eluted (0.3 mL/min) by using a gradient of 0-400 mM NaOAc in              
100 mM NaOH during 40 min. Each elution was followed by a washing step (5 min,          
1 M NaOAc in 100 mM NaOH) and an equilibration step (20 min, 100 mM NaOH). 
Detection was performed using a Dionex ED40 detector in the pulsed amperometric 
detection mode. 
 
CE-LIF 
Samples for CE-LIF were prepared using the ProteomeLab Carbohydrate Labeling and 
Analysis Kit (Beckman Coulter, Fullerton, CA). To samples containing approx. 0.1 mg of 
carbohydrate was added 5 nmol of maltose as an internal standard and mobility marker. 
This mixture was dried using the SpeedVac Concentrator Savant ISS110 (Thermo Electron 
Corp., Waltham, MA). The mono- and oligosaccharides present in the dried sample were 
labeled with 9-aminopyrene-1,4,6-trisulfonate (APTS). Separation of the derivatized 
carbohydrates was performed using a ProteomeLab PA 800 characterization system 
(Beckman Coulter) equipped with a polyvinyl alcohol-coated capillary (50 μm x 50.2 cm). 
Detection was done with a laser-induced fluorescence detector (LIF) (Beckman Coulter) at 
an excitation wavelength of 488 nm and an emission wavelength of 520 nm after 40 cm 
CE-LIF and in vitro fermentation of konjac glucomannan 
 
 121 
capillary length. The capillary was rinsed with water (5 min, 30 psi) and then with 
separation gel buffer (2 min, 30 psi); the rinsing buffer was exchanged every 20 samples. 
Subsequently, samples were loaded hydrodynamically (4 s at 0.5 psi, representing approx. 
14 nL of sample solution) on the capillary, which was kept at 25 ºC. Separation was 
performed in the reversed polarity mode (30 kV, 20 min) in a 25 mM acetate buffer        
(pH 4.75) containing 0.4% polyethylene oxide. 
 
Results 
Production and characterization of KGM material 
Knowledge of the characteristics of KGM material is essential for understanding the 
changes the material undergoes upon fermentation with human gut flora. All KGM 
materials produced were derived from the native polymeric KGM. The sugar composition 
of the native KGM showed a mannose:glucose molar ratio of 1.5:1 and galactose 
contributing to the total sugar content with a mole percentage of 1%. The DA was 
determined to be 7.9%. For a structural characterization, incubation of the polysaccharide 
was performed with endo-β-(1,4)-mannanase and endo-β-(1,4)-glucanase.                
MALDI-TOF MS was used for a first screening of the KGM oligosaccharides obtained 
after the enzymatic digestion of the polymer. The mass spectra obtained showed the sodium 
(Na) and potassium (K) adducts of hexose oligomers. Besides, masses were found that 
indicate the presence of one to three acetyl groups bound to hexose oligomers. Applying a 
mass window ranging from m/z 500 to 2500 made it possible to detect oligosaccharides of 
DP3-DP14. Monomers, dimers, and oligosaccharides with DP > 14 were not detected with 
this method. The use of a purified endo-β-(1,4)-glucanase resulted in the appearance of 
oligosaccharides covering the whole range of DP3-DP14 (Figure 1A).  
Instead, incubation with endo-β-(1,4)-mannanase resulted in oligosaccharides showing a 
smaller DP range of DP3-DP9 (Figure 1B). Comparison of the MALDI-TOF mass spectra 
of the endo-β-(1,4)-mannanase digest and the endo-β-(1,4)-glucanase digest revealed a 
different distribution of acetyl groups on the oligosaccharides with different DPs. The insets 
in Figure 1 show the degree of acetyl substitution of the oligosaccharides, based on the 
signal heights of the MALDI-TOF mass spectra. Within one DP the total height of all Na 
and K adduct signals was set to 100% and the relative amount of DP having x, y, z, or k 
acetyl groups was indicated. This is merely an indication, because it was only assumed that 
all oligomers would have the same response. The higher the DP, the higher seems to be the 
amount of single-acetylated and multiple-acetylated oligosaccharides for both substrates. 
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Figure 1. MALDI-TOF mass spectra of (A) KGM endo-β-(1,4)-glucanase digest and (B) KGM endo-β-(1,4)-
mannanase digest. Masses indicated represent sodium adducts. *, Single-acetylated DP; **, double-acetylated DP; 
***, triple-acetylated DP. Insets represent the degree of acetylation per DP. (Ac = acetyl group.) 
 
The DA of smaller oligomers is higher for the endo-β-(1,4)-mannanase digest.  
Because MALDI-TOF MS is only a screening of the oligomers present, another method 
was needed for a more detailed characterization. HPAEC-PAD is commonly used for 
characterizing oligosaccharidic material. Comparison of the HPAEC-PAD separation of the 
series mannose, mannobiose, and mannooligosaccharides with the series glucose, 
cellobiose, and cellooligosaccharides (Figure 2A) revealed a complex elution profile in 
which elution was certainly not based on size alone. Cellobiose is eluting almost 
contemporaneously with mannopentaose. The mixed glycosidic linkages of glucose and 
mannose present in KGM make the chromatograms of KGM oligomers even more complex 
and an assignment of the DPs impossible (data not shown). Therefore, the recently 
established CE-LIF method was tested for its capacity to separate complex oligomer 
mixtures resulting from KGM digests. 
Electrophoretic separation demands charged molecules. Therefore, the neutral 
oligosaccharides were labeled with the threefold negatively charged fluorescent dye APTS.  
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Figure 2. (A) HPAEC PAD chromatogram of cello-oligomers and manno-oligomers; (B) CE-LIF 
electropherogram of cello-oligomers and manno-oligomers. *, Maltose (internal standard). 
 
For the standard mixtures a groupwise migration according to the DP was obtained with 
CE-LIF (Figure 2B), which presents a crucial advantage compared to the separation 
obtained by HPAEC-PAD. Analyzing the endo-β-(1,4)-mannanase and endo-β-(1,4)-
glucanase digests with CE-LIF resulted in electropherograms showing distinct peak clusters 
with a repeating pattern, especially for the endo-β-(1,4)- glucanase digest (Figure 3). Free 
APTS as well as mono- and oligosaccharidic components of the endo-β-(1,4)-mannanase 
digest migrated completely between the migration times 3 and 7.5 min, resulting in a 
separation window of < 4.5 min. The peak clusters of the endo-β-(1,4)-glucanase digest 
were distributed over the whole separation time of 20 min (electropherograms shown were 
all zoomed in to a maximum of 15 min). For an identification of the DPs in these complex 
mixtures of nonacetylated and acetylated oligosaccharides, BioGel P2 fractions of the 
endo-β-(1,4)-mannanase and endo-β-(1,4)-glucanase digests were analyzed with CE-LIF. 
The DPs of those fractions were estimated by MALDI-TOF MS. Subsequently, it was 
possible to assign each of these distinct peak clusters appearing in Figure 3 with their 
respective DP. 
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Figure 3. CE-LIF electropherogram of (A) KGM endo-β-(1,4)-mannanase digest and (B) KGM endo-β-(1,4)-
glucanase digest. 
 
The endo-β-(1,4)-mannanase and endo-β-(1,4)-glucanase digest showed complementary 
peak patterns. Clearly, CE is able to separate both acetylated and nonacetylated 
oligosaccharides in a single run, whereas the alkaline HPAEC elution does not give any 
information on the presence of acetylated oligosaccharides. Saponified substrates were 
subjected to CE-LIF analysis to investigate if all peaks originally present in 
electropherograms of nonsaponified substrates were still present after saponification. Peaks 
that were not present any more were assigned as peaks representing acetylated oligomers. 
For the endo-β-(1,4)-mannanase digest, disappearance of peaks mainly at the end of each 
DP cluster was observed (Figure 4A), whereas for endo-β-(1,4)-glucanase, the 
disappearence of peaks was not restricted to the end of the DP clusters (Figure 4B). 
Acetylation is more abundant for higher DPs in the endo-β-(1,4)-glucanase digest, whereas 
saponification effects already clear changes with DP3 and DP4 in the endo-β-(1,4)-
mannanase digest. 
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Figure 4. CE-LIF electropherograms of (A) initial and saponified KGM endo-β-(1,4)-mannanase digest and       
(B) initial and saponified KGM endo-β-(1,4)-glucanase digest. *, Maltose (internal standard). Vertical dotted lines 
indicate peaks that are no longer present after the saponification experiment. 
 
In vitro fermentation of KGM material  
Because methods were now available for a structural characterization, they were applied to 
the monitoring of the in vitro fermentation of KGM substrates. Therefore, oligosaccharides 
were prepared by enzymatic digestion of the KGM polymer with endo-β-(1,4)-mannanase 
and a crude cellulase mixture. Four different KGM substrates and a fermentation blank 
(without any carbohydrate source added) were fermented in duplicate by a fecal slurry 
consisting of a mix of feces from three human volunteers. In summary, the substrates used 
were a cellulase and an endo-β-(1,4)-mannanase digest of KGM. The enzymatic digests 
were used for the fermentation experiments in their monomer-free forms. To test the 
influence of the presence of monomers, the cellulase digest was as well fermented in its 
monomer-containing form. The behaviour of the KGM oligosaccharides was compared to 
the fermentation behavior of the parental native polysaccharide KGM. The substrates were 
autoclaved to exclude bacterial contamination. MALDI-TOF mass spectra of autoclaved 
enzymatically treated KGM material showed largely reduced signal intensity or even a lack 
of signals for acetylated oligosaccharides. All oligosaccharidic KGM mixtures could, 
therefore, be considered as substrates low in or without acetyl groups. For estimating 
bacterial growth and activity, OD and pH in the samples taken during the fermentation 
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experiment (up to 72 h) were measured. HPSEC, MALDI-TOF MS, and CE-LIF analysis 
were used to monitor the in vitro fermentation and utilization of the polymer or the 
individual oligosaccharidic carbohydrate components. Results from the duplicate 
experiment were comparable and are not further considered. All KGM samples showed an 
increase in optical density and a decrease of pH from an average pH 6.5 to a common end 
point of pH 4.7-4.8 during 72 h of in vitro fermentation. With the monomer-containing 
cellulase digest, the pH reached the end point after only 24 h, whereas for the 
polysaccharide a more gradual decrease to the end point pH after 72 h was found. The 
result for the monomer-free cellulase digests was situated between these two extrema 
mentioned. In contrast, the monomer-free endo-β-(1,4)-mannanase digest behaved similarly 
to the monomer-containing cellulase digests. The fermentation blank showed neither an 
increase of OD nor a decrease in pH upon 72 h of fermentation time. Studying the 
degradation pattern of the monomer-containing cellulase digest by CE-LIF revealed the 
following characteristics: Monomeric material was fermented during the first 24 h, and di- 
and trimers were largely fermented especially between 24 and 72 h. For the larger  
oligomers, no changes were observed during the in vitro fermentation (Figure 5A). The 
fermentation of the monomer-free cellulase digest resulted in a different pattern compared 
to its monomer containing analogon (Figure 5B). During the first 24 h, no changes within 
the oligosaccharidic material were observed. Between 24 and 72 h, DP6 was completely 
and DP5 largely degraded, whereas DP4 was more resistant. The areas of the first peak, 
identified as a dimer (migration time of 4.7 min), and the peaks belonging to DP3 
(migration time between 5.05 and 5.3 min) decreased also over time. The decrease in areas 
over time for the latter peaks described was 50% higher in the monomer-containing 
analogue, compared to the monomer-free preparation. The CE-LIF electropherograms of 
the cellulase digest at t = 0 h (Figure 5) did not completely match with the 
electropherogram obtained for the endo-β-(1,4)-glucanase digest (Figure 3B), as the latter 
one showed additional side peaks aside from the common main peaks found for both 
electropherograms. The CE-LIF electropherograms of the monomer-free endo-β-(1,4)-
mannanase digest did not show a distinct degradation pattern. The increase of 
oligosaccharides with the size of DP3 indicated, nevertheless, an ongoing carbohydrate 
fermentation upon 72 h of fermentation. MALDI-TOF MS results of the KGM mixtures 
confirmed the degradation of oligosaccharidic material during the 72 h in vitro fermentation 
and did not provide any further information. 
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Figure 5. CE-LIF electropherograms obtained after 0, 24, and 72 h of fermentation of (A) KGM cellulase digest 
containing monomers and (B) monomer-free KGM cellulase digest. *, Maltose (internal standard). 
 
Analysis of CE-LIF electropherograms, MALDI-TOF mass spectra, and HPSEC 
chromatograms resulted in complementary information concerning the fermentation of the 
KGM polymer. As observed by the shift in molecular weight in Figure 6A, the polymer, 
which had originally a Mw of ≥ 500 000 (≥ DP 3000), was gradually degraded to 
oligomeric material during 72 h of fermentation. By integrating the areas under the curves it 
could be stated that the oligomers formed were also utilized to some extent. The peak areas 
representing oligomeric material increased to only 35% of the decreased area belonging to 
polymeric material in the HPSEC chromatograms. In Figure 6B, the emergence of 
oligomers during the fermentation of the polymer is shown by CE-LIF electropherograms. 
The intensity of the oligomers increased, with DP5 being the most abundant DP after 72 h. 
MALDI-TOF mass spectra showed, in addition to the emerging series of hexoses, the 
appearances of series of masses representing single-acetylated hexoses. 
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Figure 6. (A) HPSEC chromatograms obtained after 0, 24, and 72 h of fermentation of the KGM polysaccharide; 
(B) CE-LIF electropherograms obtained after 0, 24, and 72 h of fermentation of the KGM polysaccharide.             
*, Maltose (internal standard). 
 
Discussion 
Characterization of KGM material  
To study the influence of the chemical structure and the KGM mixture composition on the 
fermentability, the KGM material used for fermentation was characterized in the first part 
of this study. Combination of MALDI-TOF MS with results obtained by applying the 
recently established CE-LIF method contributed to a structural approach on endo-β-(1,4)-
mannanase and endo-β-(1,4)-glucanase digests of KGM. For KGM with a M:G ratio         
of 1.5:1, the KGM chain provided more cleaving sites for an enzymatic digest with            
endo-β-(1,4)-mannanase, which is expected to cleave the glycosidic linkage between two 
mannose residues (DP3-DP9 in MALDI-TOF mass spectra) than for an enzymatic digest 
with endo-β-(1,4)-glucanase, which is expected to cleave the glycosidic linkage between 
two glucose residues (DP3-DP14 in MALDI-TOF mass spectra). Not only the excess of 
mannose residues in the KGM polysaccharide but also the fact that endo-β-(1,4)-
mannanases cleave M-G bonds in the konjac glucomannan polysaccharidic chain28 explains 
the good degradability of KGM with endo-β-(1,4)-mannanase as observed with MALDI-
TOF MS. The enhanced degradation with endo-β-(1,4)-mannanase was confirmed with 
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CE-LIF, which provided oligosaccharide separation that showed advantages over the 
commonly performed separation with HPAEC-PAD and can be considered as the method 
of choice for the structural analysis of complex carbohydrate oligosaccharides. Besides the 
fast separation (20 min per run), the mole-based detection, and the detection of acetylated 
oligosaccharides, a distinct separation in peak clusters representing oligosaccharides of the 
same DP was obtained with CE-LIF. A complementary structural composition was found 
for the endo-β-(1,4)-mannanase and the endo-β-(1,4)-glucanase digests of KGM. 
Saponification experiments resulted in the detection of acetylated oligosaccharides that 
differed in position in the electropherograms of the endo-β-(1,4)-mannanase and            
endo-β-(1,4)-glucanase digest. The results obtained for the saponification experiment with 
CE-LIF analysis (Figure 4) have to be compared with the results found for the acetylation 
pattern with MALDI-TOF MS (Figure 1). Both digests showed an increased intensity for 
acetylated oligosaccharides with increasing DP in their mass spectra as well as in their 
electropherograms. However, the endo-β-(1,4)-glucanase digest showed a lower release of 
acetylated oligosaccharides for DP2-DP4. The endo-β-(1,4)-glucanase is therefore assumed 
to be less tolerant toward acetylation in the glucomannan backbone. 
 
Hypothesizing the chemical structure of KGM  
By combining results, it was possible to form a hypothesis on the chemical structure. Peak 
assignment was done by transferring information given by Cescutti et al,10 who examined 
enzymatic digests of KGM produced by endo-β-(1,4)-mannanase (issuing from                
Aspergillus niger) and cellulase (issuing from Penicillum funiculosum) with CE and         
1H NMR spectroscopy. Additionally, the migration profile of oligosaccharide standards 
consisting of β-linked glucose or mannose moieties was considered. The action pattern of 
an enzyme is highly dependent on its origin as well as the sugar composition of the 
substrate.29 Threfore, the action pattern of the endo-β-(1,4)-glucanase and endo-β-(1,4)-
mannanase used can be the easiest verified by evaluating the dimers formed by these two 
enzymes (Figure 7A). The endo-β-(1,4)-glucanase digest resulted in one dimer only, which 
did not migrate at the same time as either the cellobiose standard (GG; migration time of 
standard GG is indicated as ** in Figure 7A; G stands for glucose) or the mannobiose 
standard (MM; migration time of standard MM is indicated as *** in Figure 7A; M stands 
for mannose). The peak was identified as MG, as endo-β-(1,4)-glucanases are not supposed 
to cleave glycosidic linkage after mannose residues, but it showed clearly that the               
endo-β-(1,4)-glucanase used is capable of cleaving the linkage between glucose and 
mannose residues.  
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Figure 7. Hypothesis on the structure of KGM; CE-LIF electropherograms of mirrored zoom-ins of Figure 3 for 
the KGMendo-β-(1,4)-mannanase digest (normal view) and endo-β-(1,4)-glucanase digest (mirrored view) for (A) 
DP2 and (B) DP3. *, Maltose (internal standard); ++/**, migration time of GG/GGG standard, respectively; 
+++/***, migration time of MM/MMM standard, respectively. 
 
For the endo-β-(1,4)-mannanase digest, two dimers were identified, of which one could be 
identified as MM. The earlier-migrating dimer was assigned as GM, having a slightly later 
migration time than the dimer assigned as MG in the endo-β-(1,4)-glucanase digest, and 
explains the capability of the endo-β-(1,4)-mannanas used to cleave linkages between 
mannose and glucose. Within each DP, standards composed of glucose units migrated 
earlier than standards composed of mannose units (Figure 2B). On the basis of the latter 
fact, each peak cluster representing one DP in the KGM digests was divided into two 
subgroups, as demonstrated for DP3 in Figure 7B. According to the migration profile of 
the references, the subgroup migrating earlier (subgroup I) was assigned to be the one 
richer in glucose (migration time of standard GGG is indicated as ++ in Figure 7B), 
whereas the subgroup migrating later (subgroup II) was assigned to be the one richer in 
mannose (migration time of standard MMM is indicated as +++ in Figure 7B). A 
hypothesis on the structures was formed on the basis of the relative concentrations of 
trimeric structures as identified by Cescutti et al.10 For the endo-β-(1,4)-mannanase digest 
GGM and GMM were reported to occur in a ratio of 1.00:0.52. Therefore, the peak in 
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subgroup I was assigned as GGM and the most abundant peak in subgroup II as GMM. 
Also, MMM was identified in subgroup II by its respective standard and was, as well as 
MGM, reported to be a minor component of the trimeric fraction.10 However, no peak was 
assigned to MGM in the electropherogram. Comigration was assumed. Due to the 
saponification trials performed, peaks migrating later than GMM were assigned to 
acetylated trimers. Having used a cellulase preparation, the information given by            
Cescutti et al (MMG:MMM:MGG 1.83:1.00:0.2)10 was not completely adaptable to the 
digestion with endo-β-(1,4)-glucanase performed in the present study. Neglecting the 
formation of MMM, which is, considering the formation of dimers, not probable to occur 
by using this pure endo-β-(1,4)-glucanase, the two trimers were assigned for MGG in 
subgroup I and MMG in subgroup II. This structural characterization confirmed the action 
expected for the enzymes applied and justified the assumption of a clustered migration 
according to the predominance of glucose or mannose in the oligomers. Oligomers found in 
the endo-β-(1,4)-glucanase digest were assigned to carry exclusively glucose residues at the 
reducing end, revealing that endo-β-(1,4)-glucanases are not able to cleave the frequently 
occurring mannotri, -tetra, and  -pentaose segments present in the KGM polymer chain.30 
On the other hand, oligomers found in the endo-β-(1,4)-mannanase digest were assigned to 
carry exclusively mannose residues at the reducing end but predominantly glucose residues 
at the non-reducing end. Similar observations were made by Shimahara et al.28,31 The 
repeating peak pattern obtained in the electropherograms [especially for the endo-β-(1,4)-
glucanase digest] supports the block model for the KGM polymer instead of a random 
distribution of glucose and mannose residues. However, the higher the DP, the more peaks 
remain unknown, due to the increasing complexity of the KGM oligosaccharides and 
possible comigrations. From the literature, it is not known on which sugar residue acetyl 
groups are preferably situated in KGM. However, as acetylation intensity is increasing for 
the higher-MW oligosaccharides in the endo-β-(1,4)-glucanase digest, which are assumed 
to be especially rich in mannose, it can be assumed that the acetyl groups are preferably 
attached to the mannose residues. Furthermore, saponification of endo-β-(1,4)-mannanase 
digests resulted in a preferred disappearance of peaks belonging to subgroup II, 
representing oligosaccharides richer in mannose. The investigations made for the 
acetylation of a glucomannan from Lupinus varius seed showed as well acetylation of the 
mannose residues in the glucomannan chain.32 
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In vitro fermentation of KGM material 
In the second part of this study, native KGM and oligosaccharide mixtures representing 
cellulase and endo-β-(1,4)-mannanase digests of KGM were successfully fermented by 
mixed fecal slurries. Autoclaving the substrates before fermentation significantly decreased 
the level of acetylation. Autoclaving should be replaced by another sterilization method 
(e.g., based on filtration) in subsequent fermentation studies. However, choosing a 
sterilization method based on filtration may be difficult to apply for viscous 
polysaccharides such as KGM. During the fermentation course of 72 h, different 
degradation patterns for the respective KGM substrates were observed. Due to the use of a 
cellulase preparation instead of a pure endo-β-(1,4)-glucanase, the initial peak pattern on 
CE-LIF showed additional side peaks for the cellulase digest, which can be explained by 
the presence of endo-β-(1,4)-glucanases as well as exo-β-(1,4)-glucosidases in the cellulase 
preparation used.22 With the monomer-containing cellulase digest, a complete utilization of 
the abundant amount of monomers occurred during the first 24 h. Dimers and trimers were 
largely degraded, and oligosaccharides of DP4-DP6 did not change upon 72 h of 
fermentation. Monomers effect the inhibition of enzymes responsible for degrading 
oligosaccharides of higher Mw and promote the prevalence of certain species. The 
promotion of lactic acid bacteria (esp. Streptococcus species) by monomeric material and 
the simultaneous suppression of Bacteroides and Bifidobacteria species have been reported 
by Olano-Martin et al33 and explain the rapid drop in pH during the first 24 h of 
fermentation. For the monomer-free cellulase digest, differences in the degradation pattern 
were observed when compared to the monomer-containing analogue. This emphasizes the 
necessity of removing monomers before fermentation experiments, as they are also 
absorbed in the upper gastrointestinal tract and do not reach the colon. Besides the 
degradation of DP2 and DP3 a degradation of oligomers ≥ DP5 was observed after an 
adaptation time of 24 h. DP4 was more resistant to fermentation. Comparable to that,   
Kabel et al found a preferential fermentation of low substituted acetylated 
xylooligosaccharides with a DP of 3 and a DP > 7.8 The lack of easily accessible material in 
the monomer-free cellulase digest stimulated the development of an environment having 
other bacterial enzymes and/or even bacterial species present, which are responsible for the 
degradation of higher-Mw oligomers. The contribution of a broader range of bacteria may 
explain the less pronounced decrease in pH during the first 24 h (pH ≥ 5). Nevertheless, a 
final pH of  4.6 was reached after 24 h, which is suitable for a suppression of pathogenic 
species.1 According to the mass spectra and electropherograms, there was hardly any 
change in the carbohydrate profile during the 72 h fermentation course of the monomer-free 
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KGM endo-β-(1,4)-mannanase digest. The large pH drop and increase in OD during the 
first 24 h pointed nevertheless to an ongoing degradation, most probably consisting of an 
utilization of low-Mw material hidden by a meanwhile degradation of high-Mw oligomers 
out of the range of detection by MALDI-TOF MS and CE-LIF. The structural composition 
has obviously a big influence on the fermentation behavior: studying the structure of the 
endo-β-(1,4)-mannanase digest led to the conclusion that glucose or cellobiose is most 
frequently situated at the non-reducing end. For the cellulase digests it was assumed to be 
mainly mannose. Consequently, by the activity of bacterial exoenzymes, another set of 
mono- and dimers is provided for bacterial metabolization. High amounts of released 
glucose and therefore a predominance of lactic acid bacteria are as well indicated by the 
rapid drop in pH during the first 24 h of the fermentation of the endo-β-(1,4)-mannanase 
digest, which is similar to the behavior observed for the monomer containing cellulase 
digest.  
The fermentation of the parental polysaccharide was monitored by HPSEC, which showed 
the gradual degradation of the polymer (∼500 kDa) to an oligosaccharide mixture             
(≤ 4 kDa) after 72 h. Emerging oligomers were characterized by MALDI-TOF MS and CE-
LIF. The peak profile in the electropherograms, of which each DP cluster could be 
subdivided into two subgroups again, did not match exclusively with the profile of one of 
the enzymatic digests but was a combination of both, indicating the action of a broad range 
of endo- and exoenzymes expressed in the human colonic flora in order to break down a 
complex polysaccharide. The pH decreased very gradually and was still ≥ 5 after 24 h. As 
was described by Van Laere et al, the degradation of a polymer is a synergistic action, 
resulting in the expression of a broad variety of enzymes and bacteria.34  
Our study showed that the availability of advanced analytical methods is crucial for 
monitoring and understanding the behavior of complex carbohydrate structures during their 
in vitro fermentation. Structural features, composition, and method of preparation of the 
KGM mixtures had a large influence on the respective fermentation with human fecal flora. 
Combining results obtained from fermentation studies is necessary for a good 
understanding of bacterial action. Therefore, the inclusion of the on-line CE-LIF-MS 
coupling, allowing the assignment of peaks present in CE-LIF electropherograms with their 
respective masses, is aimed for. Furthermore, biomolecular methods such as Polymerase 
Chain Reaction-Denaturing Gradient Gel Electrophoresis (PCR-DGGE), a method used for 
investigating complex bacterial communities, and quantitative PCR, with which it is 
possible to establish a prebiotic index for potential prebiotic substrates, are currently 
applied for in vitro fermented konjac glucomannan substrates in our laboratory. 
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The determination of the bacterial metabolization products (organic acids) with GC and 
GC-MS will be our further approach to completely understand the fate of prebiotic 
substrates subjected to human gut flora. Although in vitro fermentation experiments do not 
allow a precise prediction of the fermentation in vivo (lack of buffered gut environment, 
strict anaerobicity and influence of other food components, adaptation of the flora subjected 
to prolonged exposure to specific prebiotic, strong influence of chosen concentrations of 
substrate to inoculum in in vitro experiments), they show clearly that the structural 
modification of oligosaccharides presents an effective way to influence the microbial 
community in the gut. 
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Abstract 
Enzymes from a balanced human gut flora are promising tools to design prebiotic 
oligosaccharides. Konjac glucomannan (KGM) and oligosaccharides thereof are potentially 
prebiotic substrates, which may even reach the distal part of the gut due to their structural 
complexity. In this study, the structural composition of oligosaccharides produced from 
KGM by enzymes of fecal bacteria was compared to two KGM digests produced by fungal 
endo-β-(1,4)-glucanase (EG) or endo-β-(1,4)-mannanase (EM). The oligosaccharide 
mixtures were separated according to their size and pools were subsequently analysed for 
their sugar composition. Capillary electrophoresis with laser induced fluorescence detection 
(CE-LIF) was used for the characterization of the oligosaccharide pools as such and after 
digestion by the exo-acting enzymes exo-β-(1,4)-glucanase and β-(1,4)-mannosidase. The 
KGM-oligosaccharides produced by the fecal enzyme mixture resulted in a series of 
homologous oligosaccharides with a constant mannose/glucose ratio of 1.5:1, representing 
the mannose/glucose ratio of the initial polysaccharide. A homologous series composed of 
mannose-rich oligosaccharides, which must be partly branched was observed for the EG-
digest, whereas a short series of oligosaccharides with an equal ratio of mannose and 
glucose was observed for the EM-digest. A backbone composed of short mannose- and 
glucose sequences, to which branches rich in mannose are attached was indicated for the 
KGM polysaccharide. Finally, the in vitro fermentability of the structurally different 
oligosaccharides is evaluated and their use as prebiotic substrates is discussed. 
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Introduction 
Oligosaccharides, intended to specifically stimulate gastrointestinal bacteria beneficial to 
the host’s health1,2 are frequently added to food products. Commonly used oligosaccharides 
are galactooligosaccharides (GOS) and fructooligosaccharides (FOS), which have been 
extensively studied for their prebiotic potential.3,4 These short-chain oligosaccharides are 
rapidly fermented in the colon. In order to prevent colonic diseases, which mainly take 
place in the distal part of the colon, more complex prebiotic oligosaccharides are needed, 
able to survive the entire gastrointestinal transit.5,6 The production of tailor-made 
oligosaccharides for this purpose is of great interest.2 Complex polysaccharides can be used 
for the enzymatic production of a variety of oligosaccharide mixtures. 
Glucomannan from Amorphophallus konjac C. Koch (KGM) represents an interesting 
polysaccharide for the production of structurally different oligosaccharides. KGM, which is 
composed of β–(1,4)-linked mannose- and glucose-units in a molar ratio of 1.5:1 enables 
the enzymatic hydrolysis by endo-β-(1,4)-glucanase (EG) as well as by endo-β-(1,4)-
mannanase (EM).7 The monosaccharide units are acetylated to an extent of 5-10%.8 
Branches are estimated to occur once upon every 10-11 hexose units in the main chain.9 
Little is known about the precise structure of KGM, such as the sequence of glucose and 
mannose within the backbone, precise length and distribution of the side chains and 
location of acetyl groups, although several studies have been performed.10-12 The complex 
structural composition make the KGM polysaccharide and the oligosaccharides derived 
hereof potential substrates for reaching the distal colon, which is the desired target site for 
bioactive carbohydrates.13 In a previous study, we tested KGM as well as two different 
KGM oligosaccharide sets, produced by EM and EG, for their in vitro fermentability by 
human gut flora.7 The structural composition of the oligosaccharides showed to influence 
the fermentability by human fecal bacteria. For the in vitro fermentation of the 
polysaccharide, the formation of an unknown oligosaccharide series, different from the 
mixtures obtained by the glucomannan hydrolysis with fungal EG or EM, was described.7  
No conclusions on the structural composition of the oligosaccharides, which were formed 
during in vitro fermentation could be drawn.7 The structural characteristics of 
oligosaccharides produced during the in vitro fermentation of polysaccharides provide 
information on the action of the enzymatic machinery of the colonic flora and has been 
recognized as valuable tool for the design of target-specific prebiotic oligosaccharides.14,15   
In the present study, the structural composition of oligosaccharides produced from KGM by 
enzymes of fecal bacteria is determined. For this purpose, it is compared to two KGM 
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digests produced by fungal EG and EM. The KGM-digests were fractionated according to 
their size and subsequently studied for their monosaccharide composition. Their 
degradability by exo-β-(1,4)-glucanase and β-(1,4)-mannosidase was followed 
quantitatively by capillary electrophoresis with laser-induced fluorescence detection 
(CE-LIF).16 Besides enabling the evaluation of the different enzymatic degradation 
mechanisms on KGM, the combination of the results allowed to draw some conclusions on 
the molecular structure of the KGM polysaccharide. 
 
Materials and Methods 
Materials and Enzymes 
The KGM polysaccharide was obtained from Kalys (St-Ismier, France). The KGM of the 
species Amorphophallus konjac had a molecular mass of approx. 500 kDa, a 
mannose/glucose molar ratio of 1.5:1 and a degree of acetylation (DA) of 7.9%.7 All 
chemicals used were of analytical grade. 
Endo-β-(1,4)-glucanase VI (EC 3.2.1.4) and exo-β-(1,4)-glucanase III (EC 3.2.1.91)  were 
purified from a crude cellulase preparation from Trichoderma viride (Maxazyme, DSM 
Food Specialities, Delft, The Netherlands) as described by Beldman et al.17 Endo-β-(1,4)-
mannanase (EC 3.2.1.78) was purified from a commercial Aspergillus niger enzyme 
mixture (Gamanase III, Novozymes, Bagsvaerd, Denmark) according to Düsterhöft et al.18 
Beta-(1,4)-mannosidase from Helix pomatia (E.C.3.2.1.25)19 was purchased from Sigma-
Aldrich (St Louis, MO). 
The enzymes from human fecal bacteria originated from a supernatant, which was obtained 
from an in vitro fermentation of KGM after 24 h fermentation time. The in vitro 
fermentation was performed with a mix of three human fecal samples, according to 
Albrecht et al.7 The composition of the medium was adapted according to Sunvold et al.20 
The concentration of KGM at the start of the fermentation was 3 mg/mL and the 
fermentation bottle was incubated with 200-fold diluted fecal slurry. The incubation 
volume was 20% (v/v) of the volume of substrate and medium present in the fermentation 
bottle. In order to prevent the loss of acetyl groups from KGM, the fermentation flasks were 
not autoclaved, but pasteurized prior to fermentation (70 ºC, 30 min). The fermentation 
liquid taken after 24h incubation was centrifuged (5 min, 2300g, room temperature), the 
bacterial cell material was discarded and the supernatant containing the soluble enzymes 
from human fecal bacteria was stored at -40 ºC. 
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Enzymatic hydrolysis and sample preparation 
The enzymatic digests of KGM using endo-β-(1,4)-glucanase VI and endo-β-(1,4)-
mannanase were prepared according to Albrecht et al.7 The enzymatic digests of KGM with 
enzymes from human fecal bacteria were prepared by adding 2 mL of the supernatant to 
10 mL of a 1.5 mg/mL KGM solution in water prior to incubation for 24 h at 37 ºC. 
Samples were mixed continuously during incubation (head-over-tail). Enzymes were 
inactivated (10 min, 100 ºC) and the samples were centrifuged (5 min, 10 000g, room 
temperature). 
The KGM digests were fractionated into oligosaccharide pools on a BioGel P2 column 
(26 mm x 900 mm, 200-400 mesh; Bio-Rad, Hercules, CA). Five mL of the supernatants 
were applied onto the column and were eluted with millipore water (1.5 mL/min) at 60 °C 
using an Akta Explorer system (GE Amersham, Uppsala, Sweden). The eluate was 
monitored by a refractive index detector (Shodex RI-72, Showa Denko K.K., Tokyo, Japan) 
before fractions (5 mL) were collected. The fractions were pooled according to the RI 
profile and freeze-dried. 
 
For their characterization, 100 µL of the oligosaccharide pools (approx. 0.1 mg/mL) were 
incubated with 1.35 mU exo-β-(1,4)-glucanase III or 19.7 mU β-(1,4)-mannosidase. The 
incubation (24 h) with exo-β-(1,4)-glucanase III was performed in 20 mM sodium citrate 
buffer pH 3.5 at 30 ºC and the incubation with β-(1,4)-mannosidase (24 h) was performed 
in 10 mM sodium acetate buffer at pH 4.5 at 45 ºC, shaking conditions. The enzymes were 
inactivated by heating the samples for 10 min at 100 ºC and the hydrolysate was 
centrifuged (5 min, 10 000g, room temperature) prior to analysis. 
 
Analytical methods 
Monosaccharide composition  
The enzymatic digests and the oligosaccharide pools  derived thereof were hydrolyzed with 
2 M trifluoroacetic acid for 1 h at 121 °C. Subsequently, the acid was evaporated and the 
residue was repeatedly washed with methanol. The hydrolysates were re-dissolved in 
millipore water and analyzed for their monosaccharide composition by HPAEC-PAD on a 
Dionex ISC 3000 system (Dionex, Sunnyvale, CA). The system was equipped with an 
analytical  Carbopac PA–1 column (2 mm x 250 mm; Dionex) and a guard column (2 mm x 
50 mm; Dionex). Separation was performed by elution with water, and 0.5 M sodium 
hydroxide was added post-column to the eluent for detection by PAD.21  
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Pools of DP2 were supplementary reduced prior to acid hydrolysis in order to determine the 
monosaccharide units located at the reducing end. The pools were, therefore, treated with 
sodium borohydride in ammonium hydroxide as described elsewhere.22 
 
Degree of acetylation (DA)  
Acetyl groups released from KGM during incubation with the enzyme mixture from fecal 
bacteria were determined by the analysis of acetic acid on a Dionex Ultimate 3000 HPLC 
system (Dionex). The system was equipped with an Aminex HPX 87H column (Bio-Rad) 
and a Shodex RI72 detector (Showa Denko K.K., Tokyo, Japan). The eluent used was 
5 mM sulphuric acid (0.6 mL/min, 40 °C). 
 
HPSEC                         
The molecular weight distribution of the polysaccharides and the enzymatic digests was 
determined by High Performance Size Exclusion Chromatography (HPSEC) using an 
Ultimate 3000 HPLC system (Dionex), equipped with an RI72 refractive index detector 
(Showa Denko K.K., Tokyo, Japan). 20 µL sample solutions (1 mg/mL) were injected and 
separation was performed on three Tosoh TSK gel superAW columns in series (AW4000-
AW3000-AW2500, each 6 mm x 150 mm; Tosoh Bioscience, Tokyo, Japan) in 
combination with a guard column (3.5 mm x 46 mm; Tosoh). For elution, 0.2 M sodium 
nitrate was used at a flow rate of 0.6 mL/min at 55 °C. The system was calibrated with 
pullulan standards (Sigma Aldrich; mass range 180 Da – 790 kDa). 
 
MALDI-TOF MS 
For matrix–assisted laser desorption/ionisation time-of-flight mass spectrometry 
(MALDI-TOF MS) of oligosaccharides, an UltraflexTreme TOF/TOF (Bruker, Bremen, 
Germany) equipped with a nitrogen laser of 337 nm was used. The measurement was 
performed in the positive mode. After a delayed extraction time of 200 ns, the ions were 
accelerated with a 25 kV voltage. Data from averaging 100 laser shots were collected, with 
lowest laser energy applied in order to obtain sufficient spectra intensity. 
The mass spectrometer was calibrated with maltodextrin. Samples were prepared as 
described previously.7 
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CE-LIF 
The sample preparation for CE-LIF, which includes the derivatization of the carbohydrates 
with the fluorescent dye APTS (9-aminopyrene-1,4,6-trisulfonate) was done using the 
ProteomeLab Carbohydrate Characterization kit (Beckman Coulter, Fullerton) as described 
previously.7 Separation of the derivatized carbohydrates was performed using a 
ProteomeLab PA 800 CE system (Beckman Coulter) equipped with a polyvinyl alcohol-
coated capillary (50 µm x 50.2 cm). Detection was done with a laser induced fluorescence 
detector (LIF) (Beckman Coulter) at an excitation wavelength of 488 nm and an emission 
wavelength of 520 nm after 40 cm capillary length. 
Samples were loaded hydrodynamically (7 s at 0.5 psi, representing approx. 14 nL sample 
solution) on the capillary, which was kept at 25 °C. Separation was performed in the 
reversed polarity mode (30 kV, 20 min) in a 25 mM acetate buffer (pH 4.75) containing 
0.4 % polyethylene oxide. Between sample runs, the capillary was rinsed with water 
(5 min, 30 psi) and with separation buffer (2 min, 30 psi). 
 
Results and Discussion 
Production of oligosaccharides from the KGM polysaccharide  
A digest of KGM with a mixture of soluble enzymes from an in vitro-fermentation of KGM 
with human inoculum (fecal enzymes; FE) was produced in this study. In order to compare 
the hydrolysis of the KGM chain by fecal enzymes with the hydrolysis of KGM by fungal 
enzymes, an endo-β-(1,4)-glucanase (EG)- and an endo-β-(1,4)-mannanase (EM)-digest of 
KGM were included, which were available from our previous research.7 The 
oligosaccharides resulting from the different KGM digests could be distinguished by CE-
LIF and the proportions of the DPs to the total digests were calculated (Figure 1 and Table 
in Figure 1).  
A repeating pattern, composed of two peaks per DP was observed for the FE-digest, with 
oligosaccharides DP ≥ 8 contributing to 50% to the total digest (Figure 1A). Monomers 
and dimers were present in trace amounts only in the FE-digest. Although only soluble 
enzymes were present in the enzyme mixture from fecal bacteria, the degradation profile of 
KGM (Figure 1A) was comparable to the oligosaccharide profile, which was previously 
obtained during in vitro fermentation.7 During in vitro fermentation also cell-associated 
bacterial enzymes may have been involved. Acetylated oligosaccharides were present in 
trace amounts only in the FE-digest, as investigated by MALDI-TOF MS (results not 
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shown). The lack of acetylated oligosaccharides in the FE-digest points to the activity of 
acetyl-esterases present in the FE-mixture. 
The oligosaccharides resulting from the EG-digest comprise a large DP-range (DP > 15; 
Figure 1B), with oligosaccharides of DP ≥ 8 contributing for 55% of the total digest. 
Acetylated oligosaccharides, as previously7 determined by MALDI-TOF MS before and 
after saponification of the oligosaccharides, are indicated in Figure 1B. Although showing 
an oligosaccharide pattern similar to the FE-digest, most peaks of the EG-digest showed 
different migration times compared to the FE-digest. 
Mannose (16%), dimers (45%) and trimers  (27%) are the main degradation products in the 
EM-digest (Figure 1C). Tetramers and pentamers are minor enzymatic hydrolysis products 
(6% and 3%, respectively). This can be explained by the mannose/glucose ratio of the 
polymer (mannose/glucose 1.5:1) and the ability of EM from A.niger  to cleave mannose-
mannose and mannose-glucose-linkages.23 Acetylated oligosaccharides, as previously7 
determined by MALDI-TOF MS and deacetylation experiments are indicated in Figure 1C.  
 
 
Figure 1. CE-LIF electropherograms of konjac glucomannan hydrolyzed by (A) enzymes from human fecal 
bacteria (FE) (B) endo-β-(1,4)-glucanase (EG) and (C) endo-β-(1,4)-mannanase (EM). *: maltose (internal 
standard). Ac: acetylated oligosaccharides. Inlay represents relative proportions of oligosaccharides per DPs 
within the digest. 
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Characterization of enzymatic hydrolysis products from KGM 
Size exclusion chromatography (SEC) of the enzymatically digested polysaccharide 
resulted in pools of distinct DPs for DP2-DP7, with minor contamination of the preceding 
and following DP (data not shown). CE-LIF electropherograms of the FE-, EG- and EM-
digest, which were used for further investigation, are shown in Figure 2. Tri- and tetra-
saccharides present in the respective pools of the FE-digest (Figure 2A) were separated 
more clearly compared to the total digest (Figure 1A), most probably due to impurities 
present in the total digest.  
Monosaccharide composition of KGM pools 
For an overview, monosaccharide composition analysis of the oligosaccharide pools was 
performed. The molar ratio of mannose/glucose for the oligosaccharide pools is presented 
in Table 1. For each digest, a characteristic trend in mannose/glucose ratio was observed. 
The oligosaccharide pools of the FE-digest showed a constant mannose/glucose ratio    
(1.5:1, mannose/glucose) up to DP7. The initial mannose/glucose ratio of 1.5:1 in the KGM 
polysaccharide chain is thus maintained. It can, therefore, be concluded, that the hydrolysis 
of KGM by fecal enzymes is not sugar-dependent.   
Although the EG-digest showed a homologous series of peaks, which is also found for the 
FE-digest, the trends in mannose/glucose ratio were not similar. The molar ratio for the  
EG-digest was 1.4 mol mannose per mol glucose for DP3 and DP4. The mannose/glucose 
ratio significantly increased to 2.4:1 for DP7.  
 
Table 1. Molar ratios of mannose (M) and glucose (G) in pools of enzymatic konjac glucomannan digests. 
FE = digest with enzymes from human fecal bacteria. EG = endo-β-(1,4)-glucanase-digest. EM = endo-β-(1,4)-
mannanase-digest. For dimers, the ratios after sample reduction are indicated. 
 
 FE-digest 
M/G 
EG-digest 
M/G  
EM-digest 
M/G 
DP1 - 0 : 1 8.8 : 1 
DP2 - 0.9 : 1 2.3 : 1 
DP2 after reduction* - 6.4 : 1 0.7 : 1 
DP3 1.3 : 1 1.4 : 1 0.9 : 1 
DP4 1.5 : 1 1.4 : 1 1.0 : 1 
DP5 1.5 : 1 1.9 : 1 1.1 : 1 
DP6 1.5 : 1 2.3 : 1 - 
DP7 1.5 : 1 2.4 : 1 - 
*: only the sugar located at non-reducing end is detected. 
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Figure 2. CE-LIF electropherograms of BioGel P2-pools from konjac glucomannan digest with (A) enzymes from 
human fecal bacteria (FE), (B) endo-β-(1,4)-glucanase (EG) and (C) endo-β-(1,4)-mannanase (EM). *: maltose 
(internal standard). The peaks within the respective pools are indicated. 
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Increased mannose ratios were expected for the higher-Mw pools of the EG-digest since 
mannose is present to a larger extent than glucose in the KGM polysaccharide, and EG is 
only able to cleave the glycosidic linkage between glucose-glucose and glucose-mannose, 
but not between mannose-mannose and mannose-glucose.24 
The mannose ratio in the DP3-DP5-oligosaccharide pools of the EM-digest was constantly 
low and equal to glucose (0.9-1.1 mol mannose per mol glucose). DP5 is the highest-Mw 
oligosaccharide pool produced by the hydrolysis of KGM by EM. With a mannose/glucose 
ratio of 1.1:1 for DP5, sequences of > 2 glucose units are indeed not expected to occur in 
the KGM polysaccharide.23  Taking into account monomeric mannose, which was present 
in considerable amounts in the total digest (16% of the total peak area; Table in Figure 1) 
these results highlight the good accessibility of the enzyme to the glucomannan chain, as 
was indicated before.23  
Summarizing, for both, EG- and EM-digest, a more sugar-dependent enzymatic degradation 
of the KGM than for the fecal enzymes was indicated by the monosaccharide compositions 
of the oligosaccharide pools.  
 
Structural composition of dimers from endo-β-(1,4)-glucanase-(EG) and endo-β-(1,4)-  
mannanase-(EM) digests 
Before characterizing higher-Mw oligosaccharides from the FE-, EG- and EM-digests, we 
firstly confirmed the composition of the dimers as present in the EG- and EM-digest. For 
these dimers a theoretical assignment has previously been established,7 as discussed below.  
The sugar compositions of the dimer-pools were also determined after reduction with 
sodium borohydride in order to determine the sugar unit located at the reducing end 
(Table 1). Combining this information with the number and proportion of compounds 
present in the respective EG- and EM-pool (Figure 2B and Figure 2C) enabled the 
assignment of the dimers. MG was assigned as the component present in the dimer-pool of 
the EG-digest (Figure 2B, peak EG-2), which is in agreement with the structure 
hypothesized in our previous study.7 Supplementary, a small proportion of GG can be 
assumed to be present, due to the ratio of 0.9 mannose per mol glucose. 
GM (EM-2.1) and MM (EM-2.2) were assigned for the EM-digest (Figure 2C) and the 
assignment is in agreement with  previous data.7 The ratios of 2.3 mannose per mol glucose 
before reduction and 0.7 mol mannose per mol glucose after reduction in the EM-digest 
match with the CE-LIF peak proportions of EM-2.1 (GM; 43%) and EM-2.2 (MM; 57%). 
The structural assignments as made for the dimer-pools is summarized in Table 2. 
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Table 2. Composition of dimer-pools from endo-β-(1,4)-glucanase (EG)- and endo-β-(1,4)-mannanase-(EM)-
digest of konjac glucomannan, as determined by monosaccharide composition analysis. The relative proportion of 
the respective structure in the pool is indicated. Peak numbers are according to Figure 2. 
 
 peak structure %  of pool 
EG-digest 2 MG ~ 100% 
 - GG traces 
EM-digest 2.1. GM 43% 
 2.2. MM 57% 
 
 
Characterization of KGM oligosaccharide pools with exo-enzymes 
Knowledge of the monosaccharide composition is not sufficient for the assignment of 
oligosaccharides of DP > 2, due to the increase in structural possibilities. The hydrolysis of 
the oligosaccharides by exo-enzymes, which results in a sequential release of mono- and 
disaccharide units located at the non-reducing end will provide additional structural 
information. As KGM is composed of glucose and mannose, a cellobiase (exo-β-(1,4)-
glucanase III (exo-glucanase) from Trichoderma viride)17 and a β-(1,4)-mannosidase 
(β-mannosidas; from Helix pomatia)19 were used. In order to firstly understand the action of 
these enzymes on KGM, the trimer-pools of the EG- and EM-digests were used. A 
theoretical assignment has previously been established for these oligosaccharides and will 
be discussed below. Subsequently, the information obtained was used for the assignment of 
the oligosaccharide structures as present in the FE-digest. 
 
Mode of action of exo-β-(1,4)-glucanase III (exo-glucanase) and β-(1,4)-mannosidase  
(β-mannosidase) towards KGM trisaccharides 
The dimers and monomers, which resulted from the incubation of the trimer-pools with the 
exo-enzymes, are listed in Table 3. The dimers MG, GM and GG can hardly be 
distinguished by CE-LIF if present together. Therefore, their combined presence is 
annotated with H2 in Table 3.  
The trimer-pool of the EG-digest is composed of two structures (Figure 2B), previously 
theoretically assigned as MGG (EG-3.1) and MMG (EG-3.2).7 EG-3.1 was only slightly 
degraded by exo-glucanase to H2 and glucose (G), whereas EG-3.2 was not at all degraded. 
For the EM-digest GGM, MMM and GMM were previously assigned to the compounds 
EM-3.2, EM-3.3 and EM-3.4, respectively (Figure 2C).7 Only GGM (EM-3.2.) was 
degraded by exo-glucanase.  
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Table 3. Mode of action of exo-(1,4)-glucanase (exo-glucanase) and β-(1,4)-mannosidase (β-mannosidase) on 
trisaccharides from konjac glucomannan hydrolyzed by endo-β-(1,4)-glucanase (EG),  endo-β-(1,4)-mannanase 
(EM) and fecal enzyme mixture (FE). Peak numbers are according to Figure 2. The M/G ratio was calculated 
based on the relative proportion of the respective structure in the pool. H2: GM/MG/GG.  
 
 peak exo-glucanase β-mannosidase structure 
 
%  
of pool 
M/G 
EG digest 3.1. (G, H2) M, G 
GG 
MGG 26 % 1.4 : 1 
3.2. - MMG 74 % 
EM digest 3.1. - M, H2* MGM 12 % 0.9 : 1 
3.2. M, GG  - GGM 64 % 
3.3. - M, H2* MMM 6 % 
3.4. - - GMM 18 % 
FE digest 3.1. - - MGG 8% 1.5 : 1 
3.2. - M, G 
H2 
MGM 42% 
3.3. - MMG 36% 
3.4. - - GMM 14% 
( ): no complete degradation. *: hydrolysis products result from EM-3.1 and EM-3.3 
 
Thus, exo-glucanase can cleave off the terminal disaccharide unit GG attached to a 
reducing mannose-unit. A release of the terminal MG-unit, attached to a reducing glucose-
unit is limited. GM linked to a reducing mannose-unit cannot be hydrolysed by 
exo-glucanase.  
Except for GGM (EM-3.2) and GMM (EG-3.4), all other structures were degraded by 
β-mannosidase. Thus, β-mannosidase showed to be able to remove terminal mannose-units, 
independent of being β-linked to a mannose- or glucose-unit. Beta-mannosidase completely 
hydrolyses repeating mannose-units (e.g. MMG to 2M and G or MMM to 3M), which was 
concluded from the quantitative amounts of mannose released in the digested pools 
(data not shown).  
Although not detected by us before,7 a fourth structure (MGM, Figure 2C, peak EM-3.1) 
was assigned in the DP3 pool of the EM-digest, due to its resistance to exo-glucanase 
digestion and its degradation to M and H2 by β-mannosidase. The presence of MGM in a 
KGM digest produced by EM from A.niger has been previously described.11   
 
Information on the mode of action of the exo-enzymes was thus obtained by hydrolysing 
the trisaccharide-pools. Simultaneously, the mono- and disaccharides resulting from the 
hydrolysis of the trisaccharide-pools confirm our previous theoretical assignments of the 
oligosaccharide structures.7 The structural assignments of the trisaccharides is in agreement 
with the monosaccharide composition as mentioned in Table 1, considering the relative 
proportions of the individual oligosaccharides within the pools (Table 3).  
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The trisaccharides FE-3.1, FE-3.2, FE-3.3 and FE-3.4 of the FE-digest were assigned as 
MGG, MGM, MMG and GMM, respectively (Figure 3 and Table 3). The presence of 
both, glucose and mannose as reducing end units in the fecal enzyme digest indicates a 
multiple-enzyme-system and a different mode of action of the bacterial enzymes on the 
KGM polysaccharide compared to the fungal enzymes. 
 
 
Figure 3. CE-LIF electropherograms of DP3-pools of konjac glucomannan hydrolyzed by (A) enzymes from 
human fecal bacteria (FE), (B) endo-β-(1,4)-glucanase (EG) and (C) endo-β-(1,4)-mannanase (EM). The peaks 
within the respective pools are indicated. 
 
Assignment of higher-Mw KGM-oligosaccharides based on their degradation with         
exo-enzymes  
Knowing the structure of the various DP2- and DP3-peaks and the mode of action of the 
enzymes allowed the use of the exo-enzymes for the structural investigation of higher-Mw 
KGM oligosaccharides. In order to subsequently draw some conclusions on the structural 
composition of the KGM polysaccharide, attention was paid not only to the investigation of 
oligosaccharides from the FE-digest, but also to the oligosaccharides in the EG- and       
EM-digest. The KGM-pools investigated were degraded to different extents by the exo-
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enzymes. Table 4 summarizes the decrease in total initial peak area of the oligosaccharides 
in the pools upon incubation.  
 
FE-digest 
For the FE-digest, the susceptibility to hydrolysis by exo-glucanase increased with 
increasing size of the oligosaccharides (Table 4). Oligosaccharides of the DP5-pool 
showed the lowest degradability by exo-glucanase as well as by β-mannosidase. This low 
degradability may be deduced to a complicated structural composition and may thus 
explain the predominant presence of DP5 oligosaccharides during the in vitro 
fermentation.7  
 
Table 4. Degradability by exo-β-(1,4)-glucanase and β-(1,4)-mannosidase of oligosaccharide-pools from konjac 
glucomannan hydrolyzed by fecal enzymes (FE), endo-β-(1,4)-glucanase (EG) and endo-β-(1,4)-mannanase (EM). 
 
 FE-digest EG-digest EM-digest 
exo-glucanase β-mannosidase exo-glucanase β-mannosidase exo-glucanase β-mannosidase 
DP3 0 % 86 % 7 % 97 % 64 % 31 % 
DP4 23 % 43 % 59 % 86 % 95 % 72 % 
DP5 22 % 34 % n.d. n.d. 49 % 50 % 
DP6 85 % 38 % 81 % 83 % - - 
DP7 96 % 54 % n.d. n.d. - - 
 
Interestingly, all FE-pools degraded by exo-glucanase showed the presence of GGM, 
MGM, MMG and GMM, as exemplified by the hydrolysis of the DP4-pool in Figure 4A. 
These tri-saccharides are the components of the DP3-pool from the FE-digest (Table 3). 
The homologous peak series observed for the FE-digest can thus be explained by the 
presence of a number of core-structures, which are extended either linear or branched. 
Clearly, a variety of structures is present.  
Beta-mannosidase-digestion of the FE-pools of a given DPx resulted in the emergence of 
mainly oligosaccharides of DPx-1 and mannose, as exemplified for the hydrolysis of DP4 
in Figure 4A. The action of β-mannosidase is thus hindered by the presence of a 
subsequent glucose unit and indicates the frequent occurrence of mannose-glucose repeats 
in the oligosaccharides of the FE-pool.  
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Considering the ratio of 1.5 mannose per mol glucose, which represents the distribution as 
present for the intact KGM polysaccharide, the FE-mixture seems to act less sugar-
dependant on the KGM-chain compared to the fungal enzymes.  
 
EG-digest 
For the EG-pools the degradability of oligosaccharides with exo-glucanase and 
β-mannosidase significantly increased with increasing DP (Table 4). The degradability by 
exo-glucanase was surprising, since high mannose ratios were found for the higher-Mw 
EG-pools (Table 1). A simple structural extension by mannose-units at the non-reducing 
end of the oligosaccharides present in the preceding pool is thus not the case. The profiles 
of the tetramer-pool, composed of EG-4.1 and EG-4.2, after digestion with exo-glucanase 
and β-mannosidase are shown in Figure 4B.  
The presence of a branched oligosaccharide was assumed for EG-4.1, as exo-glucanase 
resulted in the appearance of glucose, dimers and a trimer at the migration time of MMG, 
whereas β-mannosidase resulted in a complete degradation to monomers and dimers. 
Exo-glucanase may act differently on branched structures than on linear structures as 
observed for the DP3-pools. Nevertheless, the good degradability by both enzymes 
indicates the presence of mannose at the non-reducing ends and a core unit which contains 
glucose for DP-4.1, e.g. M[M]GG (Table 5). For DP-4.2 a single or combined presence of 
MMGG or/and MMMG was assumed (Table 5), as concluded by its resistance to 
exo-glucanase digestion and degradation by β-mannosidase (Figure 4B).  
An increased presence of branched oligosaccharides rich in mannose may explain the 
presence of the homologous series up to DP > 15, as observed for the EG-digest. 
 
Table 5. Structural propositions for tetrasaccharides from endo-β-(1,4)-glucanase-(EG) and endo-β-(1,4)-
mannanase-(EM)-digest of konjac glucomannan. Peak numbers are according to Figure 2. 
 
 peak structural proposition 
EG-digest 4.1. M[M]GG 
 4.2. MMGG/MMMG 
EM-digest 4.1.  [M]GGM 
 4.2.  GMGM.  
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Figure 4. Action of exo- β-(1,4)-glucanase (exo-glucanase) (A/B/C-II) and β-(1,4)-mannosidase (β-man) (A/B/C-
III) on tetrasaccharides resulting from konjac glucomannan digest with (A-I) enzymes from human fecal bacteria 
(FE), (B-I) endo-β-(1,4)-glucanase (EG) and (C-I) endo-β-(1,4)-mannanase (EM). FE-4.1/-4.2, EG-4.1/-4.2, EM-
4.1/-4.2 are according to Figure 2. 2a: GG/GM/MG. 2b: MM. 3a: MGG°. 3b: MGM°. 3c: GGM°. 3d: MMG°. 3e: 
GMM°. °:structures are linear or branched. *:maltose internal standard. 
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EM-digest 
Although DP4- and DP5-pools were present in the EM-digest, their contribution to the total 
digest is minor, as shown in Figure 1. These DP-pools are thus less important. Equal 
proportions of glucose and mannose were found for the EM-tetramer-pool (Table 1). The 
oligosaccharides in the DP4-pool (EM-4.1 and EM-4.2) are well-degraded by 
exo-glucanase (Figure 4C). A branched structure was assumed for EM-4.1 ([M]GGM, 
Table 5), due to the presence of GGM in the β-mannosidase-digest. Additionally, a 
compound at the migration time corresponding to MGG was present in the exo-glucanase 
digest, which may correspond to the branched [M]GG. The dominant presence of dimers 
(H2) in the exo-glucanase digest was assumed to result from EM-4.2. EM-4.2 was not 
degraded by β-mannosidase and was thus assigned as GMGM (Table 5).  
No conclusions could be drawn on the structural composition of oligosaccharides present in 
the DP5-pool. 
 
Characterization of the KGM polysaccharide 
Different opinions on the structure of the KGM polysaccharide exist. A blockwise 
distribution of mannose units within the KGM polysaccharide chain was claimed by 
Shimahara et al,10 whereas a random distribution was proposed by Cescutti et al.11 The 
significantly increased ratio of mannose within oligosaccharides DP > 4 in the EG-digest as 
observed in our research supports the existence of a blockwise distribution of mannose 
units within the KGM polysaccharide chain.  Ramification of the KGM-backbone with side 
chains rich in mannose would explain the homologous peak series of DP > 15 as obtained 
for the EG-digest. It would also justify the good degradability of the polysaccharide by EM 
to mainly monomers, dimers and trimers. The small hydrolysis products and the equal 
mannose/glucose ratio in the DP-pools for EM confirm the absence of more than two 
sequential glucose units in the KGM chain as suggested by Shimahara et al.10 Repeating 
glucose/mannose-containing core structures in the KGM main chain, to which mannose-
rich branches are attached, were assumed by us, as indicated by the structural assignments 
M[M]GG (EG-4.1) and [M]GGM (EM-4.1). Our research supports the attachment of the 
side chains to glucose-units in the backbone, as was proposed by Katsuraya et al,12 but 
disagrees with the findings of Maeda et al9 and Smith et al25 who propose branching at both 
glucose and mannose units in the polysaccharide backbone.  
KGM is an acetylated polysaccharide (DA 5-10%).8 The distribution of the acetyl groups 
has not yet been determined. An attachment of the acetyl group to the mannose unit can be 
assumed due to the presence of higher-Mw acetylated oligosaccharides in the EG-digest 
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(Figure 1), which are rich in mannose. A hypothetical structure of the KGM polysaccharide 
as revealed by our study is shown in Figure 5. 
 
 
Figure 5. Excerpt of the konjac glucomannan polysaccharide as revealed by this study. Acetyl groups are placed 
arbitrarily on the mannose units. 
 
Evaluation and implication of the hydrolysis of KGM by fecal enzymes  
For the degradation of KGM by human gut bacteria, an enzyme machinery is activated, 
which results in the presence of a broad range of non-acetylated oligosaccharides. The FE-
mixture seems to act in a less sugar-dependent way on the KGM-chain compared to the 
fungal enzymes tested. This can be concluded from the ratio of 1.5 mannose per mol 
glucose for the oligosaccharides produced, which represents the sugar distribution of the 
intact KGM polysaccharide. A multi-enzyme-system expressed by the fecal bacteria is 
indicated by the presence of KGM hydrolysis products of consecutive mannose-glucose-
units. Gut bacteria adapt their enzyme expression to the substrates provided, as has been 
previously concluded from an in vitro fermentation of arabinoxylan.26  
Surprisingly, in the FE-digest mono- and dimers were absent. With the absence of mono- 
and dimers and the presence of a large range of oligosaccharides obtained for the FE-digest 
and the in vitro fermentation,7 endo-acting enzymes, which have different modes of action 
on KGM compared to the fungal enzymes used in this study, may therefore be prevailing. 
The oligosaccharides observed may represent suitable intermediate degradation products, 
which serve as nutrients for the survival of other gut bacteria. Bacterial cross-feeding has 
been recognized as gastrointestinal utilization mechanism for polysaccharides.27  
Ac
Ac
mannose glucose Ac = acetyl group
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Monitoring and characterizing intermediately formed oligosaccharides during in vitro 
fermentation provides an insight into the degradation mechanism of complex 
polysaccharides in the gastrointestinal tract. The structural composition of oligosaccharide 
mixtures influences their utilization by fecal bacteria, as was previously observed.7 
Oligosaccharides produced by EM, which are of small size carrying a glucose unit at their 
non-reducing end, resisted more to in vitro fermentation than oligosaccharides produced by 
cellulase.7 The endo-enzymes of the fecal microbiota show a different mode of action on 
KGM and only the determination of the prebiotic index28 (PI; defined as PI = 
[(Bifidobacteria/total bacteria) – (Bacteroides/total bacteria) + (Lactobacilli/total bacteria) – 
(Clostridia/total bacteria)]) would give information on the prebiotic value of the different 
oligosaccharide mixtures. Prebiotic oligosaccharides produced by fecal enzymes would 
require the characterization and identification of these enzymes for their subsequent large-
scale use for the production of oligosaccharides. The production of functional 
oligosaccharides by the enzymes from health beneficial bacteria or the gut microbiota has 
been already recognized for the production of galactooligosaccharides,14,15 although not yet 
commercially applied.  
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Research aim and approach 
Knowledge on the gastrointestinal fate of diet-related oligosaccharides is limited. 
Nevertheless it is necessary in view of the structure-function relationship of these 
oligosaccharides. The aim of this PhD research was, firstly, to provide a suitable method for 
the isolation, identification and quantification of oligosaccharides in complex food and 
body matrices, and, secondly, make use of the method for an advanced understanding of the 
gastrointestinal fate of diet-related oligosaccharides, with focus on infant nutrition. 
Human milk oligosaccharides (HMOs), which represent the most optimal functional 
oligosaccharides in baby nutrition, galactooligosaccharides (GOS), which are 
representatives of a prebiotic with market position, and konjac glucomannan (KGM) and  
oligosaccharides derived hereof, representing a structurally complex and potentially 
prebiotic substrate, were used in this PhD research. Their gastrointestinal fate was 
monitored in vitro or in vivo, by making use of the sensitive analytical tool CE-LIF/MS. 
Screening the gastrointestinal metabolization of oligosaccharides showed to provide a 
mirror for monitoring the gastrointestinal adaptation towards different kinds of diet-related 
oligosaccharides. The findings of this PhD research project and their possible nutritional, 
scientific and application-related implications are discussed in this chapter.  
  
Qualitative and quantitative analysis of complex oligosaccharides by CE-LIF/MS 
The increasing scientific, public and industrial interest in the bioactive mechanism of 
functional oligosaccharide mixtures demands their advanced qualitative and quantitative 
analysis from complex matrices, such as food and body liquids. Furthermore, high 
requirements for the assessment of gastrointestinal functionality and quantity in the product 
are imposed for the approval of these oligosaccharides as functional ingredients by 
European legislation (EG 1924/2006).1 At present, oligosaccharide contents in food are 
usually determined by the total monosaccharide content after enzymatic incubation of the 
samples with β-galactosidase (AOAC 2001.02 for GOS)2 or inulinase (AOAC 997.08      
for inulin and FOS).3 Unfortunately, high concentrations of dimers and monomers (lactose 
in case of milk-based products; glucose/fructose/sucrose in case of fruit-based products) 
can influence the enzymatic determination of the low amounts of oligosaccharides present 
in the matrix. In order to fulfil the high demands of oligosaccharide analysis at present, an 
analysis on an individual oligosaccharide level is preferable.  
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CE-LIF was introduced as a sensitive qualitative and quantitative tool for the analysis of 
individual oligosaccharides from food matrices in chapter 2. Preceding the quantification 
step, low amounts of GOS were reproducibly extracted from matrices rich in 
monosaccharides, sucrose, lactose and maltodextrin. A selective purification of the 
oligosaccharides was achieved by the combination of the enzymatic degradation of 
maltodextrins by amyloglucosidase pretreatment and solid phase extraction on graphitized 
carbon material.3,4 Due to the mole-based derivatization of oligosaccharides with the 
fluorescent APTS,5 the reducing oligosaccharides can be quantified, even if individual 
oligosaccharide standards are not available. Furthermore, the migration of neutral 
oligosaccharides of low Mw by CE-LIF is predictable, as it is influenced by the size of the 
molecules. With other advanced techniques based on liquid chromatography (HPAEC and 
separation based on porous graphitized carbon), a prediction of the migration time of 
unknown compounds is not possible.6,7 In our research, CE-LIF analysis showed to be a 
valuable method for the analysis of complex oligosaccharide mixtures, namely GOS 
(chapter 2), HMOs (chapter 3-5) and KGM oligosaccharides (chapter 6 and chapter 7). In 
previous research, CE-LIF was successfully used for the separation of oligosaccharides 
from pectins and hemicelluloses.8-10  Supplementary, the possibility of on-line coupling to 
mass spectrometry makes CE-LIF an attractive tool for studying oligosaccharides before 
and after gastrointestinal metabolization, where numerous unknown structures can be 
formed. 
CE-LIF can thus be considered as a candidate for the establishment of official, validated 
methods for the qualitative and quantitative analysis of a broad range of reducing 
oligosaccharides on an individual level. Nevertheless, validation including ring-tests should 
be done for a broad range of matrices.  
 
Some analytical challenges remain. CE-LIF analysis requires the derivatization of the 
carbohydrates with a charged fluorescent. In this research APTS is used, which reacts with 
the reducing carbohydrates via reductive amination. Non-reducing carbohydrates can be 
important components in functional oligosaccharide mixtures (e.g. fructooligosaccharides 
or α-(1,1)-linked GOS), but are not labeled by APTS-derivatization. Alternative methods    
(e.g. liquid chromatography based methods on porous graphitized carbon (PGC) or 
hydrophilic interaction liquid chromatography (HILIC)) have, therefore, to be considered, if 
non-reducing oligosaccharides are of interest. Or else, harsher labeling techniques than 
reductive amination with APTS should be applied for the non-reducing oligosaccharides, 
e.g. techniques based on hydrazone-bond formation.11 Peak overlap is a general problem for 
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the analysis of complex oligosaccharides with any analytical technique. It is of special 
concern for higher-Mw oligosaccharides, for which the number of isomers is usually high 
and the concentration of the respective oligosaccharides is low. The use of complementary 
techniques may give a broader insight into the oligosaccharide composition. 
The recent developments on CE-MS hyphenation by sheathless interface12 and the 
possibility to use polyvinylalcohol-coated capillaries not only for off-line CE-LIF analysis, 
but also for CE-MS coupling13 may make CE even more powerful for the analysis of low 
amounts of complex oligosaccharides in near future.  
 
HMOs from breast milk 
The composition of the HMOs in breast milk depends on the mother’s Secretor- and Lewis-
type and has extensively been studied.14-16 In chapter 5, the breast milks of eleven mothers 
were monitored during six months of lactation. For eight mothers, Le(a-b+)-secretor-
characteristic HMO-profiles composed of non-substituted and (α1,2)-/(α1,3)-/(α1,4)- 
fucosylated and sialylated HMOs were obtained. For two mothers, Le(a+b-)-non-secretors-
characteristic HMO-profiles composed of non-substituted and (α1,3)-/(α1,4)-fucosylated 
and sialylated HMOs were obtained. Only one mother showed Le(a-b-)-secretor-
characteristic HMO-profiles composed of non-substituted and (α1,2)-/(α1,3)-fucosylated 
and sialylated HMOs. The Le-/Se- gene expression of the European population, which is 
approximately 70% Le(a-b+), 20% Le(a+b-) and 10% Le(a-b-),17,18 is represented by this 
study group. The geographical distribution of the Le-/Se- gene expression has to be taken 
into account when performing research on the HMO-composition in breast milk. Studies on 
the breast milk composition among Mexican mothers resulted in a prevalence of > 99 % 
secretors, whereas a study among Philippine mothers resulted in a percentage of only 46% 
secretors.18 Secretor-characteristic (α1,2)-fucosylated oligosaccharides were recognized as 
receptor analogs for pathogenic bacteria and the quantity of these oligosaccharides in breast 
milk is even discussed as a quality parameter of human milk.19 The increased proportion of 
secretors among certain populations was proposed to be a genetic response to the increased 
presence of certain pathogenic bacteria in the regions of these populations.19   
Markedly during the first few months of lactation differences in the expression of 
fucosylated oligosaccharides within the Le(a-b+)-secretor-group were observed in the 
present study, as was shown in chapter 5 by the LNFP I/III / LNDFH I ratio. This ratio was 
either  < 1.5:1 or ≥ 2:1. With CE-LIF, it is not possible to distinguish between (α1,2)- and 
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(α1,3)-fucosylated oligosaccharides, which is a disadvantage in view of the biological 
significance of (α1,2)-fucosylated oligosaccharides.  
The HMO-content decreases with proceeding lactation time.16,20-22 In the present study, a 
decrease of 40% of the total, initially present HMO-concentration was found after three 
months lactation. This corresponds well with previous studies, where a decrease of 
approximately 20% and 50% was found after two months and three months, 
respectively.16,21 Overall, the HMO-profile of breast milk does not significantly change 
during the lactation course. (Alpha1,3)-fucosylated oligosaccharides present an exception, 
as their concentration increases with time.16,20,22 Correspondingly, after 3 months, a plateau 
in HMO-concentration was stated in the present research (chapter 5) and could be deduced 
to an increase in (α1,2)-/(α1,3)-FL-concentration. The change in abundance from (α1,2)- to 
(α1,3)-fucosylated oligosaccharides was proposed to be a consequence of a decreased 
activity of the secretor gene in time20 or might be an adjustment of breast milk to different 
biological needs in time.   
 
Gastrointestinal metabolization of diet-related oligosaccharides 
In the present research, 16 oligosaccharides in baby feces, which could not directly be 
linked to the oligosaccharide structures in the respective diet, were annotated by means of 
CE-MSn (Table 1). Their presence was associated with the gastrointestinal metabolization 
of diet-related oligosaccharides, as discussed below.  
 
Breast-fed babies 
Three-stage model of gastrointestinal development 
By studying feces of breast-fed babies and the corresponding breast milks during the first   
six months postpartum (chapter 5), the gastrointestinal metabolization of HMOs could be 
schematized and was sub-divided into three continuous stages. Shortly after birth (stage 1), 
fecal oligosaccharide profiles of exclusively breast-fed babies are composed of either 
neutral or acidic HMOs. HMO-degradation products (LnNT Y, LNFP Y) can be present. 
Their origin from higher-Mw HMOs, which contain the bifidogenic lacto-N-biose unit 
(LNB),23 indicates the easy utilization of this unit by the characteristic breast-fed 
microbiota. The fact that no HMO-degradation products were detected in previous studies 
can be deduced to the peak identification, which was then limited to HMO-standards.24-26 
The screening of the individual oligosaccharides was not performed.27-30 
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With advancing time postpartum, we monitored the gradual development to a fecal 
oligosaccharide profile composed exclusively of blood group characteristic 
oligosaccharides (stage 2). These oligosaccharides were assigned as conjugates of HMO-
units and blood group-specific antigenic determinants (either, A, B or H(0)) from the 
gastrointestinal mucus (chapter 5). Comparable results were previously found for fecal 
samples of a preterm- and aterm-baby both belonging to blood group A.28,29 As sample 
amounts were limited, no results could previously be drawn for other blood group types.27 
Even more, the fecal presence of neutral HMOs in a previous study, in which fecal samples 
were exclusively collected shortly after birth thus led to the conclusion, that there occurs no 
gastrointestinal metabolization of HMOs in the neonatal gut.26 
At an advanced time postpartum, when solid food has been introduced, these personalized 
oligosaccharide profiles disappear (stage 3). Oligosaccharides, which were newly 
introduced with the diet are now present (starch-derived structures). No information on 
fecal oligosaccharide profiles during weaning (stage 3) has been available so far. 
 
Table 1. Overview on oligosaccharides resulting from gastrointestinal metabolization, as assigned in the present 
study.  
 
         glcNAc/galNAc glucose/galactoseglucose galactoseglcNAcfucose galNAc  
α1,2
α1,3
α1,2
α1,3
α1,2
α1,3
α1,2
α1,3
α1,2
α1,3
α1,2
α1,3
α1,2
α1,3
α1,2
α1,3
HMO-
degradation products
Blood group characteristic HMO-metabolization products
Blood group A Blood group B Blood group H(0)
Unknown 
metabolization products
(mucus-derived)
α1,2 β1,4β1,6
β1,4
β1,4β1,6β1,4
LnNT Y 
m/z 382; chapter 3
LNFP Y 
m/z 431; chapter 3
A-tetrasaccharide
m/z 377; chapter 4/5
A-pentaccharide
m/z 425; chapter 5
A-hexaccharide
m/z 498; chapter 4/5
A-heptaccharide
m/z 547; chapter 5
B-tetrasaccharide
m/z 363; chapter 5
B-pentaccharide
m/z 412; chapter 5
B-hexaccharide
m/z 485; chapter 5
B-heptaccharide
m/z 533; chapter 5
H(0)-trisaccharide
m/z 309; chapter 5
H(0)-tetrasaccharide
(2 isomers) 
m/z 357; chapter 5
[if Le(a-b-)-milk fed]
H(0)-hexasaccharide
m/z 479; chapter 5
m/z 328; chapter 4
m/z 377; chapter 4
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Genetic influence  
During this research we observed a considerable influence of the oligosaccharide 
composition of the breast milk on the oligosaccharide profiles of the feces of the baby. 
The breast milk profiles, as found for the mothers, were present in their initial Secretor- and 
Lewis-specifc form in the baby feces during stage 1 (chapter 5). For none of the babies 
studied, a catabolism or re-synthesis of Secretor-/Lewis-specific HMOs was observed in the 
feces as was suggested in previous research.27,29 Furthermore, the ratio of 
LNFP I/III : LNDFH I in breast milk seems to have an influence on the presence of either 
an acidic or neutral HMO-profile during stage 1 (chapter 5). Whereas consumption of 
breast milk having a LNFP I/III / LNDFH I -ratio of ≥ 2:1 favoured the presence of a fecal 
oligosaccharide profile composed of acidic HMOs, predominantly neutral HMOs were 
found to be present in the feces if the LNFP I/III / LNDFH I -ratio in the breast milk          
was  < 1.5:1. 
The ABH(0)-blood group system does not influence the presence of HMOs in human 
milk.31 In the feces of breast-fed babies, ABH(0)-specific metabolization products are 
abundantly present during stage 2 (chapter 4 and chapter 5), resulting in personalized 
oligosaccharide profiles. For formula-fed babies, blood group specific oligosaccharides are 
absent (chapter 5). Thus, their production clearly depends on the gastrointestinal presence 
of HMOs. Our study also indicated a dependence of the formation of these blood group 
characteristic oligosaccharides on the HMO-composition in breast milk. A baby with blood 
group H(0), having a Le(a-b-)-mother, showed a different fecal oligosaccharide profile 
during stage 2 than three assumed blood group H(0)-babies having Le(a-b+)-mothers 
(chapter 5). We, therefore, assume that the presence of blood group specific 
oligosaccharides in stage 2 largely depends on the composition of the breast milk, which is 
dependent on the mother’s Secretor- and Lewis-type. Secondly, the secretor-status of the 
child has to be considered, as the presence of ABH(0)-oligosaccharides at the non-reducing 
terminus of mucin glycoproteins in the colon is dependent on the host’s ability to express 
(α1,2)-fucosidase.31. The ability of expressing (α1,2)-fucosylated oligosaccharides may 
change during the first years of life.32  
Among the 27 fecal samples of breast-fed, formula-fed and mixed-fed two months old 
preterm babies (chapter 5) were the samples of two twin-pairs and one triplet-pair. One 
twin-pair was predominantly breast-fed (A6/A7, chapter 5), and the other twin pair (B7/B8, 
chapter 5) and the triplet pair (B5/B6/B10, chapter 5) were predominantly formula-fed. 
High similarities in fecal oligosaccharide profiles, resulting in high similarity by statistical 
means (AHC), were observed for the twin pairs and two siblings of the triplet pair. 
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The oligosaccharide profiles as were found for the breast-fed twin-pair A6/A7 are shown in 
Figure 1.  
The highly similar fecal oligosaccharide profiles highlight the influence of breast milk and 
a similar gastrointestinal metabolisation in the gastrointestines of the siblings.  
These results confirm the influence of the host’s genotype on the gastrointestinal 
microflora, which was concluded previously, after studying the gastrointestinal microflora 
of genetic relatives.33  
 
 
Figure 1. Fecal oligosaccharide profiles (CE-LIF) of predominantly breast-fed twin pair A6/A7 (chapter 5) at the 
age of two months. 
 
Possible gastrointestinal function of blood-group characteristic metabolization products 
Blood group specific oligosaccharides were assumed to be conjugation products of HMO-
units and antigen-specific, non-reducing termini of intestinal mucin glycoproteins      
(chapter 5). The production of blood group active oligosaccharides in the intestine of 
breast-fed babies results in soluble analogs of the antigenic structures, which were initially 
fixed to the intestinal mucus layer.  Having soluble receptor analogs available may be 
useful for a better distribution of these immuno-determinant groups within the colon, and 
may enable their transport to distanced body tissues subsequent to their absorption.        
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This may result in an enhanced protection against pathogenic bacteria, which can be bound 
to the respective soluble receptor analog before attaching to a similar epitope within the 
gastrointestinal mucus layer. The formation of personalized, soluble receptors may thus 
contribute to the overall health effects, which are attributed to the consumption of breast 
milk and the stimulation of the immune system. 
 
Breast- and formula-fed babies 
Influence of gestational age, dosage and kind of oligosaccharides  
Overall, after two months, the fecal oligosaccharide profiles obtained from preterm born 
breast-fed babies (chapter 4 and chapter 5, baby “I”) indicated a less advanced 
gastrointestinal metabolization and degradation than the profiles of term born breast-fed 
babies after the same time postpartum (chapter 5). From a medical point of view, preterm 
birth is characterized with immature digestive functions34-36 and a slower microbial 
colonization pattern.37 Additionally, the intestine of preterm born babies is still short.38 The 
under-developed digestive functioning in a short intestine may result in a supply of residual 
small carbohydrates (e.g. lactose) to the colon and serve as nutrient for the microflora, 
which thus does not have to utilize the more complex carbohydrate structures. 
GOS was absent in the feces of formula-fed, preterm babies (0.4 g/dL GOS) after two 
months (chapter 4). Blood group characteristic oligosaccharides were not detected. Instead, 
some babies showed an abundance of a structure assigned as HexNAc-Hex-Hex in their 
fecal extracts, which was assumed to originate from gastrointestinal mucins. The functional 
role of this oligosaccharide is not known.  
In a parallel study, results indicated a possible dependency of the fecal recovery of GOS on 
the gestational age and concentration of GOS in the formula. For babies, who got formula 
supplemented with 0.5 g/dL GOS, we observed fecal oligosaccharide profiles of hexose-
oligosaccharides of mainly DP4, when the samples were collected at an age                       
of  < one month and the baby was born at a relatively early gastrointestinal age (Figure 2).  
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Figure 2. Fecal oligosaccharide profiles (CE-LIF) of preterm born babies fed with infant formula supplemented 
with 0.08 g/dL GOS or 0.5 g/dL GOS and GOS reference. Gestational age and sampling time are indicated 
(w: weeks; d: days). *: internal standard maltose. 
 
As the fecal oligosaccharide profiles showed only limited similarity with the GOS-standard, 
gastrointestinal degradation and metabolization of GOS is already ongoing at that time 
point. No fecal oligosaccharide profiles showing a pronounced presence of hexose-
oligosaccharides were observed for preterm babies, who got a formula supplemented with a 
low dosis of GOS (0.08 g/dl), independent of the time of gestation and sampling after birth 
(Figure 2). 
In an earlier microbiological study on the microflora of formula-fed babies, a dosage-
dependent bifidogenic effect of GOS/FOS (9:1)-supplementation was found.39 Higher 
Bifidobacteria-counts were observed for the babies who got formula supplemented with   
0.8 g/dL GOS/FOS (9:1) compared with the babies who got formula supplemented with  
0.4 g/dL GOS/FOS (9:1).39 For the babies who got formula supplemented with 0.8 g/dL 
GOS/FOS (9:1), fecal oligosaccharide profiles showing high-Mw FOS and low-Mw 
oligosaccharides were recovered after one month postpartum (Figure 3).24 As the 
oligosaccharide profile of the initial GOS-mixture was not shown by the authors and the 
fecal oligosaccharide profile was not confirmed by MS analysis,24 a partial metabolization 
of GOS at that time point cannot be ruled out. 
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Figure 3. Fecal oligosaccharide profile (HPAEC-PAD) of a term born baby fed with infant formula supplemented 
with 0.8 g/dL GOS/FOS (9:1), at 28 days postpartum. Reprinted from Thurl et al, with permission from WILEY 
publishers.24  
 
Remarkably, the higher–Mw FOS (DP > 10)40 seem to survive the gastrointestinal passage, 
although supplied in a ten times lower dose than GOS. Thus, the presence of GOS may 
have influenced the degradability of the higher-Mw FOS. Correspondingly, GOS may delay 
the gastrointestinal metabolization of HMOs and may stimulate the appearance of unknown 
structures (Hex-[Fuc]-HexNAc-Hex and HexNAc-Hex-Hex) in the feces, as was observed 
for mixed-fed babies and mixed- and formula-fed babies, respectively (chapter 4).  
 
Influence of gastrointestinal microflora development on oligosaccharide metabolization 
The gastrointestinal postnatal microbiota succession of breast- and formula-fed babies is 
different. Results from several studies were summarized in chapter 1.41-45 Table 2 gives a 
literature overview on the colonic microflora development. It incorporates the observations 
made for the oligosaccharide profiles at the respective postnatal stages in our study. For all 
stages, relations between bacterial composition and oligosaccharide profiles are observed.  
The mixed, facultative anaerobe flora, as present in the first few weeks of life, is primarily 
not capable to completely degrade or metabolize the complex HMOs. The presence of 
HMO-building blocks, such as lacto-N-biose (LNB), stimulates the gradual development to 
the  “simple” flora of stage 2, of which Bifidobacteria contribute to a considerable level.44  
 
 
 
Chapter 8
 
 170 
Table 2. Gastrointestinal colonization and fecal oligosaccharide composition in the postnatal period.       
Microflora composition is merely indicative, as information was derived from different studies.41-45 
 
   microflora composition41-45 fecal oligosaccharide composition 
1. first weeks  
(stage 1) 
breast-fed/ 
formula-fed 
mixed flora; large contribution of 
facultative anaerobe species 
breast feeding: 
neutral HMOs/acidic HMOs/   
(degradation-, metabolization 
products) 
 
formula feeding: 
supplemented oligosaccharides/ 
degradation-, metabolization products 
2. pre-weaning 
(stage 2) 
  breast-fed anaerobic, “simple” flora: 
Bifidobacteria/ Bacteroides  
breast feeding: 
blood group characteristic 
oligosaccharides; no HMOs 
 
   formula-fed maintenance of mixed flora: 
anaerobic/ facultative anaerobic  
 
with prebiotic supplementation: 
mixed flora with increased counts of 
Bifidobacteria/Lactobacilli 
formula  feeding: 
absence of diet-related 
oligosaccharides/ predominant 
“mucus”-derived structure possible 
3. weaning 
(stage 3) 
breast-fed/ 
formula-fed 
mixed flora: anaerobic/ facultative 
anaerobic 
breast feeding: 
oligosaccharides from solid food; no 
HMOs 
 
formula feeding: 
no experimental data available; 
no oligosaccharides expected 
4. post-weaning breast-fed/ 
formula-fed 
installation of “adult” flora;  
anaerobic; 
predominantly Bacteroides 
breast-/formula feeding: 
no experimental data available; 
no oligosaccharides expected 
 
 
On the contrary, the flora of formula-fed babies is not specifically stimulated with factors 
such as LNB during stage 1. The flora composition remains thus diverse and facultative 
anaerobes are still present in stage 2.  
If functional oligosaccharides are supplemented to infant formula, beneficial colon bacteria 
are stimulated.39 The species stimulated are probably different to the species stimulated 
during breast feeding and the overall flora composition was found to be more diverse.43  
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Overall, less dramatic changes in flora development were thus observed for formula-fed 
babies compared to breast-fed babies in the postnatal period.44 The residing microbiota of 
(exclusively) formula-fed babies should, therefore, adapt to the degradation of the          
diet-related oligosaccharides earlier than the microbiota of (exclusively) breast-fed babies. 
This has indeed been observed in the present research (chapter 4).  
The specific flora of breast-fed babies is able to conjugate HMO-units to blood group 
specific carbohydrate residues from the gastrointestinal mucosa during stage 2. The less 
specific flora of formula-fed babies is able to degrade a broad range of carbohydrates. Such 
carbohydrates include mucins from the colon.46 The presence of mucin-related 
oligosaccharides (HexNAc-Hex-Hex; Hex-[Fuc]-HexNAc-Hex) in the feces of formula-fed 
and mixed-fed babies may be a mirror for a diverse microbiota. The gastrointestinal mucus 
layer is a barrier, which hinders the systemic invasion of toxins and pathogenic bacteria. Its 
use as main nutritional source for the gastrointestinal microbiota is judged as not 
favorable.47 Enhanced mucin-degradation in case of a too low enteral supply of nutrients 
was previously proposed.48 Alternatively, increased mucin secretion may be the response to 
the presence of luminal factors, such as organic acids.49  
The change to stage 3 (weaning) has been described as less pronounced for formula-fed 
babies than for breast-fed babies as the flora-composition does not change significantly.44  
A rapid adaptation to the new food and thus no, or minor, fecal recovery of diet-related 
oligosaccharides is expected. In contrast, weaning has been described as a critical period for 
breast-fed babies, with a possibility of increased susceptibility to gastrointestinal             
disorders.44 The flora changes significantly and the recovery of diet-related 
oligosaccharides may be a witness of a not yet stabilized flora, similar to what was 
observed for stage 1. During the development of an “adult” flora in the post-weaning 
period, an adaptation of the microflora to the diet-related oligosaccharides is expected in 
time also for breast-fed babies, leading to the disappearance of diet-related oligosaccharides 
in the feces. 
  
Microflora adaptation to carbohydrate substrates 
Our study showed that the enzyme machinery produced by the colonic microflora adapts 
gradually to the respective carbohydrate substrates, as introduced at the beginning of each 
stage. The composition of this respective microflora may be different, depending on the 
substrate, to which the flora has to adapt to. Several studies proved the adaptation to 
carbohydrate substrates in vitro, e.g. to arabinoxylan and arabinogalactan,50,51 which was 
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indicated by elevated levels of enzyme activity necessary for the degradation of the 
respective substrate.  
In this research, a broad range of carbohydrate substrates was incubated with an enzyme 
cocktail from fecal bacteria in order to test its degradation potential. An overview is given 
in Table 3. The enzyme cocktail, resulted from fecal bacteria, which had been adapted      
in vitro to the degradation of konjac glucomannan (chapter 6 and chapter 7). Remarkably, 
the cocktail of fecal enzymes showed only pronounced activity towards substrates with 
backbones similar to konjac glucomannan, except for its activity towards maltodextrin. 
Even high degrees of substitution, as is the case for locust bean gum galactomannan, did 
not hinder its activity, reflecting the complexity of the initial glucomannan substrate the 
fecal bacteria were initially grown on.  
Enzymes, which are not necessary to degrade the carbon source provided are thus not 
expressed by the microflora. Correspondingly, the change to another carbohydrate substrate 
in the colon of breast-fed babies during weaning requires an adaptation of the microflora 
and its enzyme machinery. The fecal presence of diet-related oligosaccharides at the 
beginning of stage 3 (chapter 5) represents this adaptation period. 
Interestingly, the incubation of maltodextrin, cellodextrin and galactomannan polymers 
(Table 3) did not result in oligosaccharide profiles reflecting a straightforward degradation 
to smaller oligosaccharides and monomers, which was the case when using fungal enzymes 
(e.g. endo-β-(1,4)-mannanase) to digest these substrates. Instead, a vast variety of 
oligosaccharide structures was obtained, indicating transglycosylation. This is exemplified 
by the incubation of tara galactomannan with either fungal endo-β-(1,4)-mannanase or the 
mixture of fecal enzymes in Figure 4.  
The transglycosylation activity of beneficial gut bacteria has already been recognized as a 
potential source for producing target-specific functional oligosaccharides.52,53 The gene-
sequencing of beneficial gut bacteria, which exhibit transglycosylation activity may be a 
helpful tool for this purpose.54  
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Table 3. Incubation of carbohydrate structures with enzyme cocktail from in vitro fermentation of KGM             
by human inoculum. M: mannose; G: galactose 
 
carbohydrate substrate Result from incubation with cocktail of fecal enzymes, 
pre-grown on konjac glucomannan  
pectin 
dextran 
arabinogalactan 
decrease in Mw; no oligosaccharide formation 
no reaction 
no reaction 
inulin no reaction 
GOS no reaction 
maltodextrin transglycosylation 
cellodextrin transglycosylation 
tara galactomannan  
M/G 1.5:1 
degradation/transglycosylation 
guar galactomannan  
M/G 2.9:1 
degradation/transglycosylation 
locust bean gum galactomannan  
M/G 3.4:1 
degradation/transglycosylation 
konjac glucomannan de-acetylation/degradation 
 
 
 
 
Figure 4. CE-LIF oligosaccharide profiles of tara galactomannan degraded by endo-β-(1,4)-mannanase (EM), 
fecal enzyme mixture (FE) and tara galactomannan blank. Assignment according to Daas et al.55 
M: mannose; G: galactose; *: internal standard maltose. 
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Future perspectives 
Feeding practice 
A general protocol for postnatal feeding does not exist as gastrointestinal maturation and, 
thus, the response to enteral feeding is individual-dependent. Nevertheless, some guidelines 
have been implemented in current practice. A six-months period exclusive breast feeding is 
recommended by the WHO56 and the introduction of complementary food between four and 
six months was considered as safe by the EFSA.57 There are, however, cases where breast 
feeding is not possible or not advisable, e.g. for HIV-infected mothers or in case of preterm 
birth.58,59 Since the neurological and gastrointestinal functioning of preterm born babies 
may still be immature, parenteral nutrition may be necessary after birth. Furthermore, 
excessive amounts of enteral food may lead to inflammatory bowel diseases in the 
underdeveloped intestine of preterm born babies.60 On the other hand, enteral feeding 
stimulates gastrointestinal maturation and an increase in mucosal mass.61 Minimal enteral 
nutrition, which combines parenteral nutrition with small amounts of enteral nutrition has, 
therefore, been recognized as method of choice for preterm nutrition.62  
Individual needs may have to be considered when choosing appropriate infant food and 
appropriate timing. Fecal oligosaccharide profiles mirror the gastrointestinal response to 
enteral feeding and may thus contribute to design an individual postnatal feeding protocol. 
 
Supplementation of infant formula 
Although infant formula have been on the market for many years, research is still on-going 
in order to improve the present formulations towards more optimal breast milk replacers. 
Breast milk has a unique composition and cannot simply be replaced by animal milk. 
Figure 5 exemplifies the proportions of the major components from bovine milk and 
human milk.  
Bovine milk has a higher protein content compared to human milk, which can, besides of 
evoking allergies, stimulate a too rapid growth and thus increase the risk of overweight 
when feeding it to neonates.63 The composition of the protein-fraction is casein-based in 
bovine milk. In human milk, the protein fraction is whey-based and contains the bioactive 
lysozym and lactoferrin.63 These differences have to be considered in the production of 
infant formula. Furthermore, the supplementation of infant formula with breast milk 
characteristic long-chain polyunsaturated fatty acids (e.g. arachidonic acid and 
docosahexaenoic acid) are currently common practice.64 
 
General Discussion 
 
 175 
9
38
70
13
human milk [g/L]
protein
fat
lactose
oligosaccharides
34
38
48
1
bovine colostrum [g/L]
protein
fat
lactose
oligosaccharides
 
 
Figure 5. Composition of human milk and bovine colostrum.63,65  
 
The emulation of the bioactive HMOs in infant formula is of special importance, but it is 
also very challenging due to the complexity of the HMO-structures. GOS and FOS are 
currently used as prebiotic supplements in infant formula. Although bifidogenicity has been 
proven for these oligosaccharides,39,66-68 also other gastrointestinal species may be 
stimulated and the fermentation speed may be relatively quick, especially for the short-
chain GOS. More complex substrates may further penetrate the colon, but may stimulate a 
rather diverse flora.69 A better understanding on the gastrointestinal metabolization and 
successive flora development in breast- and formula-fed babies provides knowledge for an 
advanced supplementation of infant formula in the direction of breast milk.  Results of                      
in vitro fermentation studies of HMOs with specific bacterial strains and the present 
research highlight the importance of lacto-N-biose-containing structures for the 
establishment of a breast-fed-like microflora.23 The decoration of these oligosaccharides 
with e.g. fucose (especially (α1,2)-linked) is necessary in view of their direct anti-adhesive 
functions.19 The role of secretor-specific fucosylated oligosaccharides in the defence 
mechanism and their possible impact on the gastrointestinal metabolization has to be 
considered. An advanced knowledge on the bioactivity of these structures may even result 
in a selective supplementation of secretor-specific oligosaccharides to the feeding of babies 
who receive non-secretor-milk. To date, the enzymatic synthesis of HMOs or their 
production with recombinant bacteria is not feasible in terms of yield and costs.70 The 
extraction of oligosaccharides from animal milk may offer an alternative. The 
oligosaccharide content of domestic animals is, however, low, e.g. 1-2 g/L for bovine 
colostrum, and even less for mature bovine milk or milk from goat or sheep, compared to 
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approximately 12-13 g/L in human milk.65,71,72 In addition, the composition of these 
oligosaccharides is different compared to HMOs. Only few oligosaccharides of bovine milk 
are similar to the ones occurring in human milk. About 40 different oligosaccharides are 
known to be present in bovine milk.73 These are mainly acidic oligosaccharides.73,74  
Bovine milk oligosaccharides, for which a structural composition has been established are 
listed in Table 4. Besides sialylated oligosaccharides, bovine milk contains acidic 
oligosaccharides, which are decorated with glycolylic acid (Neu5Gc). Concentrations of 
neutral oligosaccharides have not yet been determined and may thus be quite low. Few 
phosphorylated oligosaccharides are present in bovine milk. 
 
Table 4. Summary of oligosaccharides from bovine colostrum, and their corresponding presence in human milk. 
As investigated by Parkkinen et al,74 Thurl et al16 and as reviewed by Urashima et al.65 n.d.: not determined. 
Neu5Ac: sialic acid. Neu5Gc: glycolylic acid. PO4: phosphate group 
 
structures bovine colostrum 
(mg/L)65,74 
human milk 
(mg/L)16,65 
neutral oligosaccharides   
Gal-(β1,4)-GlcNAc conc. n.d. - 
GalNAc-(β1,4)-Glc conc. n.d. - 
Gal-(β1,3)-Gal-(β1,4)-Glc conc. n.d. traces 
Gal-(β1,4)-Gal-(β1,4)-Glc conc. n.d. traces 
Gal-(β1,6)-Gal-(β1,4)-Glc conc. n.d. traces 
Gal-(α1,3)-Gal-(β1,4)-Glc conc. n.d. - 
Gal-(β1,4)-[Fuc-(α1,3)]-GlcNAc conc. n.d. - 
GalNAc-(α1,3)-Gal-(β1,4)-Glc conc. n.d. - 
Gal-(β1,4)-GlcNAc-(β1,6)-[Gal-(β1,3)]-Gal-(β1,4)-Glc conc. n.d. - 
acidic oligosaccharides   
Neu5Ac-(α2,3)-Gal   
Neu5Ac-(α2,3)-Gal-(β1,4)-Glc (3’SL) 95 240-310 
Neu5Ac-(α2,6)-Gal-(β1,4)-Glc (6’SL) 19 1140-1310 
Neu5Gc-(α2,6)-Gal-(β1,4)-Glc conc. n.d. - 
Neu5Gc-(α2,3)-Gal-(β1,4)-Glc 1 - 
Neu5Ac-(α2,6)-Gal-(β1,4)-GlcNAc 47 - 
Neu5Gc-(α2,6)-Gal-(β1,4)-GlcNAc conc. n.d. - 
Neu5Ac-(α2,3)-Gal-(β1,3)-Gal-(β1,4)-Glc 2 - 
Neu5Ac-(α2,8)-Neu5Ac-(α2,3)-Gal-(β1,4)-Glc 28 - 
phosphorylated oligosaccharides 
Gal-(β1,4)-Glc-3-PO4 
Neu5Ac-(α2,6)-Gal-(β1,4)-GlcNAc-1-PO4 
Neu5Ac-(α2,6)-Gal-(β1,4)-GlcNAc-6-PO4 
 
conc. n.d. 
2 
0.7 
 
- 
- 
- 
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Milks from other animal species have to be taken into consideration when looking for a 
potential source of HMO-analogs. A remarkably, high concentration of fucosylated and 
sialylated oligosaccharides, structurally corresponding to HMOs, was found in the milk of 
elephants (20 g/L).75 The oligosaccharide structures of elephant milk are, however, mainly 
based on LnNT instead of LNT.75 On the opposite, high levels of LNT and considerable 
amounts of sialylated and fucosylated oligosaccharides were found in the milk from 
chimpanzee.76 ABH(0)-specific oligosaccharides showed to be predominant components of 
feces from breast-fed babies in stage 2. Milk of polar bears contains ABH(0)-blood group 
specific oligosaccharides77 and may thus be of scientific interest to find out more on the 
potential health-beneficial functionalities of these oligosaccharides.   
 
Concluding remarks 
The results obtained during this study broadened the knowledge on the gastrointestinal fate 
of diet-related oligosaccharides, mainly with reference to infant nutrition. Screening the 
gastrointestinal metabolization of oligosaccharides points to the gastrointestinal adaptation 
to enteral food. Future studies have to focus on the correlation of analytical information on 
individual oligosaccharides, information on the respective gastrointestinal microflora 
composition, and medical information. With the emergence of sophisticated analytical 
techniques for oligosaccharide analysis and advanced approaches on the identification of 
the gastrointestinal microflora composition by means of molecular techniques, e.g. 
phylogenetic microarrays,78 scientists have potential tools at hand for an advanced 
understanding of the structure-function relationship of diet-related oligosaccharides.  
Genetic factors, such as ABH(0) blood groups, Lewis- and Secretor type, influence the 
gastrointestinal fate of diet-related oligosaccharides in the gastrointestine of neonates. A 
large and diverse subject group has, therefore, to be involved in the design of in vivo studies 
in future. The high-throughput and short analysis times of the present analytical techniques 
do not limit the large sample numbers necessary for these studies. 
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Summary 
The consumption of functional oligosaccharides can positively influence host’s health, as 
these oligosaccharides show bioactivity during their gastrointestinal passage. Functional 
oligosaccharides are of special interest for infant nutrition. During the postnatal period, the 
gastrointestinal tract undergoes a profound development. The changes in morphology and 
functionality, including the establishment of a balanced microbiota, are influenced by 
enteral food. Non-digestible oligosaccharides play an important role. Nevertheless, little is 
known on the gastrointestinal fate of these oligosaccharides, which would help to 
understand their biological functioning. A general introduction on the neonatal 
gastrointestinal development and functional oligosaccharides, including their potential 
gastrointestinal metabolization, is given in chapter 1.  
The research project firstly aimed at providing a suitable analytical method for the analysis 
of diet-related oligosaccharides in complex matrices. This method was used in order to gain 
advanced knowledge on the gastrointestinal metabolization of these oligosaccharides. A 
variety of in vitro and in vivo sample materials was studied, focusing on human milk 
oligosaccharides (HMOs) and galactooligosaccharides (GOS). These oligosaccharides 
frequently occur in infant nutrition. Supplementary, the potentially prebiotic konjac 
glucomannan polysaccharide (KGM) and oligosaccharides derived thereof were included in 
the study. 
In chapter 2, capillary electrophoresis with laser-induced fluorescence detection (CE-LIF) 
is introduced for the sensitive qualitative and quantitative determination of individual GOS 
extracted from food matrices. The matrices investigated were infant formula, fruit juice, 
and a maltodextrin-rich preparation, to which a commercial GOS-mixture was added in a 
product concentration range from 1.25 to 30%. It was possible to reproducibly separate 
GOS from the high amounts of particularly lactose and maltodextrins as present in the 
matrices by means of solid-phase extraction on graphitized carbon material following 
enzymatic amyloglucosidase pretreatment. Additionally, the quantification of a range of 
structurally different oligosaccharides with a size of DP3-DP5 by CE-LIF was evaluated. 
CE-LIF showed to be a valuable tool for the analysis of oligosaccharids on nanomole-scale. 
Next, the hyphenation of CE-LIF with an electrospray mass spectrometer, capable to 
perform multiple MS analysis (ESI-MSn), was introduced for the profiling of 
oligosaccharides in human milk and feces of breast-fed babies (chapter 3). HMOs and 
gastrointestinal HMO-degradation products could be assigned. In total, 21 peaks could be 
assigned and 11 peaks could be tentatively assigned. The gastrointestinal metabolization of 
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HMOs was indicated (e.g. de-fucosylation and de-sialylation). The detailed structural 
characterization of a so far unknown lacto-N-neo-tetraose isomer and lacto-N-fucopentaose 
isomer was established in baby feces and pointed to gastrointestinal hydrolysis of higher-
Mw HMOs, releasing the bifidogenic unit lacto-N-biose. 
Having introduced CE-LIF(-MSn) as a suitable analytical tool for the analysis of 
oligosaccharides from complex matrices, this method was subsequently applied for the 
study of the fecal oligosaccharide profiles of twenty-seven two months old breast-, formula- 
and mixed-fed preterm babies (chapter 4). Feeding was found out to determine the 
presence of diet-related oligosaccharides in baby feces. In the feces of breast-fed babies, 
Secretor- and Lewis-characteristic HMO-profiles or profiles indicating an advanced 
degradation and bioconversion of HMOs, were observed. GOS supplemented to the 
formula was not recovered in baby feces. The involvement of gastrointestinal mucins in the 
bioconversion of feeding-related oligosaccharides was indicated by the fecal presence of 
four unknown structures. Two of these structures were assigned as blood group A 
characteristic tetra-saccharide and hexa-saccharide. 
In chapter 5, the occurrence of oligosaccharides in feces of breast-fed babies in their first 
six months of life and the corresponding breast milk was studied. The study comprised 
eleven mother/child pairs, with mother’s Secretor- and Lewis-type including all 
combinations [Le(a-b+), Le(a+b-), Le(a-b-)]. Whereas no major changes in HMO-profiles 
of breast milk were observed over time, three continuous stages of fecal oligosaccharide 
profiles were determined. During stage 1 (up to three months postpartum) either 
predominantly neutral or acidic HMOs were detected in the feces, which is most probably 
effected by the HMO-composition of the respective breast milk. Next, a gradual change to 
blood group specific oligosaccharides was observed. Their presence pointed to a 
gastrointestinal degradation of the HMOs, followed by conjugation with blood group 
specific antigenic determinants present in the gastrointestinal mucus layer. Eleven of these 
“hybride”-oligosaccharides present during stage 2 were annotated in this study. Finally, 
predominantly oligosaccharides characteristic for follow-up feeding were present in the 
fecal samples at the time solid food was introduced (stage 3). 
The complex konjac glucomannan polysaccharide (KGM) and oligosaccharide-mixtures, 
obtained after endo-β-(1,4)-mannanase (EM) and endo-β-(1,4)-glucanase (EG) digestion of 
the polysaccharide, were fermented in vitro by human fecal inoculum (chapter 6). The 
structural characteristics of the oligosaccharide mixtures and the in vitro fermentation of the 
polysaccharide and oligosaccharides were studied by CE-LIF and matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Different 
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fermenatation characteristics were observed, which were related to the structural 
composition of the oligosaccharide mixtures. A hypothesis on the oligosaccharide structure 
of the EM- and EG-digest was established. Subsequently, an in-depth study of the structural 
composition of oligosaccharides from KGM produced by EM and EG and a mix of 
enzymes from human fecal bacteria is described in chapter 7. EM and EG showed a 
structured degradation mechanism of KGM. EM resulted in a short series of 
oligosaccharides with equal proportions of mannose and glucose. EG resulted in a 
homologous series composed of probably branched, mannose-rich oligosaccharides with a 
glucose- and mannose-containing core-structure. Contrarily, degradation with the enzymes 
from human fecal bacteria resulted in a large variety of structurally different 
oligosaccharides, showing characteristics of both, EM- and EG-digest. The results obtained 
were also used to discuss the structural composition of the KGM polysaccharide. 
Finally, in chapter 8, the results obtained in this research and their possible nutritional, 
scientific and application-related implications are discussed. The gastrointestinal 
metabolization of diet-related oligosaccharides, as observed in the postnatal period, is 
compared to studies published on the neonatal development of the intestinal microflora. 
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Samenvatting 
De inname van functionele oligosacchariden is gezondheidsbevorderend, aangezien deze 
oligosacchariden tijdens hun passage door de darm bioactieve effecten vertonen. 
Functionele oligosacchariden zijn van bijzonder belang voor babyvoeding. Het 
maagdarmkanaal ondergaat tijdens de postnatale periode ingrijpende ontwikkelingen. 
Enterale voeding beïnvloed morfologische en functionele veranderingen en het instellen 
van een evenwichtige microbiota. Onverteerbare oligosacchariden spelen hierin een 
belangrijke rol. Kennis over de gastrointestinale lot van deze oligosacchariden is essentieel 
om hun biologische werking te verklaren maar hierover is echter tot nu toe nog weinig 
bekend. In hoofdstuk 1 wordt een algemene inleiding gegeven over de neonatale 
gastrointestinale ontwikkeling, de functionele oligosacchariden en hun gastrointestinale 
omzetting. 
De eerste doelstelling van dit onderzoeksproject was het introduceren van een geschikte 
methode voor het analyseren van voeding-gerelateerde oligosacchariden in complexe 
matrices. Vervolgens werd deze methode toegepast om meer inzicht te krijgen in de 
gastrointestinale omzetting van deze oligosacchariden. Hiervoor werd een groot aantal      
in vitro en in vivo monsters geanalyseerd. Deze studies richtten zich voornamelijk op 
moedermelk oligosacchariden (human milk oligosaccharides; HMOs) en 
galactooligosacchariden (GOS) omdat deze oligosacchariden vaak voorkomen in 
babyvoeding. Daarnaast werden konjac glucomannan polysaccharide en daarvan afgeleide 
oligosacchariden bestudeerd vanwege hun potentieel prebiotische werking.  
In hoofdstuk 2 wordt capillaire elektroforese met laser-geïnduceerde fluorescentie-detectie 
(capillary electrophoresis with laser-induced fluorescence detection; CE-LIF) ingevoerd 
voor de gevoelige kwalitatieve en kwantitatieve bepaling van individuele GOS uit 
voedingsmatrices.  Hiervoor werd babyvoeding, vruchtensap en een met maltodextrine 
verrijkt preparaat bestudeerd, waaraan een commercieel GOS-mengsel was toegevoegd in 
een productconcentratie van 1.25 tot 30%. Door middel van vaste fase extractie (solid phase 
extraction) op gegrafitiseerde koolstof, na enzymatische amyloglucosidase 
voorbehandeling, was het mogelijk om GOS reproduceerbaar te scheiden van met name de 
lactose en maltodextrinen, die in grote hoeveelheden in de matrices aanwezig zijn. 
Daarnaast werd de kwantificatie van een aantal structureel verschillende oligosacchariden 
met een grootte van DP3-DP5 door CE-LIF geëvalueerd. CE-LIF bleek een waardevolle 
techniek voor het analyseren van oligosacchariden op nanomol-niveau te zijn. 
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Vervolgens wordt het koppelen van CE-LIF met een electrospray-massaspectrometer (ESI-
MSn, met de mogelijkheid om meerdere MS-fragmentaties achter elkaar uit te voeren) 
toegepast voor het analyseren van oligosacchariden in moedermelk en faeces van 
borstgevoede baby’s (hoofdstuk 3). Eenentwintig pieken werden geannoteerd als HMOs of 
HMO-afbraakproducten en 11 pieken werden tentatief geannoteerd. De resultaten toonden 
de gastrointestinale metabolisatie van HMOs aan (bijv. de eliminatie van fucose en 
siaalzuur). De struktuur van een tot dusver onbekende lacto-N-neo-tetraose isomeer en 
lacto-N-fucopentaose isomeer in baby feces werd in detail gekarakteriseerd. Hierbij werd 
de gastrointestinale hydrolyse van HMOs met een hoger molecuulgewicht en het vrijkomen 
van de bifidogene eenheid lacto-N-biose aangetoond. 
Nadat CE-LIF(-MSn) was ingevoerd als geschikte techniek voor de analyse van 
oligosacchariden uit complexe matrices werd de techniek gebruikt voor het bestuderen van 
feces van zevenentwintig, twee maanden oude borst-, formule- en gemengd gevoed 
premature baby’s (hoofdstuk 4). De aanwezigheid van voeding-gerelateerde 
oligosacchariden in baby feces bleek afhankelijk te zijn van de voeding. In de feces van 
borstgevoede baby’s werden Secretor- en Lewis- karakteristieke HMO-profielen gevonden 
of profielen die een geavanceerde afbraak en bioconversie van HMOs lieten zien. GOS, die 
oorspronkelijk aan de formule waren toegevoegd, werden niet teruggevonden in de feces. 
De aanwezigheid van vier onbekende structuren in de feces toonde aan dat gastrointestinale 
mucines bij de bioconversie van voeding-gerelateerde oligosacchariden betrokken zijn. 
Twee van deze structuren werden herkend als een bloedsgroep A karakteristieke tetra- en 
hexa-saccharide. 
In hoofdstuk 5 werden de oligosacchariden in de feces van borstgevoede baby’s en de 
bijbehorende moedermelk in de eerste zes maanden na geboorte bestudeert. De studie 
omvatte elf moeder/kind paren. De deelnemende moeders vertegenwoordigden alle 
combinaties aan Secretor- en Lewis-types [Le(a-b+), Le(a+b-), Le(a-b-)]. Hoewel tijdens de 
eerste zes maanden geen grote veranderingen in de HMO-profielen van moedermelk 
werden waargenomen, werden er drie achtereenvolgende stadia van fecale oligosaccharide-
profielen herkend. Tijdens stadium 1 (tot drie maanden na de geboorte) werden er of 
voornamelijk neutrale of zure oligosacchariden in de feces gevonden. De aanwezigheid van 
deze oligosacchariden hangt waarschijnlijk af van de HMO-samenstelling van de 
desbetreffende moedermelk. Vervolgens werd er een geleidelijke verandering van het 
profiel naar bloedgroep-specifieke oligosacchariden waargenomen. Hun aanwezigheid wijst 
op een gastrointestinale afbraak van HMOs, gevolgd door een conjugatie van de 
afbraakprodukten met bloedgroep-specifieke antigenen, die in de gastrointestinale mucus 
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aanwezig zijn. Elf van deze “hybride”-oligosacchariden die tijdens stadium 2 aanwezig zijn 
werden in deze studie geannoteerd. Ten slotte, op het tijdstip van invoeren van vast voedsel 
waren voornamelijk oligosacchariden in de feces aanwezig (stadium 3), die karakteristiek 
zijn voor deze opvolg-voeding. 
De complexe polysaccharide konjac glucomannan (KGM) en oligosaccharide-mengsels 
hiervan, die gemaakt werden door enzymatische afbraak van de polysaccharide met endo-β-
(1,4)-mannanase (EM) en endo-β-(1,4)-glucanase (EG), werden door incubatie met 
menselijke feces in vitro gefermenteerd (hoofdstuk 6).  
De structurele kenmerken van de oligosaccharide-mengsels en het in vitro fermentatie-
gedrag  van de polysaccharide en de oligosacchariden werd bestudeerd met behulp van CE-
LIF en matrix-assisted laser desorption/ionization time-of-flight massaspektrometrie 
(MALDI-TOF MS). Vastgestelde verschillen in fermentatiegedrag konden gerelateerd 
worden aan de structurele opbouw van de oligosacchariden in de mengsels. Vervolgens 
werd er een hypothese over de structurele opbouw van de oligosacchariden in de mengsels, 
geproduceerd door EM of EG, opgesteld. Hoofdstuk 7 beschrijft een diepgaande studie 
over de structurele samenstelling van de oligosacchariden aanwezig na afbraak van KGM 
met EM, EG of een mix van enzymen afkomstig van bacteriën aanwezig in menselijke 
feces. EM en EG vertoonden een gestructureerde afbraak van KGM. EM resulteerde in een 
series van korte oligosacchariden, die gelijke hoeveelheden aan mannose en glucose 
bevatten. EG resulteerde in een homologe series van waarschijnlijk vertakte 
oligosacchariden rijk aan mannose. Deze oligosacchariden zijn waarschijnlijk gebaseerd op 
een structuur-eenheid, die mannose en glucose bevat. In tegenstelling hiermee resulteerde 
de afbraak met enzymen afkomstig van bacteriën uit menselijke feces in een groot aantal 
structureel verschillende oligosacchariden. Deze oligosacchariden vertonen kenmerken van 
zowel EM- als EG-afbraak. Aan de hand van de behaalde resultaten werd ook de structurele 
samenstelling van de KGM polysaccharide besproken. 
Tenslotte worden in hoofdstuk 8 de resultaten van dit onderzoek en de mogelijke voeding-
gerelateerde, wetenschappelijke en applicatie-gerelateerde implicaties besproken. De 
postnatale gastrointestinale omzetting van voeding-gerelateerde oligosacchariden, zoals 
aangetoond in deze studie, wordt vergeleken met gepubliceerde studies over de neonatale 
ontwikkeling van de darmflora. 
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Zusammenfassung 
Die Einnahme funktioneller Oligosaccharide kann den Gesundheitszustand positiv 
beeinflussen, da diese Oligosaccharide während ihrer Passage durch den 
Gastrointestinaltrakt bioaktive Wirkung aufweisen. Funktionelle Oligosaccharide sind für 
Babynahrung von besonderer Bedeutung. Nach der Geburt durchläuft der 
Gastrointestinaltrakt tiefgreifende Entwicklungen. Enteral zugeführte Nahrung beeinflusst 
morphologische und funktionelle Veränderungen und den Aufbau einer ausgeglichenen 
Darmflora. Unverdauliche Oligosaccharide spielen hierbei eine wichtige Rolle. Über das 
Schicksal dieser Oligosaccharide im Darm ist jedoch wenig bekannt. Erweiterte Kenntnis 
hierüber wäre nützlich um die biologische Funktion dieser Oligosaccharide zu verstehen. 
Kapitel 1 gibt eine allgemeine Einführung in die gastrointestinale Entwicklung und die 
funktionellen Oligosaccharide, einschließlich ihrer möglichen gastrointestinalen 
Umsetzung. Das Ziel dieses Forschungsprojektes war es, zuerst eine geeignete Methode für 
die Analyse von Oligosacchariden aus der Nahrung, welche in komplexe Grundmassen 
enthalten sind, bereitzustellen. Diese Methode wurde dann benutzt um unser Wissen über 
die gastrointestinale Umsetzung dieser Oligosaccharide zu erweitern. Hierfür wurde eine 
Auswahl an Proben von in vitro und in vivo Studien analysiert, wobei der Schwerpunkt auf 
Muttermilch-Oligosacchariden (human milk oligosaccharides; HMOs) und 
Galaktooligosacchariden (GOS) lag. Diese Oligosaccharide kommen oft in Babynahrung 
vor. Zusätzlich waren das möglicherweise präbiotische Konjac Glucomannan (KGM) 
Polysaccharid und hiervon abgeleitete Oligosaccharide Teil dieser Studie. 
In Kapitel 2 wird Kapillarelektrophorese mit Laser-induzierter Fluoreszenz-Detektion 
(capillary electrophoresis with laser-induced fluorescence detection; CE-LIF) für die 
qualitative und quantitative Bestimmung von individuellen GOS, welche aus 
Lebensmittelmatrices extrahiert wurden, eingeführt. Die untersuchten Lebensmittelmatrices 
(Babynahrung, Fruchtsaft und eine maltodextrinhaltige Mischung),  enthielten ein 
handelsübliches GOS-Präparat in einer Produktkonzentration von 1.25 bis 30%. 
Amyloglukosidase-Vorbehandlung und anschließende Festphasenextraktion (solid phase 
extraction) auf Graphitkohlematerial ermöglichte die reproduzierbare Trennung von GOS 
von den hohen Konzentrationen an vor allem Laktose und Maltodextrin, welche in den 
Lebensmittelmatrices vorhanden sind. Zusätzlich wurde das Quantifizieren mit CE-LIF 
anhand einer Serie strukturell unterschiedlicher Oligosaccharide mit einer Größe von DP3 – 
DP5 bewertet. CE-LIF erwies sich als eine nützliche Methode zur Analyse von 
Oligosacchariden die in nanomol-Konzentrationen vorliegen. Als nächster Schritt wurde 
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die Kopplung von CE-LIF an einen Electrospray-Massenspektrometer (ESI-MSn), welcher 
mehrere MS-Analysen hintereinander ausführen kann, für das Screening von menschlicher 
Muttermilch und Fäzes von mit Muttermilch gefütterter Babys eingeführt (Kapitel 3). 
Sowohl HMOs als auch gastrointestinale Abbau-produkte von HMOs konnten identifiziert 
weden. Insgesamt wurden 21 Peaks benannt. Für 11 weitere Peaks war eine provisorische 
Benennung möglich. Die Abspaltung von z.B. Fucose- und Sialsäure-Einheiten deutete auf 
eine gastrointestinale Umwandlung der HMOs hin. Die Strukturen eines bisher 
unbekannten Lacto-N-neo-tetraose- und eines Lacto-N-fucopentaose-isomeres, die in 
Babyfäzes vorkommen, wurden im Detail charakterisiert. Die gastrointestinale Hydrolyse 
von HMOs mit höheren Molekulargewichten, bei welcher die bifidogene Einheit Lacto-N-
biose  freigesetzt wird, wurde aufgezeigt.  
Nach dem Einführen von CE-LIF(-MSn) als geeignete Methode zur Analyse von 
Oligosacchariden aus komplexen Grundmassen wurde diese Methode für die Untersuchung 
von  Oligosaccharid-Profilen in den Fäzes von 27 zu früh geborenen Babys angewendet 
(Kapitel 4). Diese Babys wurden mit Muttermilch, Muttermilchersatz oder beidem 
gefüttert. Es konnte gezeigt werden, dass die Art der Nahrung die Anwesenheit von 
nahrungsmittelbezogenen Oligosacchariden in Babyfäzes beeinflusst. 
In den Fäzes mit Muttermilch gefütterter Babys wurden entweder HMO-Profile gefunden, 
welche charakteristisch für die jeweilige Sekretor- und Lewistyp-Zugehörigkeit sind, oder 
es wurden Profile gefunden, welche einen fortgeschrittenen Abbau und Umwandlung der 
HMOs aufwiesen. GOS, die ursprünglich in der Muttermilch-Ersatznahrung enthalten 
waren, wurden in den Babyfäzes nicht zurückgefunden. Die Anwesenheit vier unbekannter 
Strukturen in den Fäzes deutete auf eine Beteiligung des gastrointestinalen Mucins an der 
Umwandlung der aus der Nahrung stammenden Oligosaccharide hin. Eine dieser Strukturen 
wurde als Blutgruppe A-spezifisches Tetrasaccharid und eine andere als Blutgruppe A-
spezifisches Hexasaccharid identifiziert. 
In Kapitel 5 wurde das Vorkommen von Oligosacchariden in den Fäzes mit Muttermilch 
gefütterter Babys während ihrer ersten sechs Lebensmonate sowie die dazugehörige 
Muttermilch untersucht. Die Studie umfasste elf Mutter/Kind-Paare. Alle Kombinationen 
an Lewis- und Secretor-Typen [Le(a-b+), Le(a+b-), Le(a-b-)] waren durch die Mütter 
vertreten. In den Fäzes wurden in den ersten Lebensmonaten drei aufeinanderfolgende 
Stadien an Oligosaccharid-Profilen gefunden, wohingegen Muttermilch keine signifikanten 
Veränderungen aufwies. Während Stadium 1 (bis zu 3 Monate nach Geburt) wurden 
entweder vor allem neutrale oder saure Oligosaccharide in den Fäzes gefunden, was 
höchstwahrscheinlich von der Zusammenstellung der HMOs in der jeweiligen Muttermilch 
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abhängt. Daraufhin wurde ein Wechsel zu blutgruppenspezifischen Oligosacchariden 
festgestellt. Die Anwesenheit dieser Oligosaccharide deutete auf einen gastrointestinalen 
Abbau der HMOs hin, gefolgt von einer Konjugation der Abbauprodukte mit blutgruppen-
spezifischen Antigen-Strukturen, welche in der gastrointestinalen Mukus-Schicht 
vorkommen. Elf dieser Hybrid-Oligosaccharide, welche während Stadium 2 vorkommen, 
konnten in dieser Studie benannt werden. Ab der Einführung von fester Nahrung wurden 
vor allem Oligosaccharide, welche typisch für Folgenahrung sind, in den Fäzes gefunden 
(Stadium 3). 
Das komplexe Polysaccharid Konjac Glucomannan (KGM) und Oligosaccharid-
Mischungen, welche nach Inkubation des Polysaccharides mit Endo-β-(1,4)-mannanase 
(EM) and Endo-β-(1,4)-glucanase (EG) erhalten wurden, wurden in vitro fermentiert. 
Hierfür wurde ein Inokulum aus menschlichen Fäzes verwendet (Kapitel 6). Die 
strukturellen Eigenschaften der Oligosaccharid-Mischungen und die in vitro Fermentation 
des Polysaccharides und der Oligosaccharide wurden mittels CE-LIF und  matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) untersucht. 
Verschiedene Fermentations-Charakteristika wurden beobachtet, welche an die strukturelle 
Zusammenstellung der Oligosaccharid-Mischungen zurückgeführt wurden.  
Für die Oligosaccharid-Strukturen des EM- und EG-Digestes wurde eine Strukturhypothese 
aufgestellt. Anschließend wird in Kapitel 7 eine detaillierte Strukturstudie der 
Oligosaccharide, welche mittels EM, EG oder der Enzymmischung von menschlichen 
Fäkalbakterien produziert wurden, beschrieben. KGM wird durch EM und EG mittels eines 
selektiven Mechanismus abgebaut. Für EM wurde eine kurze Oligosaccharid-Serie mit 
gleichen Anteilen an Mannose und Glukose gefunden. Für EG wurde eine homologe Serie 
gefunden. Diese besteht wahrscheinlich aus verzweigten, mannosereichen 
Oligosacchariden, welche auf einer Grundstruktur basieren, die aus Glukose und Mannose 
aufgebaut ist. Für den Digest mit Enzymen aus Fäkalbakterien wurde hingegen eine große 
Anzahl strukturell verschiedener Oligosaccharide, welche sowohl charakteristische 
Eigenschaften des EM- als auch EG-Digestes aufwiesen, gefunden. Die Ergebnisse wurden 
auch für die Diskussion des strukturellen Aufbaus des KGM Polysaccharides benutzt. 
Die Diskussion der in dieser Studie erlangten Ergebnisse und die möglichen 
nahrungsmittelbezogenen, wissenschaftlichen und anwendungsbezogenen Konsequenzen 
sind in Kapitel 8 beschrieben. Die gastrointestinale Umwandlung der nahrungsmittel-
bezogenen Oligosaccharide, welche in dieser Studie beobachtet wurden, wurden mit 
Literaturdaten über die frühkindliche gastrointestinale Mikroflora-Entwicklung  verglichen. 
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